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Abstract
Vascular smooth muscle cell (VSMC) fate decisions are critical to the
pathogenesis of vascular diseases, including hypertension,
arteriosclerosis and atherosclerosis and restenosis after angioplasty.
Crosstalk between the developing pathways of Hh, VEGF and Notch are
crucial during vascular morphogenesis and modelling of the embryonic
vasculature. These pathways may be recapitulated in adult cells resulting
in altered fate decisions leading to vascular disease. The Notch signalling
pathway is tightly regulated by a number of mechanisms including
post-translational modification. The serine-threonine kinase, GSK-3β has
been shown to bind to and phosphorylate NotchIC. Using a number of
strategies including ectopic expression, siRNA technology and
pharmacological inhibition, it is demonstrated that GSK3β positively
regulates Notch receptors, Notch downstream targets and Notch
downstream target promoter activity, while inhibiting Hh downstream
target gene expression. Using recombinant Shh protein, recombinant
VEGF-A protein and siRNA targeted against VEGF-A, it is demonstrated
that Hh signalling positively modulates Notch signalling via VEGF-A.
Notch signalling is pro-proliferative and anti-apoptotic in VSMCs.
GSK-3β is shown to positively modulate VSMC proliferation. Moreover,
GSK-3β inhibits VSMC apoptosis, downstream of Notch signalling.
Altered haemodynamic forces have been implicated in the changes in
cell fate associated with vascular disease and Notch signalling modulates
VSMC fate in response to cyclic strain. Notch signalling in VSMCs is
downregulated following strain in a MAPK-dependent manner. It is
demonstrated that GSK-3β activity is decreased following strain.
Moreover, MAP-kinases, p44/42 and p38 are shown to be activated in
iv
VSMCs in a GSK-3β-dependent manner following cyclic strain. In-stent
restenosis occurs in some cases following balloon angioplasty. Stent
expansion causes a low amplitude/high mean strain environment that
promotes proliferation of VSMCs. We demonstrate that GSK-3β activity
and Notch1 levels are increased in a perfused mock coronary artery.
Similarly, Notch, Hh and VSMC proliferation are increased in a ligated
carotid artery (LCA) in vivo model of biomechanically-induced vascular
remodelling. It is identified that GSK-3β expression is regulated in this
model and that GSK-3β, Notch and Hh downstream targets are regulated
in human arteriosclerosis. Collectively, these studies suggest that GSK-3β
is involved in impaired Notch signalling leading to altered vascular cell
fate and remodelling in disease.
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Chapter 1
Introduction
1.1 Cardiovascular Disease
1.1.1 The Vasculature
The vasculature is essential in all vertebrates to distrubute oxygen and
nutrients to tissues. It is comprised of a network of blood vessels called
arteries, arterioles, veins, venules and capillaries. Blood, rich in oxygen,
is carried in arteries from the heart into the tissue capillary bed, via the
arterioles and capillaries. Exchange occurs and blood is carried back to the
heart through the venous system. The structure of a blood vessel consists
of three layers: the tunica adventia, the tunica media and the tunica intima
(Figure 1.1).
The innermost layer, the intima, is a monolayer of endothelial cells
(EC). These are the first cells of the vasculature to form during
embryogenesis (Eichmann et al., 2005). The endothelium plays an
important function in regulating vascular tone, mediating inflammatory
response, and forming a barrier for the transport of molecules into the
1
Figure 1.1: Arterial Structure
second layer, the media. The media is comprised of a compact mass of
vascular smooth muscle cells (VSMC) and elastic fibres. The endothelium
responds to a number of stimuli to regulate vascular tone. It can produce
a number of vasotransmittors such as the vasodilator nitric oxide (NO).
NO signals to the underlying smooth muscle cells, allows the opening of
calcium channels and results in smooth muscle cell relaxation.
Vascoconstrictors such as endothelin-1, operate in a similar manner to
allow vascular smooth muscle contraction.
The primary function of an adult VSMC is to contract and dilate to
regulate blood pressure and flow. VSMC contraction is triggered by an
increase in [Ca]2+ ions, due to Ca2+ release from the sarcoplamic
reticulum and Ca2+ entry from the extracellular space through
Ca2+channels. Ca2+ binds calmodulin (CAM) to form a Ca2+ -CAM
complex, which activates myosin light chain kinase and causes myosin
2
light chain contraction (Salamanca and Khalil, 2005).
During blood vessel formation, the phenotype of smooth muscle
changes such that secretion of ECM proteins is reduced and the
formation of intracellular myofilaments is increased. These contractile
smooth muscle cells show an exceedingly low rate of proliferation and
are largely nonmigratory. Adult VSMCs have been shown to convert
reversibly between this noncontractile and contractile phenotypes (Li
et al., 1999b) in response to several physiological and pathological stimuli
and there is evidence to show that there is heterogeneties between SMCs
within a given blood vessel (Owens et al., 2004).
The adventitial layer is a solid layer of fibroblasts and collagen fibres,
which give structure to the blood vessel. Adventitial fibroblasts
synthesize extracellular matrix,collagen and fibrin, and play a significant
role in arterial repair (Strauss and Rabinovitch, 2000).
Blood vessels differ in their size and structure, depending on their
position and function within the vascular system. Capillaries do not
contain smooth muscle cells and are composed primarily of endothelium
and the basement membrane upon which the endothelium rests.
Pericytes are a relatively unspecialized cell that is derived from the same
precursor cells that form endothelial cells in new vessels and can give rise
to smooth muscle cells during vessel growth (Armulik et al., 2005).
Arterioles contain scattered or one complete layer of SMCs and are
surrounded by an elastic net, rather then internal membrane, Reticular
fibers and collagenous fibers surround individual smooth muscle fibers
and condense externally to form the tunica adventitia. Small arteries are
unnamed and have at least two layers of smooth muscle cell. Small
arteries and arterioles are the determinants of vascular resistance. They
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are the primary regulators of blood pressure and blood flow within the
system. They respond to changes in nerve activity and circulating
hormones by constricting or dilating and are, therefore, referred to as
resistance vessels (Moore et al., 2003).
Large arteries, or ’elastic arteries’, have sheets of elastic tissue in their
thicker media. This is because the larger arteries, which include the aorta,
carotid and coronary arteries, are subjected to high systolic pressures and
must be compliant. Large arteries are distensible and temporarily store
blood during systole before being propelled onwards by the elastic recoil
of the arteries during diastole. Therefore, the compliancy of the aorta and
large artery is of great significance (Moore et al., 2003). The venous system,
on the other hand, is a low resistance capacitance system which contains
more then half of the total blood volume (Moore et al., 2003).The media is
thinner than in arteries as they do not need to adapt to pressure changes
(Yamboliev et al., 2002). Valves are formed by loose, pocket-shaped folds
of the tunica intima, which extend into the lumen of the vein to prevent
back flow of blood (Bianchi et al., 2007).
The aorta is the largest artery, beginning at the root of the aortic valve,
extending into the ascending artery, curving into the aortic arch and
descending into the descending thoracic aorta and ending at the
abdominal aorta. The coronary arteries originate from the root of the
aorta, immediately above the aortic valve. The common carotid artery is
a paired structure and the left and right common carotid arteries follow
the same course with the exception of their origin. The right common
carotid originates in the neck from the brachiocephalic trunk (which
comes out of the ascending aorta). The left arises from the aortic arch in
the thoracic region (Tortora and Grabowski, 1996).
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1.1.2 Vascular Disease
Cardiovascular disease (CVD) is the most common cause of death in the
USA and Europe and accounts for 36% of all deaths in Ireland (Irish Heart
Foundation Website, 2009).
Cardiovascular disease refers to the class of diseases that involve the
heart and/or blood vessels. Disease of the large arteries includes
coronary artery disease leading to myocardial infarction, carotid artery
disease, which leads to stroke, and peripheral artery disease, disease of
the lower limbs, which may result in amputation. These diseases have a
similar pathophysiology, including arteriosclerosis, atherosclerosis and
aneurysm. Arteriosclerosis refers to hardening of the medium and large
arteries and is a term that is used to describe a number of vascular
disease states. Atherosclerosis is the most common form of
arteriosclerosis, but the term arteriosclerosis also refers to a
non-inflammatory vascular remodelling event in which hardening of the
arteries occurs. An aneurysm is a localized, blood-filled dilation
(balloon-like bulge) of a blood vessel caused by disease or weakening of
the vessel wall. Aneurysms most commonly occur in the aorta. As the
size of an aneurysm increases, there is an increased risk of rupture, which
can result in severe hemorrhage or other complications including sudden
death (Tortora and Grabowski, 1996).
Risk Factors
Risk factors for cardiovascular disease include those classed as
modifiable such as diet, smoking exercise and weight. Poor nutrition
plays an important role and a diet high in saturated fat and cholesterol is
a high risk factor for cardiovascular disease. Cholesterol is insoluble in
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blood. Very-low density lipoproteins (VLDLS) are secreted by the liver
and converted to low-density lipoproteins (LDLs). LDLs carry cholesterol
to other tissues where they can be oxidized, forming a pro-atherogenic
environment. High-density lipoproteins, on the other hand, carry
cholesterol back to the liver for degradation. A diet, therefore, high in
HDLs and anti-oxidants and low in LDLs and tryglycerides is considered
appropriate for a healthy lifestyle. Increased levels of homocysteine have
also been linked to cardiovascular disease (Baccarelli et al., 2007). A diet
rich in folic acid and vitamin B6 is thought to be important in reducing
the risk of cardiovascular disease.
A figure of 11% of total cardiovascular deaths have been attributed to
smoking, mainly manifesting as chronic obstructive pulmonary disease
(Perlstein and Lee, 2006). This may be mediated by increased
inflammation and oxidative stress (Ambrose and Barua, 2004). Obesity is
another major risk factor for cardiovascular disease. Excess free fatty acid
liberation and reduced insulin action in peripheral tissues of the liver,
adipose tissue and skeletal muscle, results in endothelial dysfunction and
the onset of vascular disease (Caballero, 2003). This endothelial
dysfunction and reduced vasoconstricitive response along with
abnormality and pro-thrombotic response are also hallmarks of the
diabetic state, a major contributor to cardiovascular disease.
While these risk factors may be controlled through specific lifestyle
choices, other factors such as age, sex and genetic predisposition also
determine the likelihood of developing cardiovascular disease. There is
an age-dependent rise in hypertension and atherosclerotic disease.
Ageing in itself confers a greater risk for disease than the conventional
risk factors such as lipid levels, smoking, diabetes and sedentary lifestyle
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(Plante, 2002).
Hypertension
Hypertension is a cardiovascular risk factor. Systemic hypertension is
defined as chronically elevated blood pressure and uncontrolled high
blood pressure can lead to a number of serious complications, including
increased peripheral vascular resistance and atherosclerosis. Normal
blood pressure is considered to be 120/80 mm Hg, whereas blood
pressure of above 140/90 mm Hg is considered to be high (Owens et al.,
2004). The term ’essential hypertension’ is used if there is no definitive
cause of the condition, whereas secondary hypertension occurs as a result
of other diseases such as renal problems.
1.1.3 Arteriosclerosis
Arteriosclerosis refers to any disease involving hardening of the arteries
but is commonly used to describe age-related non-inflammatory
hardening of the conduit or ’larger’ arteries. To understand the ageing
effect on the artery, we must consider the importance of the compliance
or distensibility of the artery. Vessel compliance is inversely related to the
stiffness of the vessel wall and is related to the material content of the
wall and the relative thickness of the wall compared to its lumen
diameter (Greenwald, 2007).
The vascular wall is complex and varies according to location within
the arterial tree. The aorta is the largest and most compliant artery in the
body as it contains the largest amount of elastin. It is similar to elasticated
rubber, in that systolic pressure from the heart is absorbed passively by a
”ripple effect” along the vessel wall. The ratio of elastin to collagen falls
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with increasing distance from the heart, while the number of VSMCs per
unit volume increases (Zieman Susan et al., 2005).
The compliance of an artery may be measured by its pulse wave
velocity. The more rigid the wall of the artery, the faster the wave moves.
When the wave hits the major branching points, such as at the renal and
femoral arteries, these waves are reflected back so that they reverse
direction and travel back to their point of origin. As stiffness increases,
reflected wave amplitude increases and augments pressure in late systole
(Nichols et al., 2008). The compliance of the aorta decreases with age
(Zieman Susan et al., 2005). With ageing, an increase in the ratio of
collagen/elastin content is observed in the larger arteries (Cattell et al.,
1996). Increased MMP-2 and inhibition of its inhibitors localized
primarily in the thickened intima, perhaps due to an exaggerated VSMC
response to cytokines, is linked to the decrease in elastin (Li et al., 1999c).
The structure of the elastic lamellae become sparse with age and show
signs of fragmentation and disorganization. It is hypothesised that this
may occur due to the cumulative effect of mechanical stress and that
disintegration may be mediated by integrins and metabolic factors such
as oxidative stress (Atkinson, 1998). Non-atherosclerotic calcification of
the remaining elastin in the media also further enhances arterial stiffness
(Greenwald, 2007). Cross-linking of collagen is a major contributor to
stiffening of the artery, Advanced glycation endproducts (AGEs) are
formed by a reaction between reducing sugars and biological amines.
Because of their marked stability, glycated proteins accumulate slowly
over a person’s lifespan (Zieman and Kass, 2004). The formation of AGEs
on vascular wall and myocardial collagen causes cross-linking of collagen
molecules to each other and other proteins (Aronson, 2003). All these
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factors contribute to a decrease in the compliancy of the vessel, leading to
an increase in pulse pressure or hypertension. Indeed, aortic rigidity
precedes the development of arterial hypertension in the spontaneously
hypertensive rat (SHR) model, as it does in individuals with borderline
hypertension (Plante, 2008).
Age-related features also includes intimal thickening, decreased NO
production and increased endothelin production (Jani and Rajkumar,
2006). Intimal thickness increases considerably with aging (Virmani et al.,
1991). SMC proliferation and migration into the developing neointima,
and synthesis and secretion of ECM proteins, including collagen, elastin,
and proteoglycan causes the intima of the conduit arteries to thicken and
can predict higher risk for developing atherosclerosis (Orlandi et al.,
2006). Impaired NO and endothelin production impacts on the
vasoactive resistance arteries. However, peripheral vascular resistance is
the main determinant and a better predictor of cardiovascular risk in
subjects younger than 50, but large artery stiffness is the more important
in older subjects (Gerhard et al., 1996).
1.1.4 Atherosclerosis
Atherosclerosis is a form of arteriosclerosis, distinguished by the
formation of an atheroma or plaque. It is a slow, progressive disease that
occurs mainly in large and medium sized vessels. It is characterised by a
chronic inflammatory response in the walls of arteries and involves the
generation of an obstructive plaque that can result in additional
cardiovascular disorders, including a critical reduction in coronary blood
flow, and subsequent myocardial ischaemia (Spyridopoulos and Andre´s,
1998).
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Endothelial dysfunction is considered an early marker of
atherosclerosis. A damaged endothelium, either physical or biochemical,
results in increased endothelial permeability, a chronic inflammatory
process accompanied by a loss of antithrombotic factors and an increase
in vasoconstrictor and prothrombotic products (Hadi et al., 2005).
Increased levels of endothelin-1, thrombin and platelet-derived growth
factors (PDGF), along with reduced levels of NO and prostayclin result in
platelet adhesion and aggregation and exacerbated SMC proliferation
and migration. These responses are accompanied by accumulation of
new extra cellular matrix (ECM) by the VSMCs (Davignon and Ganz,
2004).
Figure 1.2: Development of Atherosclerotic Lesion (Stoneman and
Bennett, 2004) (LC- lipid core, FC- fibrous cap, Th-thrombus)
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Fatty streaks are the earliest visible atheroschlerotic lesions and
consist of a region of intimal thickening (Figure 1.2: Phase 1). Intimal
thickening is due to the accumulation of cellular and extracellular
substances in the space between the EC lining and the underlying medial
VSMCs (Spyridopoulos and Andre´s, 1998). Droplets of lipids are also
present in these intimal lesions, which can be found in children at an
early age. However, not all initial lesions develop into fatty streaks, and
not all fatty streaks develop into advanced lesions (Consigny, 1995).
Low-density lipoproteins (LDLs) penetrate the subendothelium due to
the increased permeability of the damaged endothelium. The LDLs may
bind to proteoglycans and undergo oxidation by free radicals. These
oxidised LDLs (oxLDLs) attract circulating monocytes. Further lipid
accumulation in the cytoplasm of macrophages gives rise to lipid-laden
foam cells. Different cell types,including ECs, platelets, and
inflammatory cells release mediators, such as growth factors and
cytokines that induce multiple effects including phenotype change of
vascular smooth muscle cells (VSMC) from the quiescent contractile
phenotype state to the active synthetic state, that can migrate and
proliferate from media to the intima (Cai, 2006).
As a lesion develops, smooth muscle cells recruited from the media
and subendothelium, embedded in connective tissue, form a fibrous cap
over the lesion (Figure 1.2: Phase 2). Plaques can be defined as stable or
vulnerable. Stable plaques have a high VSMC and collagen content and a
limited amount of lipid-laden inflammatory cells. This subsequently
forms a thick, protective fibrous cap, and while their may be an increase
of stenosis or narrowing of the blood vessel, a stable plaque is clinically
not as serious as a vulnerable plaque (Figure 1.2: Phase 5). Vulnerable
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plaques, containing a large lipid core and a thin fibrous cap with less
number of VSMCs, are prone to rupture on the the shoulder region of the
lesion, in which macrophages are concentrated (Stoneman and Bennett,
2004) (Figure 1.2: Phase 3). The components are released, where they are
free to contact with blood clotting factors and form a thrombus. This
thrombus can form an embolism, which is carried elsewhere, causing
acute coronary syndromes (Figure 1.2: Phase 4) (Stoneman and Bennett,
2004). Together with apoptosis (programmed cell death), proliferation
and migration of VSMC are vital to the pathogenesis of atherosclerosis
and plaque rupture. Rupture of the plaque is associated with increased
fibrous cap macrophage, increased VSMC apoptosis, and reduced fibrous
cap VSMC. VSMCs are the only cells capable of synthesizing structurally
important collagen isoforms, and the apoptosis of VSMC might promote
plaque rupture (Walsh et al., 2000).
Angioplasty and Restenosis
Angioplasty is the technique of mechanically widening a narrowed or
obstructed blood vessel, typically as a result of atherosclerosis. While
generally successful in the short-term, restenosis or re-occlusion of the
vessel is a major obstacle in maintaining an open lumen and may result
in the need for further surgery. Mechanical injury to the vessel leads to a
thrombogenic and proliferative phase which is typified by VSMC
proliferation, neointimal hyperplasia and eventual remodelling with
pathological changes in the cellular and protein content of the media and
adventitia (Ellozy and Carroccio, 2003).
During angioplasty, plaques are compressed against the arterial wall
by an angioplasty balloon (Figure 1.3: left vessel). To maintain the result
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of the opened lumen and to prevent the closure of the lumen by
fragmented or dissected plaques, stents, which are tubular metallic
scaffolding tubes, are usually placed in the arteries (Figure 1.3: right
vessel.). However, restenosis may still possibly occur. The use of
drug-eluting stents (DES) is a significant development in the prevention
of restenosis. The DES is designed to release pharmacological agents after
deployment to inhibit the response to injury mainly responsible for
restenosis. A coating on the surface of the stent struts which contains
some drugs can inhibit the growth of neointimal tissues (Luscher et al.,
2007).
Figure 1.3: Stent Angioplasty (Ashley and Niebauer, 2004)
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1.2 Cell Fate
1.2.1 Vascular remodelling
Vascular remodelling describes any enduring change in the size or
composition of a blood vessel and may occur to accommodate to changes
in haemodynamic forces or as a response to inflammation or injury.
Remodelling is usually an adaptive process, but it may subsequently
contribute to the pathophysiology of vascular diseases and circulatory
disorders (Gibbons and Dzau, 1994). Altered VSMC contraction and
relaxation, along with changes in cell fate (proliferation, apoptosis,
migration and differentiation) result in structural remodelling. VSMC
proliferation can cause medial thickening, while the adventitial layer is
modulated by changes in fibroblast growth. Impaired production and
degradation of extracellular matrix and stimulation of inflammatory
responses also induce a remodelling response and compromise the
compliancy of the vessel (Touyz, 2005).
Figure 1.4: Vascular remodelling (Mulvany, 1999)
In inward eutrophic remodelling, in which outer and lumen
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diameters are decreased, the media cross-sectional area is unaltered
(Figure 1.4). Therefore, while stenosis occurs, stiffening of the artery is
avoided.These vessels have the same number of smooth muscle cells and
little evidence of cell hypertrophy. It is possible that VSMC growth is
offset by levels of apoptosis (Schiffrin, 2004). However, with inward
hypertrophic remodelling (Figure 1.4), the media growth encroaches on
the lumen, causing stenosis. Inward remodelling, as described above, is
generally observed in the resistance vessels of mild hypertensive patients
and differs from that seen in large arteries (Mulvany, 1999). Increased
medial thickness, due to remodelling results in a decrease in compliance
of larger arteries and the progression of arteriosclerosis (Intengan and
Schiffrin, 2001).
Following vascular injury, neointimal hyperplasia of conduit arteries
occurs. VSMCs migrate into the neointima and play a principal role in
atherogenesis by proliferating and synthesizing a cascade of molecules.
Adaptive outward remodelling, however, where the medial growth is
outward with lumen size increase, can compensate for progressive
growth of atherosclerotic plaques, thus postponing the development of
flow-limiting stenosis (Ward et al., 2000).
1.2.2 Proliferation
Altered cell fate decisions, including proliferation and apoptosis, are
critical in a number of disease states. Adult VSMCs are not terminally
differentiated and have the ability to change phenotype in response to
changes in local environment through the expression of contractile and
synthetic genes. Proliferation of VSMCs contribute to the development of
neointimal lesions in atherosclerosis, and hypertension-related
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arteriosclerosis. Restenosis after vascular injury is also characterised by a
VSMC hyperplastic response. Production of extracellular components by
VSMCs contribute further to the remodelling event (Touyz, 2005).
Growth factors that induce VSMC proliferation and are upregulated in
atherosclerotic lesions and the neointima following angioplasty include
PDGF, basic fibroblast growth factor (bFGF), and insulin-like growth
factor(IGF)-1 (Abid et al., 2005). The ability of VSMCs to respond to
growth factors may be dependent on changes in specific ECM
components and integrins through regulation of cyclin dependent
kinases inhibitors (CKIs) (Spyridopoulos and Andre´s, 1998). MMPs are
upregulated in atherosclerotic lesions and after angioplasty and have
been shown to regulate growth factor availability, thereby promoting
proliferation (Newby, 2006)
A number of transcription factors that are known mediators of VSMC
proliferation have been linked to neointimal formation. Activation of
NF-κB is thought to play a major role in atherosclerosis and inflammatory
diseases (Monaco and Paleolog, 2004) and is known to induce
proliferation of VSMCs (Hoshi et al., 2000). Thrombin has been shown to
mediate activation of NF-κB leading to proliferation of human VSMCs
(Nakajima et al., 1994). Other transcription factors involved in VSMC
proliferation and that have been identified as inducing neointimal
hyperplasia include c-myc (De Nigris et al., 2003) and mitochondrial
transcription factor A (mTFA) (Yoshida et al., 2005).
An important inhibitor of VSMC proliferation is NO (Costa and
Assreuy, 2005). In animal models of arterial injury and vein grafts, NOS
activity and NO release are markedly altered (Jeremy et al., 1999). NO is a
flow-dependent inhibitor of VSMC proliferation, highlighting the
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importance of haemodynamic forces on changes in VSMC proliferation
(Boo and Jo, 2003).
The Cell Cycle
The cell-cycle consists of an orderly set of phases, during which specific
subsets are transcribed and assembled. The mitotic (M) phase of the cell
cycle is relatively brief and involves nucleur and cytoplasmic division.
Interphase begins with the Gap 1 (G1) phase, where biosynthesis within
the cell increases at a high rate. This includes the synthesis of enzymes
required for the S phase of interphase. At this point, DNA synthesis
occurs, resulting in replication of the chromosomes. The cell enters G2
phase, where rapid protein synthesis is carried out. This is the last stage
in the interphase, before the M phase begins. Depending on
environmental and developmental signals, cells may enter the G0 Phase,
directly afer G1 phase. This is a quiescent state and cells may remain in
this state for long periods of time (van den Heuvel, 2005). The passage of
a cell through the cell cycle is controlled by cytoplasmic proteins called
cyclins, which bind to and activate specific-cyclin dependent kinases
(CDKs). The cell cycle is therefore carefully regulated through the levels
of cyclins at specific stages of the cycle (Koledova and Khalil, 2006). The
cyclin levels are controlled both transcriptionally and by
ubiquitin-dependent proteolytic machinery (Spyridopoulos and Andre´s,
1998). The D-type cyclins (D1, D2, and D3) and their catalytic partners
CDK4 and CDK6 act early in G1 phase. These are controlled by mitogen
signals, including ERK1/2 (Sherr and Roberts, 2004). Cyclin A/CDK2
complexes are required for DNA synthesis (S Phase). Cyclin A/CDK1
and cyclin B/CDK1 pairs are then assembled and activated during the G2
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phase and M phase. CDK inhibition may occur through association with
CKIs that include p15, p16, p18. p19 and p21 among others
(Spyridopoulos and Andre´s, 1998).
1.2.3 Apoptosis
Apoptosis, or programmed cell death, is vital for normal cell turnover.
Impaired apoptosis, however, where there is too much or to little, is a
factor in many conditions including neurodegenerative diseases and
cancers, and is critical in the pathophysiology of atherosclerosis, vascular
remodelling, and other cardiovascular disorders. Cell growth, the
balance between proliferation and apoptosis, of VSMCs is an important
factor to consider in studying vascular disease.
In atherosclerosis, apoptosis is a double-edged sword and SMCs
isolated from atherosclerotic plaques have been shown to be more
susceptible to apoptosis (Bennett et al., 1995). Initially, apoptosis can
prevent lesion progression. However, in an advanced plaque apoptosis of
VSMCs promotes coagulation and inflammation. Plaque SMCs
undergoing apoptosis have the same potency to generate thrombin as
platelets. Modified LDLs can hinder phagocytosis of apoptotic VSMCs
which release and pro-coagulant factors inflammatory cytokines, as they
undergo secondary necrosis (McCarthy and Bennett, 2000). Apoptotic
cells expose phosphatidylserine on the surface early in the process. In the
presence of factors V and VII, exposed PS can then act as a substrate to
thrombin generation. Thus, apoptosis of smooth muscle cells in primary
atherosclerotic plaque could be detrimental for plaque stability and
increase the risk for thrombosis (Kockx and Herman, 2000). Apoptosis of
VSMCs within a progressive plaque also reduces the stability of the
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fibrous cap due to the loss of ECM, particularly collagen type I, produced
by the VSMCs and, thus, potentially leads to thrombosis and occlusion of
the vessel (Davies, 1996). Macrophages may promote apoptosis of
VSMCs through production of death ligands on their surface (Boyle et al.,
1998) or secretion of pro-apoptotic cytokines, including TNF and IL-1
(Rakesh and Agrawal, 2005). TGF-β and the transcription factor p53 are
important players in promoting apoptosis of VSMCs. Conversely, bFGF
and other growth factors, including PDGF. bFGF and IGF-1 and
transcription factors, such as c-myc, promote survival of VSMCs (Rakesh
and Agrawal, 2005).
In arterial injury in animal models, apoptosis of medial VSMCs occurs
rapidly within 30 min of injury (Perlman et al., 1997). This first wave of
apoptosis may be associated with the redox-sensitive activation of
stress-activated protein kinases (Pollman et al., 1999). As repair occurs,
intimal VSMC apoptosis is induced and medial VSMC apoptosis is also
observed (8-21 days in a rat carotid artery model (Bochaton-Piallat et al.,
1995)). It has been hypothesized that the early wave of medial VSMC
apoptosis may exacerbate late neointima formation by provoking a
greater wound healing response to overcome the cellular deficit and that
late apoptosis may limit lesion growth (Walsh et al., 2000). Specimens
from human patients with in-stent restenosis also display abundant
apoptotic cells (Kearney et al., 1997) and neointima cells are more
sensitive to the induction of apoptosis than media VSMCs (Erl, 2005).
Moreover, populations of SMC are phenotypically distinct within a given
blood vessel and also between blood vessels of the same vascular bed
and in vivo, sub-populations of SMCs within the same tissue express
different levels of caspase 3 and show different sensitivities to apoptosis
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(Chan et al., 2000).
Overall, our understanding of the mechanisms of VSMC apoptosis can
aid us in finding new therapeutic targets to combat vascular disease.
The Apoptotic Pathways
During early apoptosis, chromatin compaction, nuclear condensation and
fragmentation and also cell shrinkage occurs (Mignotte and Vayssiere,
1998). This is followed by the separation of cell fragments into apoptotic
bodies. Phosphatidylserine (PS) is exposed on the surface of the cell,
allowing recognition by non-inflammatory macrophages and
phagocytosis of the apoptotic body. No inflammatory reaction occurs as
there is no production of anti-inflammory cytokines and no release of
cellular constituents. This differs from necrosis, or oncosis which is the
process leading up to necrosis. Cell swelling, disruption of the cell
membrane, release of cytoplasmic contents and recruitment of
inflammatory cells are all hallmarks of oncosis (Majno and Joris, 1995) .
The activation stage of apoptosis can be triggered by a number of
stimuli that are either extrinsic or intrinsic. The extrinsic signalling
pathway involves death receptors of the tumor necrosis factor receptor
(TNFR) family that are activated by ligand binding, resulting in the
transmission of a death signal from the cell surface to the intracellular
signalling pathway (Figure 1.5). Extracellular signals may include
hormone, growth factors, nitric oxides or cytokines. Examples of the
ligand-receptor interaction are FasL/FasR and TNF-α/TNFR1. These
both involve recruitment of cytoplasmic adapter proteins e.g. FADD to
FasR, which bind to the receptor through their death domain. FADD then
associates with pro-caspase 8, resulting in the formation of a
20
death-inducing signalling complex (DISC), and allowing activation of
pro-caspase 8 and the beginning of the execution pathway (Elmore, 2007).
Figure 1.5: Extrinsic Apoptotic Pathway (McCarthy and Bennett, 2000)
The intrinsic pathway is non-receptor meditated, but results in an
intracellular signal. Radiation, hypoxia and viral stimulants that cause
DNA damage can positively induce apoptotic signalling through the
intrinsic pathway. Removal of growth factors, cytokines and hormones
can remove apoptotic suppression and allow transduction of the
intracellular signal. Changes in the inner mitochondrial membrane occur
that allow the release of cytochrome c and other pro-apoptotic proteins
from the mitochondria into the cytosol (Figurer˜efintrinsic). Cytochrome c
binds to Apaf-1 and caspase-9, allowing its activation and the beginning
of the execution pathway, similar to the extrinsic apoptotic pathway
(Rossi and Gaidano, 2003).
The execution pathway involves the activation of caspase-3, caspase-6
and caspase-7 (Nicholson and Thornberry, 2003). This pathway is tightly
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Figure 1.6: Intrinsic Apoptotic Pathway (McCarthy and Bennett, 2000)
regulated by the Bcl-2 protein family, which includes a group of
antiapoptotic proteins, such as Bcl-2, and proapoptotic proteins, such as
Bax. These proteins act upstream of caspase-3 and the relative levels of
the pro-and anti- apoptotic proteins determine the susceptibility of cells
to a death signal (Burlacu, 2003). Activation of the proteolytic caspases
results in the organised degredation of cellular organelles by the
caspases, and subsequent phagocytosis by macrophages.
1.3 Haemodynamic Forces
Blood vessels are permanently subjected to the haemodynamic forces of
pulse pressure and shear stress. Shear stress, the frictional force of blood
flow against the vessel wall, acts in parallel to the surface of the vessel and
is primarily sensed by endothelial cells (Figure 1.7). Shear stress is known
to be atheroprotective and plaques are known to occur in areas where there
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is reduced shear stress (Cunningham and Gotlieb, 2004).
Shear stress also impacts indirectly on VSMCs through the release of
vasoactive mediators and growth factors by the endothelium (Kraiss
et al., 1991). In diseased states, the intima may be denuded of the
endothelium and in this instance, shear stress may exert a direct effect on
VSMC proliferation and migration (Ueba et al., 1997), (Qi et al., 2008).
Pulse pressure creates radial and tangential forces and effects all cell
types within the vasculature. (Lehoux et al., 2006) (Figure 1.7). An
increase in mean and/or pulse pressure stretches the vessel wall, a
change which is sensed directly by the VSMC, leading to changes in its
contractile state and/or its synthetic activity. While biomechanical stretch
at physiological levels is essential to develop and maintain organic
structure and function, altered mechanical stretch may result in
pathological conditions. Pulsatile shear stress and uniaxial
circumferential stretch exists in the straight part of the arterial tree.
Disturbed flow and relatively undirected stretch are seen at branch points
and other regions of complex geometry (Chien, 2007). Atherosclerotic
plaques occur preferentially at bifurcations and curvatures of arterial
blood vessels, where there is irregular hemodynamic shear stresses
(Wernig and Xu, 2002).
Remodelling of arteries as they grow, age or become diseased leads
to changes in their composition, their geometry and the manner in which
mechanical forces are distributed within their walls. These changes can
lead to altered haemodynamics and possible further remodelling, with an
exacerbation of disease states.
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Figure 1.7: Diagram of Haemodynamic Forces (Chien, 2007)
1.3.1 Cyclic Strain
The pulsatile nature of the cardiac output imposes a cyclic pressure and
strain on the arterial wall. Arteries undergo small pulsatile
circumferential deformations relative to the deformed state caused by the
mean pressure and in situ axial extension (Cowin and Humphrey, 2001),
and physiological stretch of the human aorta has been reported to be
9-12% under normotensive conditions (Chapman et al., 2000). .
The cyclic stretch in response to pulse pressure, ∆P, is determined by
arterial compliance defined as
C =
∆ri
ri∆P
where ri is the inner radius at mean pressure and in situ length, and
∆ri is the change in radius (Cowin and Humphrey, 2001).
In hypertensive patients, increased mean blood pressure may occur
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through altered compliance of the conduit arteries and impaired
vasodilation of the resistance arteries. Both of these factors are hallmarks
of ageing (Nicita-Mauro et al., 2007), (Dohi et al., 1995) and contribute to
greater stretch of the conduit arteries. Additionaly, localised
abnormalities such as bifurcations and plaques can also lead to altered
mechanical stretch (Kaazempur-Mofrad et al., 2003).
Altered mechanical forces can contribute to pathological changes of
the vessel by inducing VSMC proliferation or apoptosis. Cyclic strain can
impact both indirectly on VSMCs, by signalling through endothelial cells,
or by directly effecting the biomechanical sensors of VSMVCs (Lacolley,
2004). There have been conflicting reports, however, on the effect of
stretch on proliferation of VSMCs. A number of studies have shown an
anti-proliferative effect of stretch on VSMCs (Sumpio and Banes, 1988),
(Morrow et al., 2005b). Rhythmical stretch was found to be important to
keep the rate of DNA synthesis and thereby the proliferation of VSMCs at
a low level (Hipper and Isenberg, 2000). Exposure of rat aortic VSMCs to
cyclic stretch blocked the proliferative effect of PDGF and thrombin (10%,
1 Hz) in a p21-dependent manner and caused an arrest of cells in the G1
phase of the cell cycle (Chapman et al., 2000). Interestingly, this same
study, found that both types of cyclic stretch, uniaxial, and equiaxial
caused an increase of cells in the fraction of cells in the G0/G1 phase of
the cell cycle. SMCs in the walls of most arteries are orientated in the
circumferential direction, whereas the motion of the wall occurs
predominantly in the radial direction so that SMCs experience a type of
unaxial stretch. Other studies have found the opposing effect of stretch
on VSMC proliferation. Li, et al. and Birukov et al. both found a positive
effect of stretch on proliferation in rabbit aortic VSMCs (Li et al., 1997),
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(Birukov et al., 1995). Bovine aortic smooth muscle cells also showed
enhanced proliferation with 0-7% strain compared to static control (Mills
et al., 1997).
A number of factors have been identified as critical to the proliferative
response of VSMCs to stretch. The proliferative response due to cyclic
stretch of SMC obtained from small resistance arteries was significantly
greater then that of VSMCs obtained from large conduit arteries
(Nakamura et al., 1998). Studies have also found that stretch potentiates
proliferation in VSMCs obtained from venular but not arterial blood
vessels (Dethlefsen et al., 1996). Opposing results have also been found
from arterial cells cultured from newborn and adult animals (Wilson,
1993), (Seifert et al., 1984). Additionally, the phenotype of VSMCs has
been found to dictate the growth response to pulse pressure in vitro
(Cappadona et al., 1999). As there is evidence to show that there are
heterogeneties between SMCs within a given blood vessel (Owens et al.,
2004), this is of important significance when considering the proliferative
profile of VSCMs. Together, these studies suggest that the source of the
VSMCs must be considered when studying the prolfiferative response of
VSMCs to changes in haemodynamic stretch.
Lack of haemodynamic forces triggers apoptosis in vascular
endothelial cells (Kaiser et al., 1997). However, a number of studies have
shown that stretch induces apoptosis in VSMCs in vitro (Sedding et al.,
2008), (Morrow et al., 2005a), (Sotoudeh et al., 2002). Increased apoptosis
occurs in SMC cultured from spontaneously hypertensive rats compared
with normotensive control rats (Hamet et al., 1996). Further study is
required, however, to understand the mechanisms involved in
stretch-induced apoptosis.
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1.3.2 Mechanotransduction
Endothelial and vascular smooth muscle cells have the ability to convert
mechanical signals into a biochemical response and do so through
receptors on the cytoskeleton and other structural components.
Mechanical stresses may directly perturb the cell surface or alter receptor
conformation, thereby initiating signalling pathways usually used by
growth factors (Zou et al., 1998). In vascular smooth muscle cells, these
mechanosensors include integrins, G-protein and G protein-coupled
receptors, tyrosine kinase receptors and ion channels. The intracellular
pathways of protein kinase C and mitogen-activated protein kinases
(MAPK) are also activated in response to mechanical stimuli (Li and Xu,
2000).
Integrins
Integrins allow attachment of a cell to the extracellular matrix and other
cells. Their covalently bound subunits, α and β, consists of a single
transmembrane domain, a large extracellular (EC) domain and a small
cytoplasmic domain. The EC domain binds to a wide variety of ECM
ligands, including fibronectin, vitronectin, laminin and collagen (Katsumi
et al., 2004). Twenty different integrin receptors can be formed.
Heterodimerization of the different combinations of the fifteen α and
eight β subunits allows the formation of twenty different integrin
receptors. Clustering with other bound integrins results in the formation
of highly organized intracellular complexes, known as focal adhesions,
that are connected to the cytoskeleton. β1 and β3 integrins have been
shown to have a role in adhesion and migration of vascular smooth
muscle cells (Clyman et al., 1992), (Lee et al., 2006) and are sensitive to
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mechanical strain in VSMCs (Wilson et al., 1995). In contrast to the
unidirectional nature of GPCRs and receptor PTKs, integrin signalling is
bidirectional with ”outside-in” signalling involving interaction of
integrins with the extracellular matrix (ECM) rather than with soluble
ligands (Sugden, 2003).
Ion Channels
Cyclic strain-sensitive ion channels, including Ca2+ and Na+ channels
increase their frequency of opening following cyclic strain. This results in
a transient increase in intracellular Ca2+, Na+ and other divalent cations,
and membrane depolarization. This may have implications of vascular
remodelling where changes in cell fate of vascular smooth muscle cell
occurs. Increased cytosolic levels of calcium stimulates quiescent cell
entry into the cell cycle, and drives proliferating cells (Landsberg and
Yuan, 2004).
Receptor Tyrosine Kinsases
Receptor tyrosine kinases (RTKs) are high affinity cell surface receptors
that include the VEGF, PDGF, and insulin receptor families. Mechanical
stretch has been shown to increase both vascular endothelial growth
factor (VEGF) expression and phosphorylate the VEGF receptor in VSMC
(Smith et al., 2001). PDGF receptors α and β are reported to be
up-regulated by mechanical stress. Binding of platelet-derived growth
factors (PDGF)s to their plasma membrane receptors leads to
auto-phosphorylation of the tyrosine residues in the the PDGF receptor
kinase domain. This leads to sequential phosphorylation events and
activation of MAPK cascades (Li and Xu, 2000).
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G protein-coupled receptors
G protein-coupled receptors are characterised by seven transmembrane
segments. G protein-coupled receptors are activated by an external signal
in the form of a ligand or other signal mediator such as cyclic strain. This
creates a conformational change in the receptor, causing activation of a G
protein (Weis and Kobilka, 2008). Small guanine nucleotide binding
proteins (small G proteins) or GTPases include five families of Ras, Rho,
Rab, Sar1/ADP ribosylation factor and Ran, which oscilate between
inactive GDP-bound G-proteins and active GTP-bound G proteins.
Growth factors, cytokines and G protein-coupled receptors (GPCRs)
allow activation of G proteins, and GDP association inhibitors and
GTP-ase activating proteins cause the small G protein to remain in its
inactive GDP-bound state. G-proteins have been shown to have
important downstream effects in VSMCs. Ras promotes cell proliferation
through activation of the Raf-MEK-ERK cascade (McCubrey et al., 2007).
RhoA, through activation of ROCK (Rho kinase), is involved in increased
sensitivity of VSMC (Loirand et al., 2006) and reduced p21Cip1 or
p27Kip1 results in Rho-induced cell proliferation in the vasculature of
hypertensive rats (Seasholtz et al., 2001).
Intracellular signalling Pathways
There are a number of second messengers that are activated following
changes in haemodynamic forces. These include activation of the MAPK,
Protein Kinase C, PI3K/Akt and NF-κβ Pathways. There are five families
of MAPKs, but each have similar features in the pathway. A MAPKs is
activated, through phosphorylation by a MAPKK (MAPK kinase).
MAPKKs are also known as MEK or MKK and examples of a MAPKKs
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are MKK1 and MKK2. MAPKKs are activated through dual
phosphorylation on a threonine and tyrosine residue adjacent to a
proline, by a MAPKK kinase such as A-RAF, B-Raf and Raf-1. These are
serine/threonine kinases, which are stimulated by extracellular stimuli
and react with Ras/Rho and PKC (protein kinase C). The five families of
MAPK are ERK 1/2 (extra-cellular signal regulated kinases), JNKs
1,2,3,(c-Jun amino-terminal kinases), p38/SAPK (stress activated protein
kinase) isoforms (α,β,γ, δ), ERKs 3,4 and ERK 5. ERK 1/2 mainly respond
to growth factors, while JKNs and p38 are mainly sensitive to stress
stimuli. Mechanical strain activates p38, JNKs and ERK1/2 in vascular
smooth muscle cells (Tock et al., 2003) and ERK 1/2 and p38 have been
shown to be pro-proliferative in VSMC in a Ras/rac dependent manner
(Li et al., 2000). Atherosclerotic lesions show requirement for JNK2 (Ricci
et al., 2004) and treatment of macrophages with JNK or p38 MAPK
inhibitors blocks oxLDL-induced foam cell formation (Muslin, 2008).
Acute hypertension and balloon angioplasty induces expression and
activation of ERK 1/2, JNKs, in rat vascular models, (Hu et al., 1997), (Xu
et al., 1996). p38 has also been implicated in the response to balloon
angioplasty and neointimal hyperplasia after vascular injury (Ohashi
et al., 2000), (Ju et al., 2002).
The protein kinase C (PKC) is a large family of serine/threonine
kinases containing several isoforms divided into three groups based on
their requirements for Ca2+ and diacylglycerol (DAG) for activation (Yan
et al., 2006). These groups are the conventional (cPKCs), the novel
(nPKCs) and the atypical (aPKCs) The protein kinase C (PKC) family is
activated by a large number of extra-cellular signals and, in turn, modify
the activity of numerous targets such as cytoskeletal proteins, MAPK and
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transcription factors (Li and Xu, 2000). Cyclic strain activation of PKC has
been shown to promote VSMC proliferation (Mills et al., 1997) and
migration (Li et al., 2003). Another study demonstrated that PKC-δ
promotes VSMC proliferation and migration through the activation of
ERK1/2 (Liu et al., 2007). A number of PKC isoforms have been linked to
hypertension (Salamanca and Khalil, 2005) and PKC-β has been shown to
have a central role in atherosclerosis and restenosis after injury (Andrassy
et al., 2005), (Harja et al., 2005).
1.4 Notch Signalling Pathway
The Notch Signalling Pathway is a developmental pathway, that has
since been identified as an important regulator of vascular smooth
muscle cell fate (Morrow et al., 2005a). Tight control of Notch Signalling is
essential to maintain physiological levels of downstream activity. Shaggy,
the Drosophila homolog of GSK-3β, is known to act downstream of
Notch (Ruel et al., 1993) and GSK-3β has been shown to phosphorylate
and regulate Notch IC. In this study, we examine the role of GSK-3β in
Notch Signalling in VSMCs (Foltz et al., 2002).
1.4.1 The Role of the Notch signalling Pathway
The Notch gene was originally identified in Drosophila where it was
isolated originally as a neurogenic gene. Embryos lacking Notch gene
function showed an increased number of neuroblasts at the expense of
epidermal precursors (Artavanis-Tsakonas et al., 1999) and much of our
understanding of the Notch signalling Pathway comes from studies on
Drosophila Notch, as well as the Notch-related genes lin-12 and glip-1 in
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Caenorhabditis elegans (Weinmaster, 1997). Notch regulates multiple
cell-cell interactions and such diversity is generated through the
activation of different notch like receptors. In 1992, a second mammalian
gene, Notch2, which encoded a protein that contained all the structural
motifs characteristic of a Notch protein, was identified (Weinmaster,
1992). Notch 3 and Notch 4 were later identified, showing specificity in
vascular smooth muscle and endothelial cells, respectively. These Notch
proteins display both overlapping and distinct tissue distributions as well
as both redundant and distinct functions (Wu and Bresnick, 2007)
Notch in the Vasculature
Notch3 is predominantly expressed in adult arterial smooth muscle cells
in humans (Joutel et al., 2000) and genetic disorders such as CADASIL
(cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy) and Alagille Syndrome demonstrate a crucial role
of the Notch pathway in vascular development. A Notch3-null mouse is
viable and fertile but and absence of Notch3 results in enlarged arteries
with abnormal distribution of elastic laminae (Mason et al., 2005).
CADASIL is caused by mutations in the Notch receptor, Notch 3, gene
and is the most common form of inherited stroke and vascular dementia
in humans (Gridley, 2007) and is characterised by systemic VSMC
degeneration (Wang et al., 2008). The mutations are located within the
EGF repeats in the extracellular domain of the Notch3 gene with a strong
clustering of the mutations observed within exons 3 and 4 (Joutel et al.,
1997). Cerebral vessels are consistently narrowed by intimal thickening
and expansion of the extracellular matrix in CADASIL. This is
accompanied by widespread disruption and degeneration of smooth
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muscle cells in vessel wall and the deposition of the granular osmiophilic
material (GOM). Karlstrom et al. has suggested that Notch3 mutations
causes reduced S1 site cleavage, which results in lower amounts of
mature heterodimeric mutant receptor to be presented at the cell surface
(Karlstrom et al., 2002) CADASIL-mutation carrying cells in culture
maintained in viable conditions undergo normal physiological signalling.
It is possible that differences in mutant and wild type would surface if the
cells were subjected to mechanical or chemical stress, as it constantly
occurs in the cerebral vasculature with increasing age (Kalaria et al., 2004).
In humans, mutations in the Notch1 locus result in a spectrum of
heart defects. The most prevalent malformations are bicuspid aortic valve
disease and calcification of the aortic valve (Garg, 2006). Alagille
Syndrome is an autosomal dominant disorder characterized by
development abnormalities of a number of organs including the liver,
heart, and eye and most cases are caused by the Notch ligand, Jagged 1,
mutations (Kamath et al., 2004).
Angiogenesis
The Notch signalling pathway is important in the regulation of blood
vessel sprouting and branching during both normal development and
tumor angiogenesis. The Notch ligand Dll4 has been shown to regulate
blood vessel sprouting and branching through the vascular endothelial
growth factor A (VEGFA) pathway in endothelial cells. During
angiogenesis, supporting cells such as pericytes and smooth muscle cells
are recruited to the vessels to provide structural support and stability for
the vascular walls (Suchting et al., 2007).
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Arterial-Vein Differentiation
Notch signalling also has a critical role to play in arterial-venous
differentiation (Figure 1.8). Arterial specification of embryonic stem cells
has been shown to be VEGF and Notch dependent, while inhibition of
Notch signalling or low VEGF levels is permissive for venous
differentiation (Lanner et al., 2007). Loss of Notch5 activity, the zebrafish
form of Notch, or its target gene gridlock, leads to a loss of the arterial
marker EphrinB2 and increase expression of the venous marker EphrinB4
(Wu and Bresnick, 2007). Suppression of Notch signalling by the
COUP-TFII transcription factor has been shown to regulate vein identity
(You et al., 2005).
Figure 1.8: Arterial Differentiation in Knockout Notch Zebrafish (Lawson
et al., 2002)
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Regulation of Cell Fate
Notch signalling has been shown to have an important part to play in the
regulation of vascular cell fate in embryogenesis and in adult cells. A role
for Notch signalling in repressing smooth muscle cell differentiation
during in vitro cell culture has been established (Proweller et al., 2005) and
expression of the constitutively active form of Notch3 IC was shown to
down-regulate the differentiation markers smooth muscle α-actin (SMA),
myosin, calponin and smoothlin in human aortic SMCs (Morrow et al.,
2005a). Also, Notch1IC or HRT2 expression inhibits myocardin-activated
SMC marker gene transcription (Proweller et al., 2005). However, some
studies have shown NotchIC/CBF-1 activity inducing SMA expression in
a number of cell types. Expression of the constitutive active ICD of
human Notch1, Notch2, or Notch4 receptors increased SMA levels in
primary human smooth muscle cells. Concurrently this study found that
the Notch downstream targets HRT1 or HRT2 repressed basal SMA
expression. A negative-feedback pathway, therefore, has been proposed
by which expression of HRT1 or HRT2, alone or in combination with
Notch activation, suppresses SMA transcript and protein levels. SMA
regulation by Notch signalling may depend on a balance between Notch
activity and HRT activity (Tang et al., 2008b).
Notch has been shown to be pro-proliferative and anti-apoptotic in
vascular smooth muscle cells (Morrow et al., 2005a) and to be modulated
by both biomechanical stimuli in vitro and following vascular injury in
vivo (Morrow et al., 2005a), (Wang et al., 2002). Notch may be, therefore, a
player in the altered vascular cell phenotype observed in
pathophysiological environments, such as vunerable plaques and
restenosis after injury.
35
1.4.2 Canonical Notch signalling
Figure 1.9: Canonical Notch signalling (Fischer and Gessler, 2007)
The canonical Notch signalling pathway involves binding of a Notch
ligand from a neighbouring cell to the transmembrane Notch receptor
(Figure 1.9). Two proteolytic cleavages release the Notch intracellular
domain (NICD) from its plasma membrane tether, allowing it to
translocate to the nucleus. In the absence of ligand binding, the
extracellular LIN-12/Notch Repeats (LNRs) prevent S2 cleavage.
Ligand-induced cleavage at a distinct site (S2 cleavage site) within the
Notch extracellular domain (NECD) by transmembrane proteases of the
ADAM/TACE family, leaves an activated membrane bound form of
Notch. This is followed by further cleavage at an S3 cleavage site, by a
γ-secretase/presenilin complex, allowing a release of active NICD, which
translocates to the nucleus (Figure 1.9). The NICD forms a complex with
a CSL(CBF1/RBP-Jκ, Su(H), Lag-1) protein, displacing a histone
deacetylase (HDAc)-co-repressor (CoR) complex from the CSL protein.
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Components of an activation complex, including MAML and histone
acetyltransferases (HAc), are recruited to the NICD-RBPJ complex,
leading to the transcriptional activation of Notch target genes (Gridley,
2007).
Structure of Notch Receptors
Figure 1.10: Schematic Diagram of Notch Receptor (Weinmaster, 1997)
Notch receptors are heterodimeric proteins that are synthesized as
single chain pre-cursors in the Golgi apparatus. Following cleavage of
full-length notch by a furin-associated convertase, the NECD associates
non-covalently with the membrane tethered NICD. The Notch receptor
proteins contain extracellular arrays of epidermal growth factor (EGF)
repeats which are involved in ligand interaction (Figure 1.10). The
EGF-repeat 11/12 are essential for ligand binding (Rebay et al., 1991).
Three Lin-Notch repeats (LNR) modulate interaction between the
extracellular (NotchECD) and the membrane-tethered intracellular
domains (NotchIC). The Notch IC includes seven ankyrin repeats (ANK),
that mediate the interaction between Notch and CSL. These are flanked
by nuclear localization signals, a praline-, glutamate-, serine, threonine-
rich sequence (PEST domain) that is involved in degradation and a
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transcription activation domain (TAD) (Fiu´za and Arias, 2007).
Figure 1.11: Schematic Diagram of Notch Ligands (Weinmaster, 1997)
Structure of Notch Ligands
There are five Notch ligands in vertebrate, Delta-like1(Delta1),
Delta-like3(Dll-3), Delta-like 4(Dll-4), Jagged 1 and Jagged 2. They are
collectively called DSL ligands after there Drosophila Delta/Serrate and
C.elegans Lag-2 counterparts. The Delta ligands are similar to Drosophila
Delta and the Jagged ligands are most similar to Drosophila Serrate. The
intracellular tails of these DSL ligands are poorly conserved, as are the
size and composition.They are composed of a DSL region responsible for
the interaction with the Notch receptor and several EGF-like repeats
(Figure 1.11). Jagged ligands contain, in the extracellular region, a greater
number of EGF repeats insertions and a cysteine-rich region closer to the
membrane. Interaction of Notch with the ligand is believed to lead to a
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conformational change that exposes the S2 site of cleavage, causing
Notch signalling activation.However, there is very little evidence that
Dll-3 physically binds to the Notch receptors or that it truly functions as a
Notch ligand (Chiba, 2006).
CBF-1 Protein
CBF-1(C Promoter Binding Factor), also known as RBP-Jκ, is the
mammalian orthologue of Drosophila Su(H) (suppressor of Hairless) and
and C.elegansLag-1. These three proteins are collectively known as CSL.
CBF-1 is a DNA-binding transcription factor that binds to the DNA
sequence GTGGGAA and is required for both repression and activation
of Notch target genes (Zhou et al., 2000). In the absence of Notch
signalling, CBF-1 interacts with Notch target gene DNA in the nucleus
and recruits co-repressors to form transcriptional co-repressor complexes.
These co-repressors include CtBP, SMRT, SHARP, CoREST, Sin3A, CIR
and MeCP2 (Fryer et al., 2002). This is followed by the recruitment of
HDACs to the site which converts the target gene into a transcriptionally
silent form .The transcriptional co-regulator, Ski-interating protein (SKIP)
may bind to the CBF1: corepressor complex and may also play a role in
the recruitment of the Notch ICD in signalling (Zhou et al., 2000). On
binding of the active Notch IC, the co-repressors are displaced and MaM
forms a ternary complex with CBF-1 and Notch. Formation of the ternary
complex on DNA requires the N-terminal domain of MAM and the
ankyrin (ANK) repeats of the ICD. This is folowed by recruitment of
transcription factors PCAF/GCN5 and CBP/p300, which allows
transcription of the target to occur (Kovall, 2007).
CBF-1 is composed of the N-terminal domain (NTD), the β-trefoil
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domain (BTD) and the C-terminal domain (CTD). CBF-1 binds to the
major groove of DNA through the NTD and the BTD contributes to
minor groove DNA binding. Both Notch IC and co-repressors bind to
CBF-1 in the BTD of CBF-1. NotchIC interacts strongly with CBF-1
through its RAM domain (Kovall and Hendrickson, 2004).
1.4.3 CBF-1 Independent signalling
Notch mutant phenotypes in Drosophila have been shown to be slightly
stronger than that of Su(H) mutants. This suggests that Su(H)-dependent
signalling does not mediate all functions of Notch (Arias et al., 2002).
Since this was initially observed, evidence has arisen to show CBF-1
independent Notch signalling in vertebrates, including inhibition of
differentiation of myoblasts by a constitutively active form of Notch1
Shawber (1996). The most commonly described mediator of CBF-1
independent signalling is deltex. While most studies have been
performed in Drosophila, Deltex-1 (DTX1), a mammalian homolog of
Drosophila Deltex, has been shown to mediate a Notch signal to block
differentiation of neural progenitor cells (Yamamoto et al., 2001) . Deltex
protein has been shown to interact with the Notch intracellular domain
(Diederich, 1994). Deltex binds to the conserved ankyrin repeats within
Notch and only the most carboxyl (sixth) ankyrin repeat has been shown
to be non-essential for this binding activity (Matsuno, 1995).
Deltex-Notch interaction prevents the cytoplasmic retention of the
Suppressor of Hairless Su(H) protein, which otherwise is sequestered in
the cytoplasm via association with the Notch ankyrin repeats and
translocates to the nucleus when Notch binds to its ligand Delta
(Matsuno, 1995). Notch IC has also been shown to antagonize signalling
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through a JNK MAP kinase pathway, in a deltex dependent manner
(Ordentlich et al., 1998).
Other proteins that are involved in CBF-1-independent Notch
signalling include NF-κB and Nurr 77 and there is also evidence to show
that ligands such as F3/concactin can activate Notch (Miele, 2006).
Notch-1 has been reported to induce NF-κB promoter activity and induce
expression of NF–κB subunits (Wang et al., 2006). The Drosophila abl
gene, and its vertebrate homologue, the protooncogene, c-abl encode
cytoplasmic tyrosine kinases with a role in Notch signalling in neurons.
This effect is mediated by the abl accessory protein, disabled, which
binds directly to Notch IC, and exerts an effect on axon guidance (Giniger
et al., 1998). Additionally, Notch 1 IC has been shown to directly interact
with nur 77, resulting in an inhibition of nur 77-dependent transcription
(Jehn et al., 1999).
1.4.4 Effectors of Notch signalling
The primary targets of the Notch signalling pathway are the Hes and HRT
genes. The HES family are the mammalian forms of the Hairy and
Enhancer of split(E(spl)) genes in Drosophila (Iso et al., 2003) and are Class
C proteins of the basic helix-loop-helix(bHLH) transcription factor family
of proteins. There are seven Hes genes, where only Hes 1, Hes 5 and Hes 7
are Notch induced. The HRT genes, HRT 1-3 (hairy-related transcription
factor 1-3), also know as Hey 1,2 and L (Hairy/Enhancer-of-split related
with YRPW motif 1, Hairy/Enhancer-of-split related with YRPW motif 2
and Hairy/Enhancer-of-split related with YRPW motif-like) , or HERP
(Hes-related repressor protein genes), encode three related bHLH
transcription factors.
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Structure of Target Genes
The HES and HRT genes contain highly conserved Orange and bHLH
domains within their respective family, but are less conserved among the
two families. A YRPW sequence in the last amino acids are conserved in
HRTs (Figure 1.12). This is a WRPW motif in HES at the C-terminal
tetrapeptide. A conserved proline residue at a specific site of the basic
domain of HES confers unique DNA-binding activity and this is replaced
by a glycine in the HRT family (Iso et al., 2001).
Figure 1.12: Schematic Diagram of HRT Family Protein Structures
(Fischer and Gessler, 2003) HLH = helix loop helix; HRT = Hairy-related
transcription factor, dHEY= Drosophila HRT
HRTs are detected in both HES-expressing and non-HES-expressing
tissues. There is much evidence to show that HRTs are effectors of Notch
signalling. All HRT promoters contain binding sites for CBF-1 and all
three genes are induced by Notch. Indeed, mutations of CBF-1 binding
sites in the promoters of HRT1, HRT2 and HES1 genes abolish activity of
their promoters (Maier and Gessler, 2000).
Both Hey and Hes proteins mainly act as transcriptional repressors by
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binding to DNA-bound activators and turning them into repressors.
Repression can occur through DNA binding, formation of homo- and
heterodimers and recruitment of co-repressors.
Mechanism of Repression
HES have different repression mechanisms then HRTs but both show
evidence of acting through both active and passive repression.
Recruitment of co-repressors is an example of active repression. HES
proteins recruit the corepressor TLE though its WRPW motif (Paroush
et al., 1994). The HRT family’s repressive activity is primarily due to the
bHLH domain rather then the YQPW motif. Their bHLH domain can
interact with mSin3 and N-CoR co-repressors (Iso et al., 2001). The HES
family may act passively through sequestration of proteins. HES1 can
form a non-functional heterodimer with other bHLH factors such as E47
and therefore disrupt the formation of functional heterodimers such as
MyoD-E47 and Mash1-E47 (Hirata et al., 2000). Similarly, HRT1 binds the
aryl hydrocarbon receptor nuclear translocator (ARNT) and inhibits
ARNT-dependent transcription of the VEGF promoter by dissociating the
ARNT complex from DNA (Chin et al., 2000)
The HES and HRT family also differ in their binding capability. Both,
however, have their basic helix-loop-helix (bHLH) domain, which
contains a basic domain capable of DNA binding. Hes 1,5, and 7 can bind
to N-box sequences (CACNAG) and class C sites (CACGNG) present in
the promoter region of their target genes, while Hey proteins show
preference for a class B E-box sequence (CACGTG) (Nakagawa et al.,
2000).
Protein dimerisation is an important mechanism for repression.
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Hydrophobic residues in the HLH motif allow them to form a hetero-or
homo-dimer (Murre et al., 1994). The Orange domain contains two
amphipathic helices that regulates the selection of bHLH heterodimer
partners (Taelman et al., 2004). HES-HRT heterodimers show a marked
increase in DNA binding activity compared to homodimers and are,
therefore, able to cooperate for transcriptional repression in in cells
co-expressing them (Iso et al., 2001).
Targets of the Effectors
Although few targets of the effectors have been identified, Hes1 has been
shown to negatively regulate its own transcription. The Orange domain
of HES1 was shown to repress transcription of its own gene and p21WAF
promoters (Castella et al., 2000). Overexpression of HES1 gene
downregulated Mash1 transcription by directly binding to the promoter
region (Chen et al., 1997). HRT2 has also been shown to downregulate its
own gene expression (Nakagawa et al., 2000).
Effectors of Notch signalling in the Vasculature
HES and HRT factors are differentially expressed in different tissues. HES
factors have been shown to be predominantly involved in neurogenesis
and development of sensory organs, and HRT factors play critical roles in
the cardiovascular system (Fischer and Gessler, 2007). HRT2 is the
homologue of zebrafish gridlock (grl) and is the only HRT gene
expressed in blood vessels in zebrafish. Knockout HRT2 mice show
cardiac impairment and failure to thrive (Donovan et al., 2002). HRT2 and
3 are predominantly expressed in VSMCs in the dorsal aorta during
development , with HRT1 transcripts restricted to the endothelial layer
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(Fischer and Gessler, 2003). HRTs are the primary transducer molecules
for the Notch Pathway in the vasculature and Notch 3 can induce HRT1,
HRT2 and HRT3 in VSMCs (Sweeney et al., 2004). HRT1 has been shown
to protect against serum deprivation and FasL-induced apoptosis in
VSMCs (Wang et al., 2003). HRT3 inhibits myocardin-induced vascular
smooth muscle cell differentiation by interfering with SRF Binding to a
CArG Box (Doi et al., 2005) .
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1.5 Regulation of Notch signalling
Figure 1.13: Primary Regulatory Mechanisms of Notch signalling
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Lateral and Inductive signalling
Notch signalling is regulated at a number of levels, as summarised in
Figure 1.13, including cell to cell interaction. This may occur through a
process know as lateral signalling that is dependent on the relative
concentration of Notch in neighbouring cells. A signal can change the
relative concentration of ligand in two initially equivalent cells, which
then take up different fates and differentiate to different tissues
(Figure 1.14). Each of the cells is able to send and receive a weak signal,
but with time one cell becomes a signalling cell and the others become
receiving cells. This is caused by a regulatory loop within the cells, which
causes activation of the receptor and results in down-regulation of the
ligand (Katsube and Sakamoto, 2005). Inductive signalling, however,
occurs between non-equivalent cells and a specific response at the
interface between the two. The signal is sharply defined across two
populations producing a different ligand. Activation of the Notch
receptor promotes production of Notch ligand, thus causing increased
Notch activation in the adjacent cell and renders cells insensitive to the
ligand produced by equivalent cells (Simpson, 1998). Notch allows
differentiation of neural precursors cells into epidermal cells by inhibiting
the proneural genes achaete(ac) and scute (sc). Mutations of Notch and
Delta show an increase in the number of precursor cells at the expense of
epidermis (Ramain et al., 2001)
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Figure 1.14: Schematic of Lateral and Inductive Notch signalling (Kimble
and Simpson, 1997)
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Numb
Numb, a negative regulator of Notch signalling, is a
phosphotyrosine-binding (PTB) domain protein that binds via its PTB
domain to two regions of Notch, the RAM domain and at the C-terminus
(Baron et al., 2002). In Drosophila, Numb blocks Su(H) protein
translocation to the nucleus in response to Notch activation, but does not
interfere with Su(H) cellular localization in the absence of Notch
receptor-ligand interactions (Frise et al., 1996). Numb and Notch act
antagonistically in specifying correct cell fate in the bristle lineage.
During asymmetric cell division in Drosophila sensory organ precursor
cells, the Numb protein localizes where it influences cell fate by
repressing signal transduction via the Notch receptor (Figure 1.14 C).
Numb acts upstream of of the S3 cleavage of Notch in this process (Guo
et al., 1996). Numb antagonizes Notch activity by recruiting α-adaptin.
This probably stimulates endocytosis of Notch and, thus, serves as a
mechanism to downregulate signalling (Berdnik et al., 2002). (Brou, 2008)
Endocytosis
Trafficking of receptor and ligand has been recognised in the last number
of years as being a key part of the regulation of Notch signalling.
Multi-ubiquitylation of DSL ligands by two E3 ubiquitin ligases,
Neuralised (Neur) and Mindbomb(Mib) is proposed to serve as a signal
for DSL ligand internalisation by promoting their interaction with
cytosilic adaptor proteins that contain ubiquitination-binding domains.
Direct ubiquitination of Delta by Neuralized allows the ligand to enter an
Epsin-dependent endocytic pathway which is required for its activation
(Kanwar and Fortini, 2004). Epsins are multidomain adaptor proteins
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that bind phosphoinositol, ubiquitin, clathrin and other accessory
proteins, and they might serve to link monoubiquitinated cell-surface
proteins to the endocytic complex. Trafficking of endocytosed-ligand
back to the surface, following these post-translational modifications,
increases the efficacy of the ligand (Wang and Struhl, 2004). Endocytosis
of NECD-bound Delta in the signal-sending cell may create pulling forces
on Notch that induce conformational changes associated with the
unmasking of the S2 cleavage site. In this model, the dynamic membrane
invaginations that take place during endocytosis are utilized to generate
the forces that dissociate the Notch heterodimer and induce its
proteolytic activation. Dynamin-regulated endocytosis is required both in
signal-sending cells, to allow activation of DSL signalling and in
signal-receiving cells to promote ligand-dependant Notch activation
(Parks, 2000). Mono-ubiquitination of the receptor is a crucial event to
target it to endocytic vesicles, where it is cleaved by γ-secretase. Notch
receptor accumulation in endosomal compartments may enhance its
exposure to γ-secretase (Gupta-Rossi et al., 2004). .
Cleavage of Receptor and Ligand
Cleavage of receptor and ligand is also an important factor in Notch
signalling regulation. As discussed, Notch receptor cleavage at S2 and S3
sites is essential for notch signalling to occur. In the absence of ligand
binding, the ADAM-protease cleavage site is buried, suggesting that
ligand-binding provokes a conformational change exposing the cleavage
site (Gordon et al., 2007). Most Notch receptors at the cell surface are
heterodimeric, single-pass transmembrane molecules and the
heterodimer is generated in the secretory pathway by a cleavage called
50
S1. In mammalian cells, this additional furin-based S1 cleavage, during
trafficking of Notch to the plasma membrane, is also required for
canonical notch signalling prior to ligand binding (Logeat et al., 1998). In
the absence of furin processing, ligand-induced signalling can occur
through activation of uncleaved Notch1 at the plasma membrane. This
uncleaved receptor signals in a CBF-1-independent manner (Bush et al.,
2001). Low amounts of the uncleaved form of the Notch 2 and Notch 3
receptor has also been detected on the plasma membrane by other studies
(Blaumueller et al., 1997), (Joutel et al., 2000).
Additionally, ligands can be similarly cleaved at S2 and S3 sites by
ADAM proteases and γ-secretase and these cleaved intracellular fractions
are important in activating ligand transcription (Dyczynska et al., 2007).
Ligand processing generates soluble, extracellular forms that can bind
Notch receptors. DSL ligands expressed at high levels have been
observed to act as antagonists of Notch present in the same cell in both
Drosophila and vertebrates (Zolkiewska, 2008). It is possible that the
intracellular domains of Delta and Jagged may signal intracellularly, and
may be, therefore, involved in bidirectional signalling (Bland et al., 2003).
Glycosylation
The extracellular domain of Notch receptors are glycosylated with
O-fucose, O-glucose glycans and N-glycans on their EGF-like repeats.
O-fucosyltransferase (O-Fut) allows the addition of a first fucose to the
EGF repeats of the Notch IC within the endoplasmic reticulum (ER).(Wu
and Bresnick, 2007). Fringe protein is a glycosyltransferase which is
responsible for transfer of N-acetylglucosamine to fucose on the
EGF-repeats in the Golgi apparatus. This has been shown to modulate
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Notch-Delta interactions (Bruckner et al., 2000) and may also be a form of
modification for Notch ligands (Panin et al., 2002). Serrate has a higher
affinity for fucosylated Notch, whereas subsequent Fringe-mediated
modification potentiates Delta-mediated Notch activation. Notch
receptors lacking O-fucose are inactive and disruption of the
glycosylation event leads to severe Notch signalling defects in Drosophila
and mammals (Lu and Stanley, 2006). Three O-fucose sites (within EGF
repeats 12, 26, and 27) are invariantly conserved in all Notch homologues
with 36 EGF repeats. The most highly conserved O-fucose sites in Notch1
were shown to be important in Notch 1 for both processing and
ligand-mediated signalling (Rampal et al., 2005). In an interesting study
by Sakamoto et al. (2002) vertebrate Notch 1, Dl-1 and Ser-1 were shown
to form homomeric or heteromeric complexes in a cell autonomous
manner. They found that the ligand/receptor complexes did not appear
on the cell surface but had a dominant-negative effect on Notch signalling
within the cell, thus supressing the cells competence to receive the notch
signal. Lunatic fringe (L-fg) was found to inhibit the cell-autonomous
association of the ligand and receptor (Sakamoto et al., 2002).
Phosphorylation
A considerably low-level of Notch IC in the nucleus is required to initiate
transcription of downstream target genes (Schroeter et al., 1998). For this
reason, tight regulation through phosphorylation is important in
maintaining this low-level of Notch IC within the nucleus. Notch IC has
been shown to be hyperphosphorylated and phosphorylated forms of
Notch have been identified in the nucleus (Foltz and Nye, 2001).
Fractionation of Drosophila embryos as well as mammalian cells in
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culture reveals that the phosphorylated IC domain localized primarily to
the nucleus (Kidd et al., 1998).
Ski-interacting protein (SKIP) and Mastermind (MAM) are able to
recruit kinases that specifically phosphorylate NICD in the TAD and
PEST domain. This marks the phosphorylated sites of Notch IC for
ubiquitination and degradation by Fbw7/Sel10 (Fryer et al., 2004). This
may stall signalling and post-activation of target genes, by coordinating
activation with turnover of the Notch IC.
Nuclear ICD may also be phosphorylated by the serine-threonine
kinase, glycogen synthase kinase-3β (GSK3β). However, this regulation
may occur off DNA because GSK-3β did not bind the HES1 promoter at
the same time as Notch in ChIP experiments (Fryer et al., 2004). This
suggests a mechanism whereby phosphorylation by GSK-3β occurs prior
to activation of transcription by NotchIC. Phosphorylation by GSK3β has
been found to downregulate Notch 2 activity by directly binding and
phosphorylating Thr-2068 and/or Ser-2070, Thr-2074, and Thr-2093 at the
C-terminal of the Notch 2 ankyrin repeat (Espinosa et al., 2003). However,
phosphorylation of Notch1IC by GSK-3β has been shown to aid stablilty
of the active receptor within the nucleus, leading to increased signalling
activity (Foltz et al., 2002). Both studies suggest a role for GSK-3β in the
complex regulation of Notch signalling, perhaps in a receptor-specific
manner.
Regulators of Notch signalling
Along with GSK-3β, many proteins have been identified as regulators of
Notch signalling, including Numb, Fringe, Deltex, among others already
discussed. Additionally, Scabrous, a secreted fibrinogen-related protein,
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acts as a negative regulator of the Notch signalling pathway by binding
to the EGF-like repeats and modulating receptor-ligand binding (Lee
et al., 2000). Itch, the mammalian form of suppressor of deltex Su(dx),
controls the degradation of the non-activated Notch 1 receptor and
targeting it, after early endocytosis, for lyosomal degredation
(Chastagner et al., 2008). A number of Notch signalling repressors within
the CBF-1 complex, including Hairless and Groucho, have been identified
(Maier, 2006). Altogether, tight control of an important signalling
pathway, such as Notch, is demonstrated by the vast number of
regulators that have been implicated in its modulation.
1.5.1 Role of GSK-3β
Drosophila shaggy kinase and rat glycogen synthase kinase-3 have
conserved activities and act downstream of Notch (Ruel et al., 1993).
Glycogen synthase kinase-3 (GSK-3) is a serine-threonine kinase.
Molecular cloning identified two isoforms of GSK-3 encoded by distinct
genes GSK-3α and GSK-3β (Woodgett, 1990). The difference in size
between the 51kD GSK-3α and 47kD GSK-3β is due to a glycine-rich
extension at the N-terminus of GSK-3α (Figure 1.15). Structurally, they
are similar with 98% homology in their kinase domain and 36% identity
in the last 76 C-terminal residues (Ali et al., 2001) .
Figure 1.15: Schematic Diagram of the GSK-3 Isoforms (Doble and
Woodgett, 2003)
54
Despite being similar, structurally, the two isoforms have been shown
to have different expression patterns, substrate preferences and cellular
functions. GSK-3α, but not GSK-3β, was shown to be necessary in
cardiomyocyte survival during zebrafish cardiogenesis (Lee et al., 2007).
GSK-3β -null mice reportedly die during embryogenesis as a result of
liver degeneration (Yao et al., 2002), whereas GSK3α knock-out mice are
viable and display improved glucose tolerance in response to glucose
load and elevated hepatic glycogen storage and insulin sensitivity.
GSK-3β is unique in that many of its substrates require
phosphorylation at a residue four amino acids C-terminal to the GSK-3β
phosphorylation site. This is performed by a priming kinase such as
casein kinase II, protein kinase A or DYRK (Liu et al., 2004) (Woods et al.,
2001). Not all substrates require this priming and an example of this is
the APC-β-catenin complex in the Wnt pathway (Woodgett, 1990).
GSK-3β was first identified as a regulator of glycogen synthesis, due
to its phosphorylation and deactivation of glycogen synthase (Hall et al.,
2001). It has since been shown to have a broad range of substrates and its
dysregulation has been associated with a wide variety of diseases,
including Alzheimers, bi-polar disease and cardiovascular disease.
Therefore, it is an enzyme that requires strict regulation and this is carried
out through a number of mechanisms. Unlike most serine-threonine
kinases, GSK-3β is constitutively expressed. It is regulated through
phosphorylation at two sites. Tyrosine phosphorylation at site 216 is
optimal, but not essential for its activity (Bax et al., 2002). It has been
shown to increase activity 200-fold (DePaoli-Roach, 1994) and has been
shown to be an autophosphorylation event (References et al., 2004).
GSK-3β is negatively regulated through phosphorylation at serine 9.
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This is may be mediated by a number of stimuli, including insulin (Pearl
and Barford, 2002). Insulin stimulation results in phosphorylation
through a phosphoinositide 3-kinase (PI-3 kinase)-dependent
mechanism. This pathway results in activation of Akt, which binds to
and directly phosphorylates both GSK-3α and GSK-3β at ser21 and ser9
respectively (Cross et al., 1995). Phosphorylation may also occur though a
MAPK pathway (Forde and Dale, 2007). Growth factors such as
epidermal growth factor (EGF) and platelet-derived growth factor
(PDGF) may regulate the phosphorylation of GSK-3β through both the
MAPK and PI-3kinase pathway (Shaw and Cohen, 1999).
Figure 1.16: Negative Regulation of the GSK-3β through ser9
phosphorylation (Doble and Woodgett, 2003)
The mechanism of GSK-3β regulation is described in Figure 1.16.
56
Phosphorylation of serine 9 on GSK-3β serves as a form of
pseudosubstrate. Both primed and unprimed substrates may be
phosphorylated by GSK-3β in its resting state. A priming kinase (PK)
directs the binding of a serine or threonine to the catalytic site (CS).
Binding of a phosphate to serine 9 on GSK-3β, by an inactivating kinase
(IK), causes the N-terminal end to fold over the active or catalytic site
(CS) of the enzyme, preventing binding and phosphorylation of the
substrate (Doble and Woodgett, 2003).
Regulation of GSK-3β is also controlled though its subcellular
location. Akt has been shown to localise in the mitochondria following
insulin stimulation, resulting in rapid phosphorylation of mitochondrial
GSK-3β (Bijur and Jope, 2003b). Apoptotic stimuli can induce nuclear
accumulation of GSK-3β (Bijur and Jope, 2001). Nuclear GSK-3β is in a
relatively greater activation state then cytosolic GSK-3β (Bijur and Jope,
2003a) and is able to regulate a number of transcription factors, such as
p53, that support cell survival (Watcharasit et al., 2003). Its ability to
associate with other proteins in subcellular compartments is also
important in selectively directing its actions towards specific substrates
and GSK-3β has a number of binding partners including Tau, presenilin,
p53 and Notch 2 (Jope and Johnson, 2004). This binding pattern is of
importance in the Wnt pathway. In the absence of Wnt, GSK-3β is active
in a multi-protein complex containing the scaffold protein axin, and APC
(Figure 1.17) . This active GSK-3β phosphorylates the transcription factor
β-catenin, targeting β- catenin for proteosomal degradation . In the
presence of Wnt, Dishevelled is activated and results in inhibition of
GSK-3β activity within the complex (Luo et al., 2007). Interestingly, this
inhibition of GSK-3β activity does not involve phosphorylation of the
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serine 9 residue. Free GSK-3β may be phosphorylated at serine 9, by
stimuli such as insulin, but enzyme bound to the complex may not (Ding
et al., 2000). Inhibition of activity occurs through the disruption of the
interaction of axin with GSK-3β , thereby dissociating β-catenin from the
complex and preventing its phosphorylation (Frame and Cohen, 2001).
Figure 1.17: Role of GSK-3β in Wnt signalling (Taketo, 2006)
GSK-3β has a diverse range of substrates, involved in many biological
processes. This includes metabolism, where GSK-3β is involved in
inhibition of glycogen synthesis, through glycogen synthase and
inhibition of protein synthesis through eIF2b (Kockeritz et al., 2006).
GSK-3β is also involved in cell division. Cyclin D1 has been shown to be
phosphorylated by GSK-3β, triggering rapid cyclin D1 degradation and
facilitating entry into the DNA synthetic phase of the cell cycle (Diehl
et al., 1998). GSK-3β is very important in development and
embryogenesis, through Wnt signalling and its target β-catenin (Li et al.,
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2006), and also regulates cytoskeletal proteins via Tau and APC (Frame
and Cohen, 2001). A number of transcription factors have been identified
as substrates of GSK-3β, and these include those involved in
proliferation, differentiation and apoptosis. Generally, its effect is
inhibitory targeting the transcription factor for degradation.
Phosphorylation of the pro-proliferative transcription factor, c-jun,
interferes with its binding to DNA and hence represses c-jun-directed
transcription (Ginger et al., 2000). However, GSK-3β can also stimulate
transcription, for example through phosphorylation of the cell survival
transcription factor, NFκβ (Ougolkov et al., 2005).
GSK-3β has been implicated in a number of diseases including cancer,
Alzheimers, bi-polar disease, diabetes and cardiovascular disease. In
Alzheimer’s disease, hyperphosphorylation of tau results in the
formation of neurofibrillary tangles, leading to neurodegeneration and
there is much evidence to demonstrate that GSK3β is involved in this
hyperphosphorylation (Hooper et al., 2008). Lithium chloride, an
inhibitor of GSK3β, has been used for many years as a treatment for
bi-polar disease and, in animal models, GSK3β manipulation has been
shown to have an effect on manic symptoms (Rowe et al., 2007). Insulin
resistance in diabetic patients can lead to GSK3β hyperactivity in some
peripheral tissues, and inhibition of GSK3β may be able to contribute to
controlling glucose levels in diabetic subjects (Jope et al., 2007). The
associated increase in GSK-3β may also have implications for
cardiovascular disease. There is a potential role for GSK-3β in
glucosamine-induced endoplasmic reticulum stress. The resulting lipid
accumulation, inflammation and apoptosis may pay a causative role in
accelerated atherosclerosis (Robertson et al., 2006). Recent evidence, both
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in vitro and in vivo, suggests that GSK-3β is a negative regulator of
cardiac hypertrophy. Inhibition of GSK-3β has been shown to reduce
myocardial cell death following ischaemia and reperfusion (Murphy and
Steenbergen, 2005). Transgenic mice, which overexpress a mutant active
form of GSK-3β (GSK-3βs9A) inhibit hypertrophy in response to aortic
banding and isoproterenol stimulation, both of which are inducers of
hypertrophy (Hardt and Sadoshima, 2002).
1.5.2 Crosstalk with other Pathways
The Notch signalling Pathway is one of a number of developmental
cell-cell signalling pathways that include Wnt, TGF-β and Hedgehog
(Hh) Barolo (2002). Crosstalk between these pathways is known to occur
during embryogenesis, to maintain tight control on all cellular processes.
It is thought that this interaction may be recapitulated in adult cells
during the pathogenesis of disease. Indeed, it is known that the Hh
ligand, sonic hedgehog (Shh) is known to up-regulate the expression of
Notch target genes during arterial differentiation and vascular
endothelial growth factor (VEGF) acts downstream of Shh and upstream
of the Notch pathway in zebrafish. Loss of Vegf or Shh resulted in loss of
arterial identity in zebrafish embryos, while exogenous expression of
these factors caused ectopic expression of arterial markers. Microinjection
of VEGF mRNA into embryos lacking Shh activity rescued arterial
differentiation. Finally, activation of the Notch pathway in the absence of
VEGF signalling could rescue arterial marker gene expression (Lawson
et al., 2002). This crosstalk between pathways is of interest as another
mechanism by which Notch is regulated in adult cells and as a possible
cause of altered phenotype in vascular disease.
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Wnt/Wingless Pathway
A Wnt protein is the ligand to Wnt/Wingless signalling, so called as
Wingless is the Drosophila orthologue of Wnt. The receptors of Wnt
signalling include Frizzled and LRP protein families. The effector of Wnt
signalling in the nucleus is β-catenin (Hayward et al., 2008). As discussed
previously, in the absence of Wnt, active GSK-3β phosphorylates the
transcription factor β-catenin, targeting β- catenin for proteosomal
degradation (Figure 1.17). On binding of a Wnt ligand, Dishevelled is
activated and disrupts the interaction of axin with GSK-3β. This prevents
the phosphorylation of β-catenin, allowing transcription to occur (Frame
and Cohen, 2001).
Wnt signalling is involved with the prepatterning required for lateral
inhibition to occur, through the creation of equivalence groups through
positional information. Notch signalling then acts on these groups to
restrict the neural potential to one or two cells through lateral inihibition.
Interactions between Wnt and Notch signalling were first uncovered in
the context of the development and patterning of the wing of Drosophila
(Hayward et al., 2008). Crosstalk between Notch and Wingless(Wg)
signalling is known to occur through Dishevelled. Dishevelled (Dsh) is a
cytoplasmic protein that binds to the carboxy terminus of the Notch
receptor (Axelrod et al., 1996). Notch is antagonized by elements of the
Wingless (Wg)-signalling cascade to allow alternative cell fate choices,
resulting in a repression of neural fate, by a Notch signalling distinct
from that involved in lateral inhibition and CBF-1 activity. Loss of
sensory organs associated with this phenotype results from a constitutive
activation of a Deltex-dependent Notch-signalling event. This activity,
mediated by Deltex (Dx), represses neural fate and is antagonized by
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elements of the Wingless(Wg)-signalling cascade to allow alternative cell
fate choices (Ramain et al., 2001).
Hedgehog signalling Pathway
Hedgehog (Hh) genes are a class of 19-kDa morphogens, of which there
are three human homologues: sonic Hh (Shh), Desert Hh and Indian Hh.
Hedgehog signalling functions through binding of the Hh ligand to its
transmembrane receptor, Patched 1 or Patched 2. The patched receptor
normally inhibits downstream signalling through interaction with a
second transmembrane protein, Smoothened. Binding of Hh ligand to
Patched removes its repressive effect on Smoothened and allows
signalling and activation of its target genes, the Gli transcription factors
1-3, to progress (Figure 1.18). The downstream targets of the Gli gene
products include both Patched and Gli (Mullor et al., 2002).
Similar to Notch, post-translational modification of Hh is important
for its signalling. Autolytic cleavage of the hedgehog precursor protein to
generate an N-terminal active polypeptide occurs and a C-terminal
fragment is responsible for catalzying the autolytic cleavage. Cholesterol
moiety is thought to mediate Hh binding to the membrane. Addition of a
palmitoyl group to the N-terminus of the mature active protein is
necessary for signalling to occur (Weed et al., 1997). Hh ligands may be
tethered to the plasma membrane of the signalling cell to effect short
range signalling, or they may be released from the signalling cell in a
diffusible form to act as a long-range signal. The release of the ligand is
regulated by a protein called Dispatched (Burke et al., 1999)
Ptc1 is a 140 kDa transmembrane protein expressed through the
vasculature in both juvenile and adult mice (Pola et al., 2001). Ptc
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Figure 1.18: Canonical Hedgehog signalling (Owens and Watt,
2003).Binding of Sonic Hedgehog (Shh) ligand to Patched (PTCH) receptor
relieves PTCH repression of Smoothened (SMO). SMO translocates to the
nucleus, where it stabilises Gli, allowing transcription of its target genes.
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regulates the activity of Smoothened (Smo), a G protein-coupled
receptor-like protein essential for Hh signal transduction. Ptc may control
Smo activity by regulating an intracellular trafficking process dependent
upon the integrity of a Ptc sterol-sensing domain (Strutt et al., 2001). In
Drosophila, Smo signals to an intracellular microtubule-attached
multi-protein complex containing Costal2 (Cos2), the protein kinase
Fused (Fu) and the transcription factor Cubitus interruptus (Ci). In the
absence of Smo, this complex regulates the cleavage of full-length Ci to a
truncated repressor protein, Ci75, in a process that is dependent on the
proteasome and priming phosphorylations by Protein kinase A (PKA)
(Ogden et al., 2008) Smo signalling results in the phosphorylation of Fu
and Cos2 in Drosophila. This causes the complex to detach from the
microtubules. Full length Ci/Gli is stabilised, and is no longer subject to
phosphorylation by PKA. It is then able to translocate to the nucleus
where it acts as transcriptional activator. Binding of Hh to Ptc blocks
Ptc-mediated Smo inhibition, allowing Smo to signal to the intracellular
components to attenuate Ci cleavage (Nybakken and Perrimon, 2002).
There is also evidence of a Gli-independent Hh pathway through
COUP-TFII (Krishnan et al., 1997). COUP-TFII is also involved in
suppression of Notch signalling during the regulation of vein identity
(You et al., 2005)
VEGF Pathway
The vascular endothelial growth factor (VEGF) pathway involves binding
of a diffusible VEGF ligand to a cell receptor tryrosine kinase. There are
five forms of VEGF ligand in mammals - VEGF-A, VEGF-B, VEGF-C,
VEGF-D and placenta growth factor (PLGF). VEGF-A, also known as
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VEGF, is the most well-characterised, with expression observed in many
cell types, including vascular smooth muscle cells (Holmes et al., 2007).
Six splice-variant isoforms have been detected, which differ in their
binding to heparin and thereby their association with the extracellular
matrix (Cross et al., 2003). VEGF165 is the most abundant and biologically
active form. It is expressed as a 46kDA homodimer composed of two
23kDA units, which has the ability to bind to the VEGF receptor
VEGFR-1 but mainly binds to VEGFR-2 (Ho and Kuo, 2007). VEGF plays
a pivitol role in both vasculogenesis and angiogenesis, through its
involvement in cell proliferation, survival and migration. It signals
through many pathways, including the Ras-RAf-MEK-ERK and MAPK
pathways in proliferation, is activated by PI-3 kinase/Akt pathway to
promote survival and also interacts with FAK, PI3Kinase/Akt and MAPK
signalling to regulate migration (Zachary and Gliki, 2001).
VEGF gene expression is upregulated by hypoxia and also by
transforming growth factor-β, angiotensin II and basic fibroblast growth
factor in VSMCs (Ferrara and Bunting, 1996). Additionally, VEGF is
upregulated in rat VSMCs following cyclic strain (Shyu et al., 2001). A
study by Inoue, et al. (1998) identified VEGF expression in human
coronary atherosclerotic lesions (Inoue et al., 1998). Also, expression of
VEGF is upregulated in mechanically injured arteries removed from
healthy rats (Tsurumi et al., 1997). Several agonists, such as thrombin,
have been shown to release VEGF in VSMC, which may help repair of
damaged endothelium following injury (Bassus et al., 2001).
The Notch and VEGF pathway are known to crosstalk in the
modulation of arteriogenesis and angiogenesis in zebrafish (Lawson et al.,
2002). Similarly, in humans, Notch1 and Dll4 are regulated by vascular
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endothelial growth factor in human arterial endothelial cells (Liu et al.,
2003) The VEGF-induced specific signalling is mediated through VEGF
receptors 1 and 2 and is transmitted via the phosphatidylinositol
3-kinase/Akt pathway but is independent of mitogen-activated protein
kinase and Src tyrosine kinase (Wu and Bresnick, 2007). The crosstalk
between the Notch and VEGF pathway in VSMCs has yet to be explored
and may contribute to the changes in cell fate apparent in atherosclerosis,
the arterial response to injury and other vascular disease.
GSK-3β and Vascular Disease
In the absence of Wnt signalling, β-catenin has been shown to be
phosphorylated by GSK-3β binding, thereby marking β-catenin for
proteosomal degradation. This can be seen in a similar manner in Hh
signalling in Drosophila. Shaggy, the Drosophila form of GSK-3β, again
in the absence of ligand binding, phosphorylates Ci, the Drosophila form
of Gli resulting in its degradation. As discussed previously, GSK-3β has
also been shown to be a possible modulator of Notch signalling in a
number of cell types, through phosphorylation of the active receptor. It is
becoming apparent that GSK-3β is a multi-faceted enzyme, critical in
many signalling events. It is tempting, therefore, to speculate that
GSK-3β may be involved in the recapitulation of signalling pathways in
adult vascular cells, resulting in altered cell fate decisions, leading to
vascular disease. Studies have shown that the Hh and Notch pathway are
important in these altered cell fates and therefore these signalling
pathways are of particular interest in identifying GSK-3β as a player in
vascular diseases such as arteriosclerosis, atherosclerosis, stroke and
heart failure.
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1.6 Summary and Rationale
Cell growth, the balance between proliferation and apoptosis, is
important in both vascular development, and maintenance of
homeostasis within the adult vasculature. Dysregulation of either cell
proliferation or apoptosis, however, is a common response to vascular
injury, contributing to the progression of vascular disease states, such as
hypertension and atherosclerosis.
The Notch signalling pathway has previously been implicated in
several aspects of vascular development, including arterio-venous
differentiation, angiogenic processes, and in the regulation of
developmental VSMC fate decisions (Proweller et al., 2005). In addition,
genetic disorders such as CADASIL (cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy) and
Alagille Syndrome demonstrate a crucial role of the Notch pathway in
vascular development. Notch has been shown to be pro-proliferative in
vascular smooth muscle cells (Morrow et al., 2005a) and to be modulated
by both biomechanical stimuli in vitro and following vascular injury in
vivo (Morrow et al., 2005a), (Wang et al., 2002).
Notch signalling is regulated on many different levels, including
post-translational modification of the Notch receptor. Phosphorylated
forms of Notch have been identified in the nucleus (Foltz and Nye, 2001)
and GSK-3β has been suggested as a possible regulator responsible for
NotchIC phosphorylation (Espinosa et al., 2003). Crosstalk with the Hh
signalling pathway has also been implicated in the highly complex
regulation of Notch signalling. Indeed, Shh is known to up-regulate the
expression of Notch target genes during arterial differentiation and
vascular endothelial growth factor (VEGF) acts downstream of Shh and
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upstream of the Notch pathway (Lawson et al., 2002).
The principal aims of this study, therefore, are to establish the
presence and activity of GSK-3β within VSMCs and determine the effect,
if any, of this kinase on Notch signalling in VSMCs in both a static and
cyclic strain environment. We aim to establish a role for Hh signalling in
the regulation of Notch in VSMCs and determine the role of GSK3β in
this signalling crosstalk. We also aim to establish a role for GSK-3β in the
Notch regulation of VSMC growth. In addition, in vivo models of altered
biomechanical force are used as an in vivo correlation of the in vitro
findings of alterations in GSK3β and Notch signalling pathway
expression due to changes in cyclic strain. This study aims to provide
increased understanding into the regulation of cell growth in VSMC, both
under physiological and pathological conditions. It aims to provide new
insights into the molecular mechanisms involved in conditions such as
hypertension and atherosclerosis and thereby, aid the development of
potential therapeutic targets in the field of cardiovascular disease.
The findings of this research project has been divided into three results
chapters with the following objectives:
Chapter 3:
The aim of this chapter is to examine the role of GSK-3β in Notch signalling
in RVSMCs.
Chapter 4:
The aim of this chapter is to examine the role of GSK-3β in the regulation of
Notch at the level of crosstalk with another developmental pathway, the Hh
pathway and to identify the role of GSK-3β in Notch-dependent changes in
RVSMC growth.
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Chapter 5:
The aim of this chapter is to identify a role for GSK-3β in the Notch response
to cyclic strain and to further elucidate the mechanism involved.
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Chapter 2
Materials and Methods
2.1 Materials
All reagents used in this study were of the highest purity commerically
available and were of cell culture standard when applicable. See appendix
for full list of materials.
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2.2 Enabling Technologies
Figure 2.1: Summary of Methods.
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2.2.1 Cell Culture
All cell culture techniques were carried out in a clean and sterile
environment using a Bio air 2000 MAC laminar flow cabinet. Cells were
visualized using an Olympus CK30 phase contrast microscope. The cell
line used in this study were RVSMCs, purchased from Cell Applications
Inc.(CA, USA) Cat No. R-354-05. The cells were grown in RPMI-1640,
supplemented with 10% foetal calf serum (FCS), and 1%
penicillin/streptomycin (P/S), and were maintained in a 37oC
humidified atmosphere of 5%CO 2/95% air in a Hera water jacketed cell
culture incubator. The cells were cultured in 175cm2 , 75cm2 , 25cm2 and
six-well plates and were routinely fed every 3-4 days. Passages 5-15 were
used for experimentation and sub-culturing of cells was carried out at
80-90% confluency by trypsinisation. Cells were washed in sterile
phosphate-buffered saline and incubated in 2x Trypsin/Ethlyenediamine
Tetracetic Acid (EDTA), diluted from the 10x stock solultion with PBS for
5 min at 37oC. A volume of 1 ml of 1x Trysin/EDTA was used per 25 cm2
tissue culture flask area. An equal volume of RPMI-1640 media containg
10% foetal calf serum (FCS), and 1% penicillin/streptomycin (P/S) was
then added to the cells to stop the trypsination process. The cell
suspension was centrifuged at 300 g for 5 min. Cells were seeded at a
density of 1 x 105 cells/cm2.
2.2.2 Cryogenic Cell Storage and Recovery of Cells.
The RVSMCs were maintained long-term in liquid nitrogen in a
cryofreezer unit. Cells to be frozen were trypsinised from the flask, spun
down in serum-containing media for 5 min at 300 g, and the pellet was
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resuspended in 20% (v/v) FBS containing dimetylsulphoxide (DMSO) at
a final concentration of 10% (v/v). 1ml of suspension was then
transferred to sterile cryovials and frozen at 80oC freezer at a rate of
1oC/minute using a Nalgene cryo freezing container. Cells were
recovered from longterm storage by rapid thawing at 37oC and
resuspension in 5ml of growth medium followed by centrifugation at 300
x g for 5 min. The resultant cell pellet was resuspended in fresh medium
and transferred to a culture flasks. The following day the media was
removed, the cells were washed in PBS and fresh culture media added.
2.2.3 Cyclic Strain
For cyclic strain studies, RVSMCs were seeded into 6-well Bioflex plates
(Dunn Labortechnik GmBH - Asbach, Germany) at a density of
approximately 1 x 105 cells/well. When the cells had reached 80%
confluency, the cells were exposed to cyclic strain. BioflexTM plates
contain a pronectin-coated silicon membrane bottom that enables precise
deformation of cultured cells by microprocessor-controlled vacuum
(Gilbert et al., 1994) (Figure 2.2). A Flexercell Tension PlusTM FX-4000TTM
system (Flexcell International Corp., Hillsborough, NC) was employed to
apply a physiological level of cyclic strain to each plate (0-15% strain, 60
cycles/min, 0-24 h) providing equibiaxial tension using the HearbeatTM
Simulation protocol. Control cells remained unstrained. Following strain,
the cells were washed twice in I x PBS, and either protein or RNA
samples were isolated as described in sections respectively.
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Figure 2.2: Flexercell Tension Plus TM Induction of Cyclic Strain
2.2.4 Stented Sylgard R©Mock Coronary Artery
A study on a stented mock coronary artery was carried out in
collaboration with Dr. Alberto Colombo (School of Engineering, DCU).
Samples of bovine aortic vascular smooth muscle cells (BASMCs) on a
perfused stented mock coronary artery were prepared by Dr. Colombo,
using the procedure outlined below. Mock coronary arteries (MCAs)
were manufactured from transparent Sylgard R© 184, a silicon elastomer.
Following coating with fibronectin,. BASMCs were seeded onto the
MCA. A bare metal stent (BMS) (provided by Medtronic Ave) was
deployed inside the MCA by means of a Basix 25 angioplasty inflation
syringe (Merit Medical Systems, South Jordan, Utah) and expanded by a
9 mm angioblasty balloon catheter. The stented MCA was then placed
into a culture chamber containing 100ml of RPMI 1640 media
supplemented with 10% FBS and primocin antibiotic (100µg/ml)
(Amaxa, MD, USA). The culture chamber consisted of a biocompatible
Plexiglas R© open box with an inlet and outlet for medium perfusion of
the MCA (Figure 2.3).
The culture chamber was then attached to a CellMax R© bioreactor
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Figure 2.3: Mock Stented Artery in Culture Chamber.
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tubing system (Figure 2.4). The BASMCs were exposed to pulsatile flow
for 7 days, following which the mock coronary artery was removed and
analysed. See appendix 4 for a detailed protocol.
Figure 2.4: Schematic of Stented MCA Bioreactor System (Courtesy of
Alberto Columbo)
2.2.5 Carotid Artery Ligation
The left carotid arteries of male C57B16/J mice (Charles River
Laboratories, Massachusetts, USA) were ligated, with the right carotid
artery acting as a high flow control. Anesthesia was induced in animals
pre-medicated with atropine sulphate (0.04 mg/kg, intra-muscular)
through administration of pentobarbital sodium (50 mg/kg,
intra-peritoneal) and halothane (inhalation). Following induction of
anesthesia, the animal was positioned on a clean operating table, with a
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Figure 2.5: Flow-Induced Remodelling in a mouse carotid ligation
model. The left panel indicates the ligation site. The middle and right panel
show hamotoxylin/eosin and α-actin staining in a remodelled ligated carotid
artery 14 days post-ligation compared to sham control.
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body pad to maintain body temperature. The animal was clipped and the
surgical site prepped using betadine solution and alcohol. A midline
cervical incision was made, and, with the aid of a dissecting microscope,
the right and left common carotid arteries were isolated. A transonic
flowprobe was used to measure carotid blood flow in both the left and
right arteries. The left common carotid artery was ligated near the carotid
bifurcation using a 6-0 silk suture. The incision was then closed using 4-0
coated Vicryl, running suture pattern. The animal was then allowed to
recover, whilst being monitered. Sham operated animals were subjected
to the same surgical techniques, with the exception of the carotid artery
ligation. Vessels were harvested from sham operated and ligated animals
at 3 days and 14 days post-ligation for RNA isolation (4 vessels per
preparation), and tissue imaging (Figure 2.5). Terminal surgery was
carried out by halothane inhalation and cervical dislocation, followed by
harvesting of the carotid arteries.
2.2.6 Human Arteriosclerotic Tissue
Human arteriosclerotic cDNA and its matched non-arteriosclerotic cDNA
was purchased from Biochain (Hayward, CA, USA).
2.3 DNA Manipulations
2.3.1 Expression and Reporter Plasmids
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Table 2.1: Expression and Reporter Plasmids
Plasmid Source Description
pcDNA3HA Dr.Jim Woodgett, HAVTHUGSSK3β expresses the
HACTHUGSK3β Samuel Lenfeld wild type form of the plasmid.
pcDNA3GSK3βCTA9GOOD Research Institute, pcDNA3GSK3βCTA9GOOD
Toronto, Canada. expresses a mutant form of GSK3β,
where the serine from position
9 has been replaced by an alanine,
forming a constitutively active
form of the enzyme.
pcDNA3GSK3βK85M Dr.Eileen Redmond, pcDNA3GSK3βK85M expresses a
Dept. of Surgery, mutant form of GSK3β, where
University of the lysine at position 85 has been
Rochester, replaced by a methionine, forming
Rochester, New York. a dominant negative form of the enzyme.
pGa50-7 Dr. Bettina Kempes, THe pGA98-1-6 reporter construct
pGa98-1-6 GSF-Institute of was generated using a 50-bp
Clinical Molecular oligonucleotide harboring both
Biology, CBF-1 binding sites of the EBV
Neuherberg, TP1 promoter, which was then
Germany. ligated as a hexamer into plasmid
pGA50-7 (Minoguchi et al., 1997).
pPGKpuro Dr. Peter Laird, Puromycin resistance plasmid
University of (Tucker et al., 1996).
Southern California,
Kerk School of
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Plasmid Source Description
Medicine,
Los Angeles,
California, USA.
pCMVLacZ Dr. Dermot Walls, Expresses the gene encoding
Dublin City β-galactosidase.
University,
Ireland.
2.3.2 Transformations
DH5α chemically competent cells were purchased from Invitrogen. A
volume of 50µl of the competent cells were placed in a sterile eppendorf.
Following quantification of plasmid DNA, 50ng of DNA was added to
the cells and the contents of the tube were mixed gently. The tube was
then placed on ice for 30 min, before being heat shocked at 42oC for 90 s.
The tube was then placed on ice again for 2 min. 1ml of sterile SOC
medium (20% tryptone, 5% yeast extract, 0.5% NaCl, 1% 0.25M KCl, 2% 1
M glucose) was then added to the tube, and the tube was incubated at
37oC for 1 h. The tube was then centrifuged for 2 min at 100 x g and the
pellet was then resuspended in 100µl of SOC medium. The culture was
then plated out on LB agar plates containing 100µg/ml ampicillin and
incubated overnight at 37oC. Non-transformed competent cells were also
plated out as a negative control. Only transformed colonies contain the
ampicillin resistance gene, and therefore grow on the
ampicillin-containing agar plates. A single colony, therefore, was
transferred to a 50ml sterile tube containing 5mls of LB broth (1%
tryptone, 0.5% yeast extract, 1.0% NaCl). This primary culture was then
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incubated at 37oC with agitation of 200 rpm for 8h. 400µl of the culture
was transferred to a 250ml sterile conical flask containing 50mls broth
and incubated overnight at 37oC with agitation of 200 x g. DNA
minipreparation were then carried out on this secondary culture as
described in Section 2.3.3. The remainder of the 5ml primary culture was
used for glycerol stocks.
2.3.3 QIAGENTMPLASMID DNA PURIFICATION
PROTOCOL
Plasmid DNA was purified using the QIAGEN-tip HiSpeed R© system
from Promega, according to the manufacturer’s instructions for plasmid
purification of animal cells. DNA was then quantified by
spectrophotometric analysis as described in section 2.3.4.
2.3.4 DNA Quantitation and Storage
To determine the amount of DNA in a sample obtained from the Qiagen
plasmid midi kit, the sample was analysed using a NANODROP 1000
Spectrophotometer (Thermo Scientific) blanked with TE. The sample was
read at wavelengths of 260 and 280 nm, and the concentration of the
DNA in the sample was calculated out as follows;
Abs260nm x dilution factor x 50 = concentration of DNA (µg/ml)
The purity of the DNA was determined by calculating the ratio of
absorbance at 260 nm to 280 nm, the value of which should be greater
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than 1.6. All samples were tested in triplicate and were kept on ice at all
times during the experiment. DNA samples were then stored at 20oC for
use in transient transfections.
Figure 2.6: Sample Nanodrop Readout for Plasmid Quantification
2.3.5 Transient Transfections
NucleofectionTM is a transfection method based on the physical method
of electroporation. NucleofectionTM uses a combination of optimized
electrical parameters, generated by a special device called
Nucleofector R©, with cell-type specific reagents. Rat aortic smooth muscle
cells were transiently transfected using a Basic Nucleofector R© Kit for
Primary Smooth Muscle Cells (SMC) from Amaxa. Cells were transfected
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with plasmid DNA at no greater then 80% confluency. Cells were
trypsinised as previously described in section 3.1.1 and counted to
determine the cell density. A volume containing 1 x 106 cells was used
per transfection. The cells were centrifuged at 300 x g for 5 min, The
pellet was resuspended in room temperature Basic Smooth Muscle
Nucleofactor Solution to a final concentration of 1 x 106 cells/100µl. 100µl
of cell suspension was mixed with a total of 3µg DNA. The nucleofection
sample was then transferred to a amaxa cuvette. The cuvette was inserted
into the cuvette holder of the Nucleofector and the appropriate
Nucleofector program was selected. After the programme was finished,
the cells were transferred from the cuvette, into an eppendorf tube and
500µl of pre-warmed culture medium containing serum and supplements
was added. The eppendorf tube was then incubated at 37oC, until all
transfections were completed. The samples were then transferred from
the eppendorf tubes into 6-well plates containing 1ml of culture medium
with serum and supplements (3 wells/sample). The cells were then
incubated at 37oC and the medium changed 16-18h post nucleofection.
Cells were routinely co-transfected with either a β-gal or green
fluorescent protein (GFP) encoding plasmid as a means to determine
approximate levels of transfection.
2.3.6 Small-interfering RNA Technolology
Small-interfering RNAs (siRNAs) are 20-25 nucleotide-long
double-stranded RNA molecules, which have the ability to interfere with
the expression of a specific gene through the RNA interference (RNAi)
pathway. RNAi is a protecting mechanism against invasion by foreign
genes and has been demonstrated in diverse eukaryotes such as insects,
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plants, fungi and vertebrates. RNAi is the mechanism of
sequence-specific, post-transcriptional gene silencing initiated by
double-stranded RNAs (dsRNA) homologous to the gene being
suppressed (Scherr et al., 2003). In the cell, long dsRNAs are cleaved into
short 21-25 nucleotide small interfering RNAs, or siRNAs, by a
ribonuclease known as Dicer. The siRNAs subsequently assemble with
protein components into an RNA-induced silencing complex (RISC),
unwinding in the process. Activated RISC then binds to complementary
transcript by base pairing interactions between the siRNA antisense
strand and the mRNA. The bound mRNA is cleaved and sequence
specific degradation of mRNA results in gene silencing (Figure 2.7).
An siRNA sequence against VEGF-A was designed as follows. A
sequence was selected in the open reading frame of the cDNA which was
at least 75-100 bp downstream of the start codon. This region was chosen
as untranslated regions near the start codon may be richer in regulatory
protein binding sites, which may interfere with binding of the siRNP
endonuclease complex. An AA dimer was located and the next 19
nucleotides was recorded, such that the G/C content of the AA-N19 base
was greater than 30% and less than 70%. Following this, the 21 base
sequence was subjected to a blast search to ensure that only one gene is
targeted. The siRNA sequence was then purchased from MWG-BIotech.
A commercially designed siRNA sequence against GSK-3β was
purchased from Applied Biosystems. The siRNA sequences were
transfected into RVSMCs as described in the previous section and a
commercially available non-specific control siRNA sequence
(MWG-Biotech) was transfected into control cells. Knockdown of target
proteins was verified by western blotting.
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Figure 2.7: The Mechanism of small-interfering RNA (siRNA).
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Table 2.2: siRNA Sequences
Target Gene Sequence of siRNA Duplex GC Content Mol. Weight
% (g/mol)
GSK3β GG CCA CAG GAA GUC AGUUAtt 48 13340
VEGF AA GUU CAU GGA CGU CUA CCA G 52 13220
Control GGA GAU UUA CGA AAC AAU ATT 28.6 13255
2.3.7 β-galactosidase Assay
A Lac Z plasmid encoding β-galactosidase was used to monitor
transfection levels. Increased levels of β-galactosidase activity was
attributed to successful transfection of the gene of interest.
β-galactosidase activity was analysed using a β-galactosidase assay kit
(Stratagene) Following transfection and cell lysis, 20µl sample was added
to a well of a 96-well plate.130µl of 1 x CPRG was added to the sample.
The reaction was incubated for 30 min up to 72 h at 37oC until the sample
turned dark red. The reaction was subsequently stopped with 80 µl of
Stop Solution (Stratagene) and optical density read at 570-595nm.
Suitable positive and negative controls were included in this assay.
2.3.8 Puromycin Selection
Alternative to transfection with a Lac Z gene, cells were co-transfected
with pPGK-puromycin plasmid, which offers puromycin resistance to
any transfected cells. Following overnight recovery untransfected cells
were selected out with treatment of cells in RPMI-1640 supplemented
with 10% FCS, 100 U/ml penicillin and 100 ug streptomycin, and 2µg/ml
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puromycin for 48 h.
2.4 Analytical Methods
2.4.1 Luciferase Assay
To analyse transactivation of luciferase tagged reporter genes, cells were
harvested 24 h post transfection. The cells were washed twice in 1 x PBS.
100 µl of 1x reproter lysis buffer (Promega) was added to each well and
the cells were harvested by scraping. The samples were transferred to
eppendorf tubes and were freeze thawed once. The lysates were
centrifuged at 270 x g for 2 min. A volume of 40µl of sample was then
added with 50µl of luciferase assay buffer (Promega) to a well of a white
96-well plate (Thermofisher Scientific) at room temperature. Light
emission was measured over a period of 60 s after a lag period of 10 s by
a luminometer (Labsystems Luminoskan). This light emission is a photon
of light produced due to promoter activation on a luciferase tagged
plasmid. The promoter activation causes the generation of the enzyme
luciferase, which catalyses the conversion of D-luciferin to oxyluciferin
thereby producing a photon of light.
2.4.2 SDS-PAGE and Western Blot Analysis
Preparation of Whole Cell Lysates
Cells were washed in 1 x PBS and then 100µl/cm2 1X RIPA lysis buffer
(20mM Tris, 150mM NaCl; 1mM Na2EDTA; 1mM EGTA; 1% Triton X-100
(v/v); 2.5mM sodium pyrophosphate; 1mM β-glycerophosphate; 1mM
sodium orthovanadate; 1µg/ml leupeptin) supplemented with
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protease-phosphatase inhibitor cocktails (1/100 dilution of stock, Sigma
Aldrich) was added to the cells. The cells were then scraped into the lysis
buffer using a cell scraper and transferred to an eppendorf. The lysates
were spun for 1hr at 4oC and centrifuged at 15, 700 x g for 20min.
Samples were stored at -20oC for short-term storage or -80oC for
long-term storage.
Bicinchoninic Acid (BCA) Protein Microassay
The bicinchoninic acid protein microassay utilizes the biuret reaction, the
reduction of Cu++ to the cuprous cation (Cu+) by protein under alkaline
conditions, with the selective colourimetric detection of Cu+) using a
reagent containing bicinchoninic acid. Bicinchoninic acid, sodium salt, is
a stable, water-soluble compound capable of forming an intense purple
complex with cuprous ion (Cu+) in an alkaline environment.This
water-soluble complex exhibits a strong absorbance at 562 nm that is
linear with increasing protein concentrations over a broad working range
of 20-2000 µg/ml. The two separate reagents used were supplied in the
commercially available assay kit (Pierce Chemicals): A, an alkaline
bicarbonate solution and B, a copper sulphate solution. A working
solution was prepared by mixing 1 part reagent B with 50 parts reagent
A. On a microtitre plate 200µl of the working solution was added to 10 µl
of the whole cell lysate or bovine serum albumin (BSA) protein standard.
The plate was then incubated at 37oC for 30 min. The absorbance of each
well was then read at 560 nm using a Tecan Spectra plate reader. All
samples and standards were tested in triplicate. Quantitation was carried
out by interpolation from a BSA standard curve (0-2 mg/ml).
88
Western Blotting
SDS-PAGE was performed as described by Laemmli using 10%
polyacrylamide gels (Laemmli et al., 1970). 10% resolving and 5%
stacking gels were prepared as follows:
Resolving Gel:
2.5
2.5
4.7
100µl
50µl
10µl
Buffer A (1.5M Tris pH8.8)
40% acrylamide stock
distilled water
10% (w/v) SDS
10% (w/v) ammonium persulphate
TEMED
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Stacking Gel:
0.75ml
0.75ml
3.25ml
50µl
25µl
7.5µl
Buffer B(0.5M Tris pH6.8)
40%acrylamide stock
distilled water
10%(w/v) SDS
10%(w/v) ammonium persulphate
TEMED
For analysis of cell lysate protein concentration was determined by
BCA assay and a equal amounts of protein were resolved on the gel.
Samples were mixed with 4X loading buffer (8% SDS, 20%
β-mercatoethanol, 40% glycerol, Brilliant Blue R in 0.32M Tris pH6.8) and
boiled at 95oC for 5 min, then immediately placed on ice. The gel was
electrophoresed in reservoir buffer (0.025M Tris pH 8.3; 0.192M Glycine;
0.1% (w/v) SDS) at 100V per gel using an Atto vertical
mini-electrophoresis system until the dye front reached the bottom of the
gel. Following electrophoresis the gel was soaked for 15 min in cold
transfer buffer (0.025M Tris pH8.3; 0.192M Glycine; 15% v/v methanol).
Nitrocelluose membrane and 12 sheets of Whatmann filter paper were
cut to the same size as the gel and soaked in transfer buffer. Proteins were
transferred to the membrane for 80 min at 125V in an ATTO semi-dry
transfer system. Following transfer membranes were soaked in Ponceau
S solution to confirm transfer of protein to the membrane and also to
normalize for variations in protein loading. Ponceau stains all transfered
bands of proteins red (Figure 2.8). Membranes were blocked for a
minimum of 1h in blocking solution [5% BSA- PBS-1%Tween].
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Membranes were then incubated overnight at 4oC with the appropriate
dilution of primary antibody in blocking solution (Table 2.3). The blots
were then vigorously washed in three changes of PBST and then
incubated for 2 h at room temperature with a suitable HRP linked
secondary antibody diluted in PBST. Following incubation in secondary
antibody, the blots were again washed in three changes of PBST.
Antibody-antigen complexes were detected by incubation in West Pico
Supersignal reagent (Pierce Chemicals). Briefly, an equal volume of
solution A and B were mixed and the blot was incubated for 5 min at
room temperature. Blots were exposed to autoradiographic film
(Amersham Hyperfilm ECL) to visualize bands present on the blot and
developed (Amersham Hyperprocessor Automatic Developer)
(Figure 2.9). Bands of interest were identified by use of molecular weight
markers. Exposure times varied depending on the antibody being used
but were typically between 1-5 min.
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Figure 2.8: Sample Ponceau Stain.
Figure 2.9: Sample Western Blot: Notch3 IC in RVSMCs
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Antibody Dilutions
Table 2.3: Antibody Dilutions
Primary Antibody Dilution Secondary Antibody Dilution
Anti Notch 1 1:1000 HRP-Conjugated Anti-rabbit IgG 1:1000
(Upstate) (Amersham Biosciences)
Anti Notch 3 1:1000 HRP-Conjugated Anti-rabbit IgG 1:1000
(Upstate) (Amersham Biosciences)
Anti HRT 1 1:500 HRP-Conjugated Anti-goat IgG 1:1000
(Santa Cruz) (Sigma)
Anti HRT 2 1:500 HRP-Conjugated Anti-goat IgG 1:1000
(Santa Cruz) (Sigma)
Anti HRT 3 1:500 HRP-Conjugated Anti-goat IgG 1:1000
(Santa Cruz) (Sigma)
Anti Patched 1:500 HRP-Conjugated Anti-goat IgG 1:1000
(Santa Cruz) (Sigma)
Anti VEGF 1:500 HRP-Conjugated Anti-rabbit IgG 1:1000
(Oncogene) (Amersham Biosciences)
Anti GSK3β 1:1000 HRP-Conjugated Anti-rabbit IgG 1:1000
(Alexis) (Amersham Biosciences)
Anti phospho-GSK3β 1:1000 HRP-Conjugated Anti-rabbit IgG 1:1000
(Cell Signal) (Amersham Biosciences)
Anti p38 1:1000 HRP-Conjugated Anti-rabbit IgG 1:1000
(Cell Signal) (Amersham Biosciences)
Anti phospho-p38 1:1000 HRP-Conjugated Anti-rabbit IgG 1:1000
(Calbiochem) (Amersham Biosciences)
Anti p44/42 1:1000 HRP-Conjugated Anti-rabbit IgG 1:1000
93
Primary Antibody Dilution Secondary Antibody Dilution
(Cell Signal) (Amersham Biosciences)
Anti phospho-p44/42 1:1000 HRP-Conjugated Anti-rabbit IgG 1:1000
(Cell Signal) (Amersham Biosciences)
Anti HA-HRP 1:1000 (NA) (NA)
(Roche)
Anti α-SMC actin 1:1000 HRP-Conjugated Anti-mouse IgG 1:1000
(Sigma) (Amersham Biosciences)
2.4.3 Polymerase Chain Reaction(PCR)
Preparation of Total RNA
Total RNA was isolated from RVSMCs using Trizol R© reagent according
to the method of Chomczynski and Sacchi (1987). The reagent, a
mono-phasic solution of phenol and guanidine isothiocyanate, maintains
the integrity of RNA while disrupting cells and dissolving cell
components. Growth media was removed and cells were washed with
PBS twice. Cells were then lysed directly by adding trizol reagent to the
flask, 1 ml per 10 cm2. The lysate was transferred to a sterile falcone tube
and incubated for 5 min at 15-30oC to permit the complete dissociation of
nucleoprotein complexes. Chloroform was added at a concentration of
0.2 ml of chloroform per 1 ml of trizol, the tube was then shaken
vigorously for 15 s and then spun down at 12,000 x g for 15 min at 2 to
8oC. The resulting aqueous phase was then transferred to a fresh tube.
RNA was then precipitated by mixing with isopropyl alcohol, 0.5 ml per
1 ml of trizol. The samples were then incubated at 15oC to 30oC for 10
min and spun down at 12,000 x g for 10 min at 2 to 8oC. The RNA was
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then visible as a gel like pellet on the side and bottom of the tube. The
supernatant was then removed and the pellet washed with at least 1ml of
75% ethanol per 1 ml of trizol used. The sample was then mixed by
vortexing and spun down at 7,500 x g for 5 min at 2 to 8oC. The
supernatant was removed and the pellet washed again in ethanol. After
washing the pellet was air-dried and the RNA re-suspended in 30-50µl of
RNase free water and incubated at 60oC for 10 min. All total RNA
preparations were stored at -80oC.
Quantification of Total RNA in Samples
To determine the amount of total RNA in samples, the sample was
analysed using a Nanodop 1000 Spectrophotomoter (Thermo Scientific)
blanked with RNase free water. 1.5µl of sample was measured at
wavelengths of 260 and 280 nm, and the concentration of the RNA in the
sample was determined as follows;
Abs260nm x dilution factor x 40 = concentration of RNA (µg/ml)
The purity of the RNA was determined by calculating the ratio of
absorbance at 260nm to 280nm. A ratio of 1.9 to 2.0 was indicative of a
highly purified preparation of RNA. A ratio lower than this was
indicative of protein contamination. Absorbance at 230 nm reflected
contamination of the sample by phenol, while absorbance at 325 nm
suggests contamination by particulates. All samples were tested in
triplicate and were kept on ice at all times during the experiment. RNA
samples were then stored at -80oC.
95
Design of PCR Primer Sets
A number of web based programs, Primer 3 Output and NCBI/BLAST
were utilized to design the primer sets used in this study (Table 2.4). The
Primer 3 program picks primers from the given sequence, and the BLAST
program allows multiple sequence alignment, which allows primers to be
designed from highly conserved areas. Primers were designed with 50%
GC content so the annealing temperature for all sets was 55-60oC.
Table 2.4: Primer Sequences
Target Gene Primer Sequence Annealing Product Size
Temp. (oC) (bp)
GSK3β for 5’ GGATCTGCCATCGAGACATT 3’ 60 169
(rat) rev 5’ GTGGCTCCAAAGATCAGCTC 3’
HRT 1 for 5’ CTGGACGAGACCATCGAGG 3’ 55 181
(rat) rev 5’ GCAGCATTTTCAGGTGATCCAC 3’
HRT 2 for 5’ CTGCACACAGCTTCCCTCTGTC 3’ 55 154
(rat) rev 5’ CTCCAACTTCTGTCCCCCAGGG 3’
HRT 3 for 5’ CGCAGAGGGATCATAGAGAAAC 3’ 55 133
(rat) rev 5’ CAGGGCTCGGGCATCAAAG 3’
Patched 1 for 5’ GCTGGAGGAGAACAAGCAAC 3’ 60 164
(rat) rev 5’ CCAGGAGTTTGTAAGCGAGG 3’
Gli 2 for 5’ CGCCTGGAGAACTTGAAGAC 3’ 60 168
(rat) rev 5’ TTCTCATTGGAGTGAGTGCG 3’
VEGF for 5’ AATGATGAAGCCCTGGAGTG 3’ 60 192
(rat) rev 5’ GCATTGCTGACAATCTTGAC 3’
GAPDH for 5’ TGCTGACTATGTCGTGGAGT 3’ 60 176
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Target Gene Primer Sequence Annealing Temp. Product Size
Temp. (oC) (bp)
(rat) rev 5’ GCATTGCTGACAATCTTGAC 3’
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
All total RNA samples were prepared by the Trizol method as previously
described in Section 2.6.1. RNA preparations were then quantified by
absorbance spectroscopy as described in Section 2.6.2. Reverse
transcriptase was carried out using an iScriptTM cDNA Synthesis Kit
according to the manufacturer’s instructions. Briefly, 2µg of RNA was
added to 1µl of reverse transcriptase enzyme and 4µl of 5x buffer in a
PCR tube. RNase and DNase free H2O was then added to make a total of
20µl sample volume. The tubes were centrifuged briefly, and placed in a
PCR Sprint thermocycler (Thermo Hybaid) and the following
programme was run: 25oC for 5 min, 42oC for 30 min, 85oC for 5 min.
The samples were then stored at -20oC and used for real-time PCR as
described in Section 2.6.5.
Real-Time PCR
Quantitative PCR was carried out using a Real time
Rotor-GeneRG-3000TM lightcycler (Corbett Research). The principle of
real time amplification detection is that the amount of fluorescence is
proportional to the concentration of product in a reaction. Higher
fluorescence indicates a higher concentration of a product. Each PCR
reaction was set up as follows:
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SYBR-Green
RNAse free water
cDNA
Forward primer(10µM)
Reverse primer(10µM)
12.5µl
8.5µl
2.0µl
1.0µl
1.0µl
Each sample was assayed in triplicate, and the program used for the
different primer sets was as follows;
Denaturing Phase
Annealing Phase
Elongation Phase
95oC - 20s
55-60oC - 30s (55 cycles)
72oC - 30s
The Comparative Ct method was used for quantitative analysis
(Figure 2.11) while Melt Curve analysis was carried out for qualitative
analysis.
Agarose Gel Electrophoresis
All DNA gel electrophoresis was carried out using a GibcoBRL Horizon
20.25 Gel Electrophoresis Apparatus. Before use the gel box was cleaned
with ethanol and the gel cast was set up as described in the
manufacturers instruction manual. A 2.5% agarose gel stock was made
up by dissolving 2.5 g of agarose in 100 ml of 1x Tris Acetate EDTA (TAE)
(40 mM Tris-Acetate, 1 mM EDTA). The agarose was dissolved by heating
in a microwave (700 mHz) at full power for 5 min. The agarose was then
poured into the cast, the comb put into place and the gel allowed to set.
Once set the comb was removed and the apparatus filled with 1x TAE
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Figure 2.10: Sample Amplification Curves: Patched 1 and GAPDH in
RVSMCs
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Figure 2.11: Sample Readout of Ct Values
buffer. Loading dye was added to the sample (17µ of loading dye to 6µl
of sample). 10µl was then loaded to each well in duplicate. The gel was
run at 80 V, 110 mA and 150 W until the dye front had migrated the
length of the gel. The gel was stained in a 2mg/L ethidium bromide
staining bath for 10-15 min, and then placed on an Ultra Violet Products
UV transilluminator for visualization. A picture was taken using a Kodak
DC290 digital camera. The gel was then disposed of in the appropriate
EtBr waste container.
2.4.4 Immunocytochemistry
Cells were washed in PBS and fixed with 0.3% formaldehyde for 15 min
at room temperature. Cells were washed twice in PBS and permeabilised
with 0.025% Triton-X-PBS. Cells were washed twice in PBS and blocked
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in 5% BSA- PBS-1% Tween for 1 h at room temperature and incubated
overnight with the appropriate primary antibody at 4oC. Cells were
washed twice for 15 min in PBS-1%Tween and incubated in the
appropriate secondary antibody for 30mins in the dark. Following, two
15 min washes in PBS, cells were visualised using the Olympus DP-50
fluorescent microscope (excitation 460-490 nm, emission 515-565 nm)
(Figure 2.12).
Figure 2.12: Sample Image using Immunocytochemistry: α-smc actin in
RVSMCs.
2.4.5 Cell Count
To analyze RVSMC proliferation, cells were seeded equally at a density of
1 x 103 cells per well after serum deprivation for 48 h. Cells were then
counted using a Sigma Brightline Haemacytometer after 5 days where the
average of 3 wells was observed. Furthermore, in parallel experiments
protein lysates were extracted and proliferating cell nuclear antigen
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(pCNA) expression was determined by western blot analysis as described
in Section 2.5.1.
2.4.6 Flow Cytometry
Flow cytometry is a method for counting, and sorting microscopic
particles suspended in a stream of fluid. FACSTM (Fluorescent Activated
Cell Sorting) is a specialised type of flow cytometry that measures the
amount of light emitted by fluorescent molecules associated with
individual cells. Lasers are used to excite the fluorescent molecules,
which are excited at one range of wavelengths and emit at a second
range. Filters in front of each of a series of detectors restrict the light that
reaches the detector to only a small range of wavelengths (Tung et al.,
2007). Examples of the fluorescent molecules that can be detected are
Annexin V, which is described in Section 2.7.3 and is used to measure the
number of apoptotic cells in a cell suspension and carboxy-fluorescein
diacetate succinimidyl ester (CFDA,SE), which can be used to measure
proliferation.
Proliferation
Carboxy-fluorescein diacetate succinimidyl ester (CFDA,SE) is a colorless
and nonfluorescent dye which passively diffuses into cells. Its acetate
groups are cleaved by intracellular esterases to yield highly fluorescent,
amine-reactive carboxyfluorescein succinimidyl ester. The succinimidyl
ester group reacts with intracellular amines, forming fluorescent
conjugates that are well-retained and can be fixed with aldehyde
fixatives. Excess unconjugated reagent and by-products passively diffuse
to the extracellular medium, where they can be washed away. The dye -
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protein adducts that form in labeled cells are retained by the cells
throughout development, meiosis, and in vivo tracing.The label is
inherited by daughter cells after cell division or cell fusion, and is not
transferred to adjacent cells in a population (Hodgkin, 1996).
For proliferation analysis, RASMCs were seeded into 6-well plates
and allowed to grow for 48 h. Cells were washed once with PBS and 1 ml
of 5 µM CFDA,SE, prepared in PBS, was added to each well for 5 min at
37oC. Following incubation, CFDA,SE was replaced with fresh media and
the cells were allowed to recover for 6 h before 48 h quiescence. Cells
were then treated and harvested afer 5 days by
trypsinization/centrifugation and washed twice with 1 ml ice-cold PBS
(containing 0.1% BSA). Cells were then placed on ice pending flow
cytometry analysis. The concentration of the dye in the cells, which is
inversely proportional to the rate of proliferation, was measured by flow
cytometry (Becton Dickinson FACSCaliber) at an excitation peak of
492nm and emission peak of 517nm. This is demonstrated in Figure 2.13,
where the control cells (red) have a lower concentration of dye and
therefore, a higher proliferative rate then the treated cells (blue).
Apoptosis
For apoptosis analysis, cells were washed once in PBS, harvested by
trypsinization, pelleted by centrifugation (300 x g for 5 min), washed in 1
ml ice-cold PBS (containing 0.1% BSA), and resuspended by gentle
pipetting. Cells were again pelleted by centrifugation and re-suspended
in 200µl of 1x Annexin-binding buffer. Propidium Iodide (0.4 µl from 100
µg/ml working solution) and 1 µl AlexaFluor 488 Annexin V were added
to the cell suspension and incubated at room temperature for 15 min.
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Figure 2.13: Sample FACS Proliferative Graph
Cells were then placed on ice pending flow cytometry analysis.
Apoptotic cells are then counted and quantified by flow cytometry
(Becton Dickinson FACS Caliber), measuring the fluorescence emission at
530nm and >575nm. Cells were divided into healthy, early apoptotic, late
apoptotic and necrotic and their numbers quantified as percentage of
total cell population (Figure 2.14).
2.5 Data Analysis
Results are expressed as mean ± s.e.m. Comparison between control
versus treated cells were made by i) Students unpaired t test and ii)
One-way Anova with statistical significance established at p<0.05.
Statistical analysis was carried out using the GraphPad Prism 5 R© for
Mac OS X application.
104
Figure 2.14: Sample FACS Apoptosis Readout. UL=upper left quadrant,
UR=upper right quadrant, LL=lower left quadrant and LR=lower right
quadrant.
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Chapter 3
Results
3.1 Introduction
Altered cell fate decisions, including proliferation and apoptosis, are
critical in many conditions including vascular remodelling, the
pathophysiology of atherosclerosis and other cardiovascular disorders.
Pathological changes in vessel structure are induced, in part, by
signalling pathways that govern SMC growth. The Notch signalling
pathway is a highly conserved develomental pathway, which controls
multiple cell differentiation processes during embryonic and adult life.
Notch 1 and 3 IC receptors control the modulation of VSMC fate in
response to growth factor stimulation (Sweeney et al., 2004).
Binding of a Notch ligand to the extracellular domain of full-length
Notch receptor causes cleavage of the receptor, and translocation of the
cytoplasmic Notch intracellular (Notch IC) domain to the nucleus. This
Notch IC is the active form of the receptor, which initiates transcription of
the downstream target genes (Gordon et al., 2008).
GSK-3β is a constitutively active serine-threonine kinase, which is
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involved in a large number of cellular processes. It has been implicated in
a number of disease states including diabetes, Alzheimers disease,
bipolar disease and cancer. GSK-3β has been shown to be able to bind
and phosphorylate active Notch1IC in vitro (Foltz et al., 2002). This
current study, therefore, examined whether GSK-3β modulates Notch
signalling in VSMCs.
The aim of this chapter was to examine the role of GSK-3β in controlling
Notch signalling in RVSMCs
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3.2 Results
3.2.1 GSK-3β and Notch signalling components are
present in RVSMCs
Vascular smooth muscle cells derived from the rat aorta were
characterised to confirm a pure culture. Vascular smooth muscle cells
stain positively for the contractile protein α-smooth muscle cell specific
actin (α-smc actin) and display a noncontact-inhibited growth pattern
(Figure 3.1 A.). A blue fluorescent stain, 4’, 6-diamidino-2-phenylindole
(DAPI) was used for nuclear staining.
Previous studies in our lab have shown the presence of Notch 1 and 3
receptors in serum-stimulated adult RVSMCs. This initial study
confirmed the presence of the intracellular domains (IC) of Notch
receptors 1 and 3 and the Notch downstream targets HRT1, 2 and 3 in
RVSMCs (Figure 3.2 A and B). The presence of GSK-3β in RVSMC was
examined and was revealed by western blotting, immunocytochemistry
and real-time PCR of GSKβ mRNA transcripts (Figure 3.1 B).
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Figure 3.1: Presence of GSK-3β in RVSMCs. A) Immunocytochemistry
staining of α-SMC actin (4x Mag.) B) (i) Immunocytochemistry staining of
GSK-3β (100x Mag.) (ii) Western blot analysis of GSK-3β (iii) Real-time PCR
analysis of GSK-3β. The experiments were performed in triplicate, with images
representative of n=3.
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Figure 3.2: Presence of Notch signalling components in RVSMCs. A) (i)
Immunocytochemistry analysis of Notch 3 (100x Mag.) (ii) Western blot analysis
of Notch1. (ii) Western blot analysis of Notch3. B) (i) Immunocytochemistry
staining of HRT 1, HRT 2 and HRT 3 expression (100x Mag.) (ii) Real-Time
PCR Analysis of HRT1, HRT2 and HRT3. The experiments were performed in
triplicate, with images representative of n=3.
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3.2.2 Enforced Expression of GSKβ - Transient transfection
of VSMCs
While transient transfection of certain transformed cell lines is highly
productive, transfection efficiency is often unacceptably low in primary,
such as VSMCs or early passage nonimmortalized cultured cells. This
may be due to poor uptake of the vector, poor processing or expression of
the vector once taken up by the cell, and inactivation or destruction of the
vector by cellular enzymes (Chen et al., 1999).
Transfection of RVSMCs was initially performed using
LipofectamineTM from Invitrogen. LipofectamineTM is a cationic-lipid
transfection reagent, which facilitates formation of a lipid-DNA complex
between the reagent and the DNA vector. Successful gene delivery by use
of the cationic liposomes involves condensation of the DNA into the
genosome and its protection from degradation by intracellular nucleases,
adhesion of the DNA-lipid complex onto the cellular surface, genosome
internalization, fusion of the internalized DNAcationic liposome complex
with the endosome membrane, escape of DNA from the endosome; and
entry of DNA into the nucleus followed by gene expression (Zhdanov
et al., 2002). By imaging of GFP protein, transfection efficency of RVSMCs
was assessed using LipofectamineTM within a range of concentrations.
The maximal efficiency achieved was approximately 30% (see appendix).
However, the cost of the reagent at this concentration, and the level of cell
toxicity observed was considerable. We then transfected RVSMCs using a
GFP plasmid and the Amaxa nucleofector system. This technology uses
an empirically derived combination of cell line-specific solutions and
nucleofector programmes to electroporate nucleic acid substrates directly
into the cell nucleus (Han et al., 2008). Electroporation involves subjecting
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the cell membranes to a high-voltage electric field, which results in their
temporary breakdown and the formation of pores that are large enough
to allow DNA to enter the cytoplasm (Potter, 2003). Optimal transfection
efficiency of approximately 70%, with low levels of cytotoxicity, was
determined using the programme setting of A-33 (as recommended by
the manufacturer for the transfection of SMCs) (Figure 3.3 A). RVSMCs
were transfected with three plasmids: an empty vector, pcDNA3, a
plasmid expressing the wild type form of GSK-3β (wt.GSK-3β) and a
plasmid expressing a mutant form of the enzyme (mut.GSK-3β). The
serine on site 9 of the mutant enzyme has been changed to an alanine.
This forms an enzyme which cannot be phosphorylated/negatively
regulated at serine 9 and therefore is a constitutively active form of
GSK-3β. GSK-3β ectopic expression was determined by analysing the
levels of HA-tag expression by Western blotting (Figure 3.3 B).
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Figure 3.3: Transfection of VSMCs. A) GFP Expression in RVSMCs
following transfection by nucleofection of a GFP-expression plasmid. B) Western
blot of HA expression in RSMCs following transfection by nucleofection of
the empty vector pcDNA3 or wild-type GSK-3β or mutant GSK-3β. The
cells were co-transfected with the puromycin resistance plasmid, pGK3puro.
Following overnight recovery, cells were incubated in puromycin-containing
growth medium (2µg/ml, 72hrs). The experiments were performed in triplicate,
with images representative of n=3. 113
3.2.3 Knockdown of GSK-3β Gene Expression in RVSMCs
Small, hairpin RNAs (shRNAs) can regulate gene expression via elements
of the RNAi machinery (Paddison et al., 2002). The shRNA hairpin
structure is incorporated into a vector allowing introduction into cells
and is then cleaved by the cellular machinery into siRNA. This can
induce sequence-specific gene silencing in mammalian cells (as described
in Section 2.4.1). RVSMCs were transfected by nucleofection with a Sigma
MISSION R© shRNA plasmid targeted against GSK-3β. Knockdown of
GSK-3β protein of < 0.05 fold was achieved using this method (see
appendix 3).
Non-commercially designed siRNA against GSK-3β was designed
using a method that was previously successful in the lab (described in
Section 2.4.1). RVSMCs were transfected with the designed sequence of
siRNA and a knockdown of GSK-3β of < 0.05 fold was achieved (see
appendix 3).
RVSMCs were transfected with a GSK-3β dominant-negative
expression plasmid (K85M-GSK-3β), where a lysine residue in the
catalytic site of the enzyme is replaced by a methionoine, and knockdown
of GSK-3β of < 0.05 fold was achieved (see appendix 3).
A commercially designed siRNA sequence targeted against GSK-3β
was purchased from Ambion. RVSMCs were transfected with the
sequence and a significant knockdown of GSK-3β protein levels was
observed (0.473 ± 0.04 fold) (Figure 3.4).
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Figure 3.4: GSK-3β Knockdown by siRNA. Western blot of GSK-3β
following transfection with Ambion-designed GSK-3β-targeted siRNA. Cells
were allowed to recover for 72 h before harvesting of cell lysates. Expression
was normalized to Ponceau levels (right frame). The experiment was performed
in triplicate, with images representative of n=3.∗∗p< 0.01 as compared to control
(students t test).
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3.2.4 GSK-3β modulates Notch Receptor Levels
The next stage of this study sought to establish a role for GSK-3β in the
modulation of Notch signalling. The effect of ectopic expression,
knockdown by siRNA and pharmacological inhibition of GSK-3β on
Notch 3IC expression was investigated using SB216763, a potent,
selective inhibitor of GSK-3β, which works in an ATP-competitive
manner (Cross et al., 2001).
Following ectopic expression of the constitutively active form of
GSK-3β, a significant increase in the levels of Notch3 IC was detected by
western blotting (2.424 ± 0.639 fold, n=3) (Figure 3.5). There was a
significant decrease of Notch3 IC protein levels, following both siRNA
knockdown and pharmacological inhibition of GSK-3β by SB216763
(25µM) (to 0.669 ± 0.049 fold, and 0.45 ± 0.16 fold, n=3) (Figure 3.6 and
Figure 3.7).
Pharmacological inhibition of GSK-3β reduced the levels of Notch1 IC
(0.75 ± 0.08 fold) (Figure 3.8). The effect of GSK-3β inhibition on Notch
receptor transcriptional expression was investigated and it was found
that Notch1 mRNA was reduced following treatment with the GSK-3β
pharmacological inhibitor (to 0.67 ± 0.04 fold)(Figure 3.9).
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Figure 3.5: Ectopic Expression of GSK-3β increases Notch3 IC levels.
Western blot analysis of Notch3 IC following transfection of RVSMCs with
the empty vector pcDNA3 or mutant GSK-3β and co-transfection with the
puromycin resistance plasmid, pGK3puro. Following overnight recovery,
cells were incubated in puromycin-containing growth medium (2µg/ml,
72 h). Expression was normalized to Ponceau levels (right frame). The
experiment was performed in triplicate, with images representative of
n=3. ∗p< 0.05 as compared to control (students t test).
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Figure 3.6: GSK-3β Knockdown decreases Notch3 IC levels Western blot
analysis of Notch3 IC following transfection of RVSMCs with GSK-3β
siRNA. Cells were allowed to recover for 72 h. Expression was normalized
to Ponceau levels (right frame). The experiment was performed in
triplicate, with images representative of n=3. ∗∗p< 0.01 as compared to
control (students t test).
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Figure 3.7: Pharmacological inhibition of GSK-3β decreases Notch3
IC levels. Western blot analysis of Notch3 IC following treatment with
SB216763 (25µM) for 24 h. Expression was normalized to Ponceau levels
(right frame). The experiment was performed in triplicate, with images
representative of n=3. ∗p< 0.05 as compared to control (students t test)
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Figure 3.8: GSK-3β modulates Notch1 IC. Western blot analysis of Notch1
IC and following treatment with SB216763 (25µM) for 24 h. Expression
was normalized to Ponceau levels (right frame). The experiment was
performed in triplicate, with images representative of n=3. ∗p< 0.05 as
compared to control (students t test).
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Figure 3.9: GSK-3β modulates Notch1 mRNA Expression. Real-time
PCR analysis of Notch1 following treatment with SB216763 (25µM) for 24
h. The experiment was performed in triplicate. ∗p< 0.05 as compared to
control (students t test).
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3.2.5 GSK-3β modulates Notch Target Genes
Having observed the positive effect of GSK-3β on Notch receptor
expression, modulation of Notch target gene expression by GSK-3β was
determined. Ectopic expression of GSK-3β resulted in an upregulation of
HRT1 and HRT2 mRNA expression (2.883 ± 0.47 fold and 2.383 ± 0.597
fold, n=3)(Figure 3.10). siRNA knockdown of GSK-3β was found to
reduce the expression of Notch target genes HRT1, HRT2 and HRT3 (0.39
±0.036 fold and 0.583 ± 0.087 fold, n=3)(Figure 3.11.), as did
pharmacological inhibition of GSK-3β (0.627 ± 0.096 fold, 0.565 ± 0.093
fold and 0.452 ± 0.093, n=3)(Figure 3.12).
The ability of GSK-3β to regulate downstream targets of Notch
signalling was then confirmed by protein analysis of HRT3 by western
blotting. Ectopic expression of constitutively active GSK-3β increased the
levels of HRT3 protein(2.02 ± 0.226 fold, n=3)(Figure 3.13). siRNA
knockdown of GSK-3β and pharmacological inhibition of GSK-3β
reduced the levels of HRT3 protein expression (0.592 ± 0.047 fold and
0.664 ± 0.146 fold, n=3) (Figure 3.14) and (Figure 3.15).
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Figure 3.10: Ectopic expression of GSK-3β increases Notch Target
Gene mRNA. Real-time PCR analysis of HRT1 and HRT2 mRNA
following transfection of RVSMCs with the empty vector pcDNA3
or mutant GSK-3β and co-transfection with the puromycin resistance
plasmid, pGK3puro Following overnight recovery, cells were incubated
in puromycin-containing growth medium (2µg/ml, 72 h). The experiment
was performed in triplicate. ∗p< 0.05, as compared to control (students t
test)
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Figure 3.11: GSK-3β knockdown decreases Notch Target Gene mRNA.
Real-time PCR analysis of HRT1, HRT2 and HRT3 and mRNA following
transfection of RVSMCs with GSK-3β-targeted siRNA. Cells were allowed
to recover for 72 h. The experiment was performed in triplicate. ∗p<
0.05,∗∗p< 0.01 as compared to control (students t test).
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Figure 3.12: Pharmacological inhibition of GSK3β decreases Notch
Target Gene mRNA. Real-time PCR analysis of HRT1, HRT2 and HRT3
mRNA following treatment with SB216763 (25µM) for 24 h. The
experiment was performed in triplicate. ∗p< 0.05, ∗∗p< 0.01 as compared
to control (students t test).
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Figure 3.13: Ectopic expression of GSK-3β increases Notch Target Gene
Protein Expression. Western blot analysis of HRT3 following transfection
of RVSMCs with the empty vector pcDNA3 or mutant GSK-3β. Cells were
allowed to recover for 72 h. Expression was normalized to Ponceau levels
(right frame). Images representative of n=3. ∗p< 0.05, as compared to
control (students t test).
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Figure 3.14: GSK-3β knockdown decreases Notch Target Gene Protein
Expression. Western blot analysis of HRT3 following transfection of
RVSMCs with scrambled or GSK-3β siRNA and 72 h recovery. Images
representative of n=3. Expression was normalized to Ponceau levels (right
frame) ∗p< 0.05, ∗∗p< 0.01 as compared to control (students t test).
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Figure 3.15: Pharmacological inhibition of GSK-3β decreases Notch
Target Gene Protein Expression. Western blot analysis of HRT3
following treatment of RVSMCs with SB216763 (25µM) for 24 h. Images
representative of n=3. Expression was normalized to Ponceau levels (right
frame)∗∗p< 0.01 as compared to control (students t test).
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3.2.6 GSK3-β modulates CBF-1 promoter activity
Canonical Notch signalling shows Notch receptor binding to a CBF-1
protein complex, allowing the transcriptional activation of Notch target
genes. Notch 1 and 3 receptor signalling was previously shown to
modulate vascular smooth muscle cell growth via a CBF-1/RBPJκ
dependent pathway (Sweeney et al., 2004). In order to further clarify the
role of GSK-3β in Notch signalling, the involvement of GSK-3β in Notch
signalling through regulation of a CBF-1-responsive system was
investigated. Using an artificial CBF-1-responsive luciferase reporter
plasmid, ectopic expression of constitutively active GSK-3β induced a
significant increase in CBF-1-regulated promoter transactivation (2.554 ±
0.359 fold, n=3). This effect was attenuated following pharmacological
inhibition of GSK-3β with SB216763. Pharmacological inhibition of
GSK-3β also significantly reduced basal levels of CBF-1-responsive
promoter activity (0.430 ± 0.261 fold, n=3)(Figure 3.16).
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Figure 3.16: GSK-3β modulates CBF-1-regulated promoter activity.
Relative luciferase activity analysis of the CBF-regulated promoter
following transfection of RVSMCs with the empty vector pcDNA3 or
mutant GSK-3β and co-transfection with the CBF-1 promoter reporter
plasmid, pGA-981-6.Following transfection, cells were incubated in
DMSO- or SB216763 (25µM)-containing media for 48 h. The experiment
was performed in triplicate. ∗∗p< 0.01 as compared to pcDNA3 control.
σ< 0.05 as compared to SB216763 treated control (One-way Anova).
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3.3 Discussion
The Notch signalling pathway has previously been implicated in several
aspects of vascular development (Proweller et al., 2005) and Notch has
been shown to be pro-proliferative and apoptotic in vascular smooth
muscle cells (Morrow et al., 2005a) and to be modulated by both
biomechanical stimuli in vitro and following vascular injury in vivo
(Morrow et al., 2005a), (Wang et al., 2002).
Strict control of Notch regulation is required to maintain a
non-pathological level of signalling. This is achieved through many
levels of regulations including cell-type specific expression of ligands.
Prior to ligand binding, various mechanisms regulate the receptor, firstly
through transcriptional control of full-length Notch receptor (FL-Notch)
expression (Seugnet et al., 1997). Post-translational modifications,
including fringe-dependent glycosylation of the EGF-repeats on the
full-length receptor, and ubiquitination leading to endocytosis positively
modulates signalling by the receptor (Bruckner et al., 2000). For ligand
binding to occur, a furin-based cleavage of FL-Notch is required and
allows presentation of a heterodimeric receptor at the membrane of the
cell (Logeat et al., 1998). Association of heteromeric Notch protein is
calcium dependent (Rand et al., 2000). Following binding of the ligand to
the receptor, endocytosis of the ligand must occur. This is thought to pull
on the Notch EC domain, causing a conformational change that allows
exposure of the S2 site for cleavage of the receptor by TACE/ADAM
proteases. This is quickly followed by presenilin-dependent γ-cleavage at
the transmembrane site on the receptor and release and translocation of
the active Notch receptor to the nucleus (Kovall, 2008). Within the
nucleus, following activation, phosphorylation and ubiquitination of the
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Notch IC is required to promote degredation of the Notch IC in the
proteosome, allowing rapid turnover of Notch IC (Baron et al., 2002).
An important form of regulation is cell-type specific expression of
Notch receptors. In higher vertebrates multiple Notch homologs have
been identified. Notch1 and Notch2 are expressed in a number of tissues.
Notch1 is expressed broadly in most tissues, including brain, liver, heart,
lung, kidney, intestine, bone marrow, skeletal muscle, spinal cord, eye
and thymus while, Notch2 is expressed predominantly in the brain, liver,
kidney and stomach, which partially overlaps the expression pattern of
Notch1 (Wu and Bresnick, 2007). There is little evidence of Notch2
activity in adult vascular smooth muscle. However, inactivation of
Notch2 in cardiac neural crest cells (precursors for vascular smooth
muscle cells in greater arteries) results in abnormally narrow aortas and
pulmonary arteries due to a decrease in smooth muscle proliferation
(Varadkar et al., 2008). Notch 4 transcripts are primarily restricted to
endothelial cells in embryonic and adult life (Uyttendaele et al., 1996).
Notch 3 is predominantly expressed in adult arterial smooth muscle cells
in humans (Joutel et al., 2000). CADASIL is caused by mutations in the
Notch receptor, Notch 3, gene and is the most common form of inherited
stroke and vascular dementia in humans (Gridley, 2007) and is
characterised by systemic VSMC degeneration (Wang et al., 2008).
It is possible to conceive that structural differences or varied
expression profiles of the receptors may lead to differential modes of
regulation. Notch1 and 2 have the broadest expression pattern, and the
most diverse biological context and also have the highest homology to
each other, while Notch3 and Notch4 are structurally diverged from
Notch1 and Notch2 , both in the extracellular and intracellular domains.
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Notch4 has fewer epidermal growth factor (EGF)-like repeats and a
shorter intracellular domain than other mouse Notch homologues
(Uyttendaele et al., 1996).
The presence of Notch 1 and Notch 3 receptors has previously been
identified in VSMCs, and this was again confirmed in this study
(Figure 3.2). It has also previously been shown that HES and HRT are
direct downstream target genes of Notch 1 and 3 signalling in VSMC
(Sweeney et al., 2004).
Based on their previously studied expression in VSMCs, and their
potential involvement in vascular disease, the decision was made to
examine further the mechanisms involved in the regulation of Notch1
and Notch3. Because of their structural differences, it is very possible that
they are differentially regulated. Notch3 specifically lacks the equivalent
of EGF-repeat 21 and lacks an EGF-repeat-sized region comprising parts
of EGF-repeats 2 and 3 (Lardelli et al., 1994). This may have an impact on
the specificity or extent of ligand binding. Subtle differences have been
reported in the transmembrane domain of Notch3 and this may
differentially regulate Notch3 intramembranous cleavage, as well as its
recruitment to the membrane or its eventual relationship with other
membrane-tethered and/or recruited proteins (Bellavia et al., 2008). The
RAM (RBP-jkappa-associated molecule), which interprets CBS (CSL
binding site) proximity and orientation has 41% amino acid identity
between Notch1 and Notch3 (Beatus et al., 2001). Similarly there is only
21% amino acid identity between Notch1 and Notch3 in the C-terminal
region containing the transactiviation and PEST domain (Beatus et al.,
2001). The PEST domain contains a peptide sequence which is rich in
proline (P), glutamic acid (E), serine (S), and threonine (T). This sequence
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is associated with proteins that have a short intracellular half-life and it is
hypothesized that the PEST sequence acts as a signal peptide for protein
degradation (Rogers et al., 1986). The half-life of Notch IC is relatively
short due to the action of ubiquitin ligase, Sel-10 (Wu et al., 2001) and
Notch proteins are degraded by the 26S proteosome in the cell.(Wu et al.,
2001).
GSK-3β is a serine/threonine kinase that functions in diverse cellular
processes including proliferation, differentiation, migration and survival
(Luo, 2009). Drosophila shaggy kinase and rat glycogen synthase kinase-3
have conserved activities and act downstream of Notch (Ruel et al., 1993)
and GSK-3β has previously been shown to have the ability to bind to and
phosphorylate Notch1 within the C-terminal PEST domain (Espinosa et al.,
2003) It therefore stands out as a potential modulator of Notch receptor
levels in VSMCs. Based on structural variations in the PEST domain of
the Notch IC, it is possible that GSK-3β modulation of Notch is receptor
specific. There also, may be a cell-type specificity to the GSK-3β effect on
Notch IC. This study sought to elucidate the effect, if any, of GSK-3β on
Notch1 and Notch3 in VSMCs.
It was, therefore, investigated if there was such an involvement in
VSMCs, thereby providing a mechanism for regulation of Notch
signalling in VSMCs and a potential therapeutic target to treat vascular
disease. This was achieved through manipulation of GSK-3β activity in
RVSMCs, by ectopic expression of GSK-3β using a constitutively-active
GSK-3β expression plasmid, pharmacological inhibition with a
well-studied specific inhibitor, SB216763, and knockdown of GSK-3β
gene expression using siRNA technology.
Knockdown of GSK-3β protein by siRNA technology was
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demonstrated for the first time in VSMCs. Gene-silencing effectiveness
depends very much on the target sequence positions (sites) selected from
the target gene. Different siRNAs synthesized for various positions
induce different levels of gene-silencing. The selection of the target
sequence is critical to the effectiveness of the siRNA and we need useful
criteria for gene-silencing efficacy when we are designing siRNA
sequences. Several factors relate to gene-silencing efficacy. They are, for
example, based on binding energy, GC content, sequence features,
hairpin formation potential, secondary features of mRNA and weighted
sums of sequence motifs and patterns (Takasaki et al., 2006). The
positional nucleotide characteristics for siRNA designs seem to be the
most important factor for identifying the effective siRNA. Our design
was based on the position relative to the start codon (which avoided
regulatory protein binding sites which may interfere with binding of the
siRNP endonuclease complex) GC content and was blasted to confirm no
non-specific targets. However, commercially available siRNA, utilises
computational models that account for the secondary features of mRNA
and weighted sums of sequence motifs and patterns (Tilesi et al., 2009).
Ambion uses design algorithm improvements, bioinformatic filtering to
predict and eliminate potentially non-effective siRNAs and incorporate
novel chemical modifications demonstrated to improve siRNA specificity.
These features may account for the improved level of GSK-3β
knockdown observed in RVSMCs compared to self-designed and
commercially purchased shRNA.
This study demonstrates for the first time that GSK-3β has the ability
to modulate Notch receptor levels in VSMCs. It is the first time that
modulation of Notch3 IC levels by GSK-3β has been demonstrated and
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the first time that modulation of Notch1 IC levels by GSK-3β in VSMCs
has been demonstrated.
Both Notch1 and Notch3 IC receptor levels were significantly
increased by GSK-3β activity (Figure 3.5, Figure 3.6, Figure 3.7 , Figure 3.8
and Figure 3.9) suggesting that the structural differences in the
C-terminal domain of Notch1 and Notch3 does not impact on the
modulation of the active Notch receptor by GSK-3β. A recent study
shows that smooth muscle Notch1 mediates neointimal formation after
vascular injury (Li et al., 2009), suggesting that regulation by GSK-3β of
Notch1 IC levels may have considerable significance, in regards to
vascular disease and warrants further investigation.
A likely mechanism for regulation of Notch IC levels by GSK-3β is
through enhancement of stability in the nucleus. Notch proteins undergo
inactivation by proteasome-mediated degradation and are regulated by
components of the ubiquitin ligase cascade. Foltz et al. (2002)
demonstrate that activated GSK-3β reduced the quantity of Notch1IC
that was degraded by the proteasome, suggesting that GSK3β activity
alters the degradation of Notch1IC by the proteasome. It is possible that
this occurs through direct phosphorylation of the Notch IC. Foltz et al.
(2002) also demonstrate that Notch1 is able to bind and phosphorylate
NotchIC in vitro. However, conserved consensus sites for numerous
serine/threonine kinases are distributed within the intracellular domain
of Notch and therefore, GSK3β could have indirect effect on Notch IC
phosphorylation through regulation of other kinases (Foltz et al., 2002).
Another possible mechanism is inhibition of antagonists which promote
degredation such as Sel-10. Mammalian Sel-10 is itself ubiquinated and
degraded by the proteosome (Oberg et al., 2001) and it is easy to speculate
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that this event is GSK-3β-dependent. Interaction of Sel-10 with nuclear
Notch requires a phosphorylation event (Gupta-Rossi et al., 2001). In
studies by Espinosa et al. (2003) and Jin et al.(2009), Notch IC
phosphorylation by GSK-3β reduced the activity of the Notch IC
(Espinosa et al., 2003), (Jin et al., 2009) . It is possible that, in this instance,
GSK-3β mediated the phosphorylation events required for Sel-10
ubiquitination. Fryer et al. identified cyclin-dependent kinase 8 (CDK8)
as a kinase that phosphorylates Notch IC in the PEST domain in the
nucleus, and was a requirement for Sel-10 phosphorylation (Fryer et al.,
2004). Based on the studies discussed above, this is also possible
candidate for modulation by GSK-3β.
The mammalian protein Itch has been shown to be able to
ubiquitinate Notch and to bind to the N-terminal portion of the
intracellular region of the molecule. Itch regulates PEST-independent
degredation of cytoplasmic Notch proteins and is required, in the absence
of ligand, after the early steps of Notch endocytosis to target it to the
lysosomes where it is degraded (Fryer et al., 2004). Furthermore
Itch/AIP4 catalyzes Notch polyubiquitination through unusual
K29-linked chains. (Chastagner et al., 2008). Notch is associated with
Itch/AIP4 in cells but their interaction requires a post-translational
modification, or a bridging factor that remains to be identified,
suggesting that Itch is another candidate for modulation by GSK-3β.
It may be the case that GSK-3β has the ability to interact with Notch
IC on multiple phosphorylation sites or indeed on multiple levels of
regulation and this may account for its apparent ability to activate and
repress Notch signalling. Another possible mechanism is that GSK-3β
prevents cleavage of Notch IC by regulating γ-secretase or presenilins.
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γ-secretase is also required for the release of the Notch IC (Mumm and
Kopan, 2000) in a presenilin-dependent manner. γ-Secretase cleavage can
occur at the cell surface or in endosomal compartments, but cleavage at
the membrane favors the production of a more stable form of NICD
(Tagami et al., 2008). GSK3β activity has previously been shown to
modify the localization and function of presenilin 1 (Uemura et al., 2007).
Presenilin 1, a causative gene product of familial Alzheimer disease, has
been reported to be localized mainly in the endoplasmic reticulum and
Golgi membranes, but endogenous Presenilin 1 also localizes at the
plasma membrane as a biologically active molecule. The serine residues
(serine 353 and 357) on presenilin 1 can be phosphorylated by GSK-3β
and GSK-3β-mediated phosphorylation of presenilin 1 down-regulates its
cell-surface expression (Uemura et al., 2007). It has, therefore, been
hypothesised that GSK-3β may be involved with cleavage of Notch IC.
However, a therapeutic level of lithium chloride (LiCl), an inhibitor of
GSK-3β, while reducing αβ formation by interfering with APP cleavage
at the γ-secretase step, did not affect Notch ICD formation from Notch
(Phiel et al., 2003). Further research is required to establish the role, if any,
for GSK-3β in cleavage of the Notch receptor.
While regulation of Notch IC by GSK-3β through post-translational
modifications or cleavage events has been investigated, other
mechanisms cannot be overlooked. Our previous study shows that cyclic
strain transcriptionally regulates Notch1 levels and strain may be one of a
number of stimuli that regulate Notch signalling at this level (Morrow
et al., 2005b). Here, a role for GSK-3β in the transcriptional regulation of
Notch1 is identified, suggesting that GSK-3β may mediate the effect of
cyclic strain on Notch IC. GSK-3β is a multi-tasking protein involved in
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many aspects of cell signalling and GSK3β acts within the Wnt/wingless
(Wnt/wg) signalling cascade by altering the stability of β-catenin. Foltz
et al. (2002) suggest that Notch IC function may be modulated by
Wnt/wg signalling through its negative effect upon GSK-3β activity
mediated by Disheveled. Crosstalk between signalling pathways is
another mechanism which warrants investigation when addressing the
role of GSK-3β in Notch signalling in VSMCs.
While Notch receptor levels were clearly shown to be modulated in
this study, this was no indicator of the effect of GSK-3β on Notch target
signalling. It could be argued that GSK-3β disrupts nuclear translocation
of the receptor and that the observed increase in Notch IC levels due to
GSK-3β activity, is due to retained cytoplasmic Notch IC that has avoided
degradation by avoiding phosphorylation in the nucleus. This would
result in a decrease in signalling activity of the active receptors in the
nucleus and a decrease in downstream target gene transcriptional
activation. A nuclear localizing signal (NLS) was identified in the
cytoplasmic sequence of Notch homologs (Stifani et al., 1992) and nuclear
localisation is essential for notch signalling. This sequence motif consists
of a stretch of approximately 60 residue that harbours a sequence motif
conforming to the definition of a casein kinase II (CKII) site/cdc2 kinase
(cdc2) site/nuclear localisation sequence. Interestingly, CK II (also called
GSK-5) is a priming kinase for GSK-3β (Woodgett and Cohen, 1984) and
may assist in modulation of Notch IC by GSK-3β. However, while a
study has shown that Akt inhibits proper nuclear localisation of NICD, a
dominant negative plasmid of GSK-3β (DN-GSK-3beta) has no effect on
the subcellular distribution of NICD (Song et al., 2008). Also, the study by
Foltz et al., revealed that GSK3β does not control the nuclear localization
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of NotchIC in embryonic fibroblasts and imply that differences in the
ability of wild-type and GSK3β null cells to activate the HES1 promoter
are not a consequence of changes in the translocation of NotchIC.
To confirm a downstream effect of GSK-3β on Notch signalling in
VSMCs, the levels of the HRT (1-3) genes, following manipulation of
GSK-3β was examined. Previous studies have focused mainly on the
effect of GSK-3β on Hes genes (Jin et al., 2009), (Foltz et al., 2002),
(Espinosa et al., 2003). HES factors have been shown to be predominantly
involved in neurogenesis and development of sensory organs, while HRT
factors play critical roles in the cardiovascular system (Fischer and
Gessler, 2007). Our previous studies showed that the HRTs are direct
downstream target genes of Notch 1 and 3 receptors in SMCs (Sweeney
et al., 2004) and that hrts are regulated in response to arterial injury
(Morrow et al., 2009). For this reason, it was decided to focus on the
regulation of the HRT family of genes in VSMCs. In this study, GSK-3β
modulation of the expression of HRT1, 2, and 3 was investigated and it
was found that GSK-3β has a positive effect on the expression of these
downstream targets at the mRNA level, which was confirmed at the
protein level by positive regulation of HRT3 protein by GSK-3β.
In the nucleus, Notch IC acts to affect transcription of its downstream
targets by binding to the nuclear protein CBF-1/RBP-Jκ. All HRT
promoters contain multiple RBP-Jκ binding sites and we have previously
identified an essential role for CBF-1/RBP-Jκ in the regulation of HRTs in
VSMCs (Sweeney et al., 2004). To further clarify a role for GSK-3β in
Notch signalling, GSK-3β involvement in Notch signalling through
regulation of the CBF-1 promoter was examined. Using a luciferase
reporter plasmid for the CBF-1 promoter binding sites, it was shown that
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GSK-3β positively modulates CBF-1 promoter activity. This further
strengthens the evidence that GSK-3β has the ability to regulate Notch
signalling in VSMCs.
The effect of GSK-3β on Notch downstream targets with a change in
Notch receptor levels has yet to be correlated. This is easily addressed by
examining if GSK-3β has the ability to recover the effect on Notch
downstream signalling, following inhibition of Notch receptor activity
using a γ-secretase inhibitor. Proteolysis of Notch receptor by a
γ-secretase at an S3 site is a conserved signalling mechanism and all four
Notch receptors require an S3-like cleavage event for CBF-1-mediated
Notch signalling (Mumm and Kopan, 2000). By inhibiting this cleavage
with a γ-secretase inhibitor, it would be possible to show that the effect of
GSK-3β on downstream Notch signalling was dependent on activity of
the Notch receptor. This would strengthens the hypothesis that GSK-3β
modulates Notch signalling in VSMCs through regulation of Notch IC
levels.
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3.4 Conclusion
Notch is proving to be a critical modulator of cell fate in vascular disease
(Li et al., 2009) and, therefore it is of considerable importance to
understand the mechanisms involved in its regulation. In this study, a
role for GSK-3β in the modulation of Notch signalling in VSMCs was
established. It was demonstrated that GSK-3β has the ability to modulate
Notch receptor activity and downstream target gene expression and acts
upstream of CBF-1 promoter activity. GSK-3β has previously been shown
to directly bind to and phosphorylate Notch1 IC (Foltz et al., 2002) and
here, a role for GSK-3β in the transcriptional regulation of Notch1 in
VSMCs was identified. This data suggests that GSK-3β may modulate
Notch on multiple levels. A number of stimuli regulate Notch signaling
and GSK-3β may interact with Notch on a number of levels, as
summarised in Figure 3.17. Crosstalk between Notch and the Wnt, VEGF
and Hh pathways is essential in the developing vasculature (Goishi and
Klagsbrun, 2004) and we have previously shown that cyclic strain inhibits
Notch receptor signalling in adult VSMCs (Morrow et al., 2005b). A
potential role for GSK-3β in Notch signalling at the level of crosstalk with
other developmental pathways and through biomechanical modulation
is investigated in the following chapters.
142
Figure 3.17: Overview of Notch Receptor Regulation in VSMCs. Notch
is regulated on a number of levels including cleavage of FL-Notch (full-length
Notch) by Furin, cleavage and tracking of receptors (by ADAM proteases, γ-
secretase, Itch), post-translation modifications (by Sel-10, GSK-3β) and through
transcriptional control of Notch receptor expression (by strain, Hh, Wnt).
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Chapter 4
Results
4.1 Introduction
Crosstalk between the developmental pathways of Hh, VEGF and Notch
are crucial during vascular morphogenesis and modeling of the
embryonic vasculature (Goishi and Klagsbrun, 2004). It has yet to be
established if this mechanism of cell fate regulation is conserved in adult
cells. This study involved Notch regulation in VSMCs at the level of
crosstalk with the Hedgehog Pathway. There are three forms of the
ligand, Sonic Hedgehog (Shh), Desert Hedgehog (Dhh) and Indian (Hh,)
which are expressed in different tissues at different times during
development. Shh and Ihh play important roles in embryonic
development, and Dhh regulates spermatogenesis (Huangfu and
Anderson, 2006). The targets of Hh signalling in vertebrates are Gli 1-3.
It has been recently shown that Shh signalling is present in adult
cardiovascular tissues and can be activated in vivo to induce robust
angiogenesis (Pola et al., 2001). Moreover, Shh and VEGF have been
shown to act upstream of Notch during arterial endothelial
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differentiation (Lawson et al., 2002). This study therefore examined if Hh
components control Notch signalling in VSMCs through VEGF
activation.
The Wnt signalling pathway has also been implicated as a modulator of
the vasculature through crosstalk with Notch (Phng and Gerhardt, 2009).
GSK-3β, a component of the Wnt pathway may, therefore, regulate Notch
signalling through crosstalk with other pathways, such as Hh. Having
established that GSK-3β has the ability to modulate Notch in VSMCs, this
study investigates if there is a role for GSK-3β in Hh signaling in VSMCs.
The Notch signaling pathway is critical for cell fate determination
during vascular development and we have previously identified Notch
as a positive modulator of VSMC growth (Sweeney et al., 2004). The role
of GSK-3β in cell fate decisions is ambiguous as it has been shown to be
pro-apoptotic or pro-survival, depending on stimulus or context (Beurel
and Jope, 2006). Previous studies have identified GSK-3β as
pro-apoptotic in VSMCs in response to stimuli such as hypoxia (Loberg
et al., 2002), or balloon injury (Park et al., 2003). However, it was
determined that GSK-3β increases Notch signaling in VSMCs in
serum-stimulated cycling cells, suggesting a pro-survival role. We
investigated, Therefore, the effect of GSK-3β on VSMCs growth under
these conditions was investigated.
The aim of this chapter was firstly to determine the role of the Hh and VEGF
pathways in the modulation of Notch signaling. Secondly, a role for GSK-3β
in regulation of Hh signaling in VSMCs was determined. Thirdly, the effect of
GSK-3β on VSMC growth was also examined.
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4.2 Results
4.2.1 Notch signalling is regulated by Hedgehog
signalling via VEGF
The role of VEGF in Notch signalling in RVSMCs was investigated by real-
time PCR, following treatment of RVSMCs with a recombinant form of
VEGF-A (25µg, 24h). and found that the Notch target gene expression of
HRT1, HRT2 and HRT3 was upregulated following treatment (3.15 ± 0.22
fold, 5.32 ± 0.46 fold and 3.04 ± 0.39 fold, n=3) (Figure 4.1).
RVSMCs were treated with recombinant Shh for 24 h. Notch target
gene HRT3 mRNA expression was upregulated following treatment (3.43
± 0.39 fold, n=3) (Figure 4.2). Selective knockdown of VEGF-A with a
targeted siRNA was confirmed at the protein level (Figure 4.2 A.) HRT3
mRNA expression was downregulated following transfection of VEGF-A
targeted siRNA to (0.57 ± 0.04 fold, n=3). This effect was attenuated (to
0.90 ± 0.05 fold, n=3) following treatment with recombinant Shh. The
effect was further enhanced following co-treatment with recombinant
VEGF (to 1.99 ± 0.45, n=3) (Figure 4.2). These findings indicate a role for
Hedgehog signalling in the regulation of Notch through VEGF.
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Figure 4.1: Notch signalling is Upregulated by VEGF. Real-time PCR
analysis of HRT1, HRT2 and HRT3 following treatment of RVSMCs
with 1% BSA or recombinant VEGF (25ng) for 24 h). Expression was
normalized to GAPDH levels, and expressed as fold increase over BSA
control. The experiments were performed in triplicate, with the graph
representative of n=3, ∗p< 0.05 as compared to control (students t test).
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Figure 4.2: Notch signalling is Regulated by Hedgehog signalling via
VEGF. A) Western blot analysis of VEGF-A following transfection of
RVSMCs with siRNA directed against VEGF or a scrambled control. B)
Real-time PCR analysis of HRT3. RVSMCs were transiently transfected
with siRNA directed against VEGF or a scrambled control. Following
overnight, recovery cells were treated with recombinant Shh (3.5µg) or
recombinant VEGF-A (25ng) for 24 h. All data was normalised to GAPDH
levels and expressed as fold change over control. The experiments were
performed in triplicate, with the graph representative of n=3, ∗p< 0.05,
∗∗p< 0.01 as compared to control (students t test).
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4.2.2 GSK-3β modulates Hh Downstream Targets
In the absence of Hh, a truncated form of Gli, which is generated by
proteolytic processing of full-length Gli, represses Hh target genes. In the
presence of Hh, Gli is fully converted to the activator form. Gli1 functions
as a strong transcriptional activator. However, loss of Gli1 gene function
in mice does not appear to result in obviously abnormal phenotypes and
therefore, Gli1 is not essential for initial Shh signal transduction in mice.
Gli3 is found predominantly in its truncated form, and functions mainly
as a transcriptional repressor (Pan et al., 2006). Gli2, is also a strong
transcriptional activator and is therefore, an appropriate target for
analysing hedgehog signalling. The hedgehog receptor, Patched 1, is also
a target gene and therefore a marker for Hh signalling (Mullor et al.,
2002).
Gli2 Promoter activity was determined using a Gli2 promoter
luciferase-tagged plasmid (pGL3b/8xGli-lcLuc). Ectopic expression of
GSK-3β decreased Gli2 promoter activity (0.62 ± 0.12 fold, n=3). This
effect was attenuated following pharmacological inhibition of GSK-3β by
SB216763 (25µM) (to 1.29 ± 0.26 fold, n=3). Pharmacological inhibition of
endogenous GSK-3β also increased Gli2 promoter activity (1.53 fold ±
0.19 fold, n=3)(Figure 4.3). Ectopic expression of GSK-3β decreased Gli2
mRNA expression (Figure 4.4). Conversely, pharmacological inhibition of
endogenous GSK-3β increased the mRNA expression levels of Gli2 (2.20
± 0.43 fold, n=3) (Figure 4.5). Similarly, Patched1 mRNA expression
levels were increased following pharmacological inhibition of GSK-3β
(2.52 ± 0.33 fold, n=3) (Figure 4.7) and decreased following ectopic
expression of GSK-3β (to 0.60 ± 0.13 fold, n=3)(Figure 4.6). Patched 1
protein levels were also increased following pharmacological inhibition
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of GSK-3β by SB216764 (3.66 ± 0.31 fold). (Figure 4.8).
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Figure 4.3: GSK-3β regulates Gli2 Promoter Activity. Luciferase activity
analysis of the Gli2 promoter activity following transfection of RVSMC
with a Gli2 luciferase-tagged reporter plasmid. The cells were co-
transfected with the empty vector, pcDNA3, or mut. GSK3β. Additionally,
cells were co-transfected with a LacZ plasmid. The cells were treated with
DMSO or SB216763 (25µM, 72 h). Protein was isolated and assayed for
luciferase activity. Luciferase assays were normalized to β-galactosidase
activities and protein levels, n= 3, and expressed as fold increase over
control (the value obtained with Gli-promoter transfected cells arbitrarily
assigned a value of 1). ∗p< 0.05 as compared to control (Anova).
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Figure 4.4: Ectopic expression of GSK-3β decreases Gli2 mRNA
Expression in RVSMCs. Real-time PCR analysis of Gli2 following
transfection of RVSMCs with the empty vector pcDNA3 or mutant GSK-
3β and co-transfection with the puromycin resistance plasmid, pGK3puro.
The experiment was performed in triplicate. Expression was normalized
to GAPDH levels, and expressed as fold increase over control. ∗p< 0.05 as
compared to control (students t test).
152
Figure 4.5: Pharmacological inhibition of GSK-3β increases Gli2 mRNA
in RVSMCs. Real-time PCR analysis of Gli2 following treatment of
RVSMCswith SB216763 (25µM) for 24 h. Expression was normalized
to GAPDH levels, and expressed as fold increase over control. The
experiment was performed in triplicate. ∗p< 0.05 as compared to control
(students t test).
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Figure 4.6: Ectopic expression of GSK-3β decreases Patched1 mRNA
Expression in RVSMCs. Real-time PCR analysis of Patched1 following
transfection of RVSMCs with the empty vector pcDNA3 or mutant GSK-
3β and co-transfection with the puromycin resistance plasmid, pGK3puro.
Expression was normalized to GAPDH levels, and expressed as fold
increase over control.The experiment was performed in triplicate.∗p< 0.05
as compared to control (students t test).
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Figure 4.7: Pharmacological inhibition of GSK-3β increases Patched1
mRNA in RVSMCs. Real-time PCR analysis of Patched1 following
treatment with SB216763 (25µM) for 24h. Expression was normalized
to GAPDH levels, and expressed as fold increase over control.The
experiment was performed in triplicate. ∗∗p< 0.01 as compared to control
(students t test).
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Figure 4.8: Patched1 Protein Expression is Regulated by GSK-3β in
RVSMCs. Western blot analysis of RVSMCs following treatment with
DMSO or SB216763 (25µM) for 5 days. Expression was normalized to
Ponceau levels (right frame). The experiment was performed in triplicate.
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4.2.3 GSK-3β modulates VSMC Proliferation
Previous studies in our lab have shown Notch to be pro-proliferative in
RVSMCs (Morrow et al., 2005a). The role of GSK-3β in controlling this cell
fate change was therefore examined. Pharmacological inhibition of
GSK-3β had an anti-proliferative effect on RVSMCs as measured by FACS
CFDA-SE analysis (Figure 4.9). This was confirmed with decreased cell
counts (to 0.52 ± 0.08 fold, n=3) and a reduction in cyclic PCNA
expression (to 0.38 ± 0.09 fold, n=3) following treatment (Figure 4.9 and
Figure 4.10). These findings demonstrate that GSK-3β is pro-proliferative
in VSMCs. This suggests that GSK-3β may modulate RVSMC cell
proliferation through control of putative Notch signalling in these cells.
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Figure 4.9: Pharmacological Inhibition of GSK-3β Decreases
Proliferation in RVSMCs: FACS Analysis and Cell Count. The
cells were incubated in CDFA dye for 5 mins, and then quiesced for 48 h.
Following treatment with DMSO or SB216763 (25µM, 5 days), cells were
A) sorted by FACS analysis or B) counted using a haemocytometer. The
experiment was performed in triplicate, with the graph representative of
n=3, ∗ ∗ p< 0.01 as compared to DMSO control (students t test).
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Figure 4.10: Pharmacological Inhibition of GSK-3β Decreases PCNA
Expression in RVSMCs: FACS Proliferative Profile. Western blotting of
PCNA protein in RVSMCs following treatment with DMSO or SB216763
(25µM, 5 days). Expression was normalized to Ponceau levels (right
frame). The experiment was performed in triplicate, with the image
representative of n=3, ∗ p< 0.05 as compared to DMSO control (students t
test).
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4.2.4 GSK-3β modulates VSMC Apoptosis
We have also previously shown in our lab that Notch exerts an
anti-apoptotic effect on RVSMCs (Morrow et al., 2005a). The effect of
GSK-3β on apoptosis in cycling VSMCs was measured by FACS Annexin
V analysis, in which apoptotic cells which were
phosphatidylserine-positive and propidium iodide-negative were
quantified. Ectopic expression of GSK-3β did not induce apoptosis of
VSMCs (Figure 4.11). No significant change was observed at its half
maximal inhibitory concentration (IC50) value (34nM)(Figure 4.11).
Inhibition of GSK3β using a concentration of SB216763 (25µM) induced
apoptosis of GSK-3β (Figure 4.12). Transfection of Notch3 did not recover
the increase in apoptosis induced by GSK-3β pharmacological inhibition,
suggesting GSK-3β modulates VSMC downstream of Notch signalling
(Figure 4.12).
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Figure 4.11: Ectopic expression of GSK-3β does not induce apoptosis
of VSMCs. FACS Analysis of apoptotic RVSMCs following transfection
of empty vector or mut.GSK3β expression plasmid and treatment with
normal RPMI media containing 10% FCS and DMSO or SB216763 (34nM,
5 days). The experiment was performed in triplicate, with the graph
representative of n=3.
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Figure 4.12: GSK-3β modulates VSMC Apoptosis downstream of Notch
signalling. (apop.= apoptosis). FACS Analysis of apoptotic RVSMCs following
transfection of empty vector or Notch 3 expression plasmid and treatment with normal
RPMI media containing 10% FCS and DMSO or SB216763 (25µM, 5 days). The
experiment was performed in triplicate, with the graph representative of n=3, ∗∗p< 0.01
as compared to p7 control. σ< 0.05 as compared to Notch3-transfected DMSO treated
control (One-way Anova).
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4.3 Discussion
This study identifies that the Hh-VEGF-Notch axis observed in vascular
development is conserved in adult cells, as the Hh pathway was shown
to be a positive modulator of Notch signalling and Hh signals via
VEGF-A to increase Notch downstream target expression in adults
VSMCs. Based on these findings, it was initially postulated that GSK-3β
modulates Notch signaling upstream of receptor activity through positive
regulation of Hh signaling. However, on further investigation it was
determined that GSK-3β, a component of the Wnt pathway, has a
negative effect on Hh signaling.
Upon binding of a Hh ligand to the receptor Patched, repression of
Smo is relieved, which is able to activate Gli by preventing its proteolysis
to a truncated non-active form. It has previously been shown that in the
absence of Hh ligands full-length Cubitus interuptus (Ci155), the
Drosophila form of Gli, is phosphorylated at three serine sites by GSK-3.
Initial priming phosphorylations by PKA and casein kinase1 are also
required to initate proteoysis. This occurs by binding of an E3SCF
ubiquitination ligase complex of which Slimb is the key substrate
recognition component. Ubiquitinated Ci155 is then partially degraded in
the proteosome. The N-termini is spared by stable folding of the Ci zinc
finger domain coupled to the proteolytic resistance of the adjacent
polypeptide region leaving a truncated Ci75 (Smelkinson et al., 2007). The
phosphorylation of Ci155 by GSK-3 is a requirement for proteolysis and
for Hh pathway silencing (Price and Kalderon, 2002). The kinesin-related
protein, Costal-2 (Cos2) facilitates Ci155 phosphorylation by PKA, CK1
and GSK-3. In the presence of Hh signalling, Ci proteolysis is inhibited
and Hh targets are activated. Binding of Hh causes partial dissociation of
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these protein kinases from Cos2 and may be resposible for the
accompanying inhibition of Ci155 (Zhang et al., 2005) .
In vertebrates, Gli1 and Gli3 are similarly degraded. In mouse
embryonic fibroblasts, Gli2 was found to be readily degraded by
phosphorylation of multiple PKA, CK1 and GSK-3 sites within the Gli2
C-terminal region. This hyperphosphorylation of Gli2 protein created
binding sites for βTrCP (the mammalian form of Slimb), which in turn
conjugated the multiple ubiquitination molecules onto the Gli2 protein
and triggered the proteosome-mediated protein degradation. Both Gli2
processing and degradation were inhibited by Shh, which also induced
Gli2 protein transcription activity Pan et al. (2006). Interestingly, Gli2 was
found to be readily degraded. The vast majority of Gli2 was found to be
in the full-length form with only a small fraction existing in the truncated
form. Phosphorylation of Gli2 was found to be essential for Gli
degredation and Gli2 transcriptional activator function Pan et al. (2006). It
is very possible that this mechanism is conserved between species. In this
study it is demonstrated that GSK-3β has a negative effect on Hh
signalling in VSMCs and suggest that this regulation is through
phosphorylation of Gli2 by GSK-3β.
Another possible mechanism which we have yet to investigate is the
possibility that GSK-3β acts downstream of either Hh or VEGF in the
Hh-VEGF-Notch axis and is positively modulated by Hh or VEGF to
exert its effect on Notch. However, ectopic expression of wild type
GSK3β in pulmonary artery smooth muscle cells (PASMCS) reduced
VEGF promoter activity via β-catenin, a direct substrate of GSK-3β
activity (Clifford et al., 2008). Secondly, VEGF negatively regulates
GSK-3β in ECs, through the Akt pathway (Takeshita et al., 2007). This has
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yet to be investigated in SMCs, but conservation of the Hh-VEGF-Notch
axis in ECs suggests that this may occur similarly in VSMCs.
It is proposed, therefore, that GSK-3β is not a key player in the
upregulation of Notch signalling by Hh in VSMCs. The more likely
mediators of regulation of Notch signaling by VEGF in VSMCs are the
ligands Delta or Jagged. This is mechanism is observed in ECs where
VEGF upregulates Dll4 expression during angiogenesis. (Liu et al., 2003).
A role for the forkhead transcription factors, Foxc1 and Foxc2, in the
direct activation of Dll4 and HRT2 promoter activity though interaction
with VEGF has also been established in ECs (Seo et al., 2006). This study
also implicated a role of MAPK in this modulation by Foxc. Investigation
of the activity of these components in VSMCs is warranted to further
elucidate the mechanisms involved in the modulation of Notch signalling
by Hh and VEGF. A summary of these proposals is outlined in
Figure 4.13.
GSK-3β has a critical role in many cell processes, particularly cell
proliferation and apoptosis. GSK-3β has been shown to be
anti-proliferative in many contexts. In VSMCs, VLDLs and endothelin-1
promote proliferation through GSK-3β (Lipskaia et al., 2003), (Tang et al.,
2008a). GSK-3β has been shown to induce apoptosis in response to
hypoxia, DNA damage, heat shock and growth factor removal (Forde
and Dale, 2007). Specifically in VSMCs, enhanced GSK-3β activity
mediated hypoxia-induced apoptosis (Loberg et al., 2002) and glucose
transporter isoform (GLUT1) inhibits apoptosis via inhibition of GSK-3β
(Hall et al., 2001). GSK-3β has been shown to act downstream of the
PI3-kinase pathway in regulation of vascular smooth muscle cell
apoptosis (Allard et al., 2008). GSK-3β also prevents vascular cell growth
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Figure 4.13: Summary of Proposed Hh-VEGF-Notch Axis in VSMCs
following balloon injury in rats (Park et al., 2003).
This study, however, demonstrates a pro-survival role for GSK-3β in
VSMCs. It has previously been established that GSK-3β is absolutely
essential for survival, as GSK3β knockout mice died during embryonic
development (Hoeflich et al., 2000). A novel pathway in which GSK-3β
facilitates Nuclear Factor-κB activity, thus preventing tumor necrosis
factor-induced hepatocyte apoptosis, due to lack of GSK-3β activity, was
identified (Ougolkov et al., 2005).
The pro-apoptotic capacity of GSK-3β is thought to primarily occur
through modulation of the tumour suppressor protein p53, and GSK-3β
has been shown to directly bind and activate p53 (Watcharasit et al.,
2003). p53 has been shown to induces cell cycle arrest or apoptosis
through transcription-dependent and independent pathways and
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endogenous p53 protects vascular smooth muscle cells from apoptosis
and reduces atherosclerosis in ApoE knockout mice (Mercer et al., 2005).
Similarly, GSK-3β has the ability to directly regulate proliferation.
Cyclin-D1, a cell-cycle protein has been found to be a direct substrate of
GSK-3β (Diehl et al., 1998) and inhibition of GSK-3β induces upregulation
of cyclin D1 and DNA synthesis activity in VSMCs (Shin et al., 2003).
GSK-3β also inhibits the pro-survival transcription factors β-catenin,
c-myc and eIF2B (Beurel and Jope, 2006)
Here, a pro-survival role for GSK-3β in VSMCs through regulation of
Notch signalling is proposed. It has previously been shown that Notch is
pro-proliferative and anti-apoptotic in VMSCS. (Sweeney et al., 2004).
GSK-3β was identified as a positive modulator of Notch signalling in
VSMCs and it is demonstrated that GSK-3β positively modulates
proliferation and prevents apoptosis of VSMCs. It is also shown that
inhibition of GSK-3β induces apoptosis downstream of Notch signalling.
Ectopic expression of GSK-3β did not induce apoptosis in cycling
VSMCs. Inhibition of GSK-3β at its half maximal inhibitory concentration
(IC50) value (34nM) (Coghlan et al., 2000) also did not induce apoptosis.
However, a concentration that significantly reduced Notch receptor level
activity (25µM) increased apoptosis in VSMCs in resting cells. Based on
these findings, it is proposed that their is a concentration dependent
effect of GSK-3β on cell growth on VSMCs. GSK-3β is essential for VSMC
survival, possibly through modulation of the Notch signaling pathways
but at higher levels of GSK-3β activity and following various stimuli,
GSK-3β has the ability to induce apoptosis. An interesting review by
Beural and Jope (2006) discusses this paradoxical nature of GSK-3β and
suggests that GSK-3β induces the intrinsical/mitochondrial pathway,
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while inhibiting extrinsic/death-receptor apoptotic signalling (Beurel
and Jope, 2006). Notch has been shown to confer protection against
diverse stimuli that trigger both the intrinsic and extrinsic pathways
(Sade et al., 2004). It has previously been shown that Notch signalling is
anti-apoptotic in VSMCs (Sweeney et al., 2004). This current study
demonstrates that Notch signalling is regulated by GSK-3β in VSMCs,
and suggests that the pro-survival activity of GSK-3β in VSMCs occurs
through modulation of Notch downstream activity.
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4.4 Conclusion
GSK-3β contributes to both cell death and survival in many cell types,
including VSMCs. We identifed GSK-3β as a negative regulator of the
pro-proliferative Hh signalling pathway, while acting as a pro-survival
kinase, through the pro-proliferative Notch pathway. Taken together, it is
evident that maintenance of appropriate levels of GSK3 activity is crucial,
because either too little or too much GSK3 activity can promote cell death
in certain conditions (Doble and Woodgett, 2003). Notch signalling has
been implicated in the vascular response to injury and the neointimal
formation observed in many pathological vascular conditions (Li et al.,
2009). It was previously demonstrated that Notch signalling is involved
in the changes in cell fate that occur with altered biomechanical stretch
(Morrow et al., 2005b). In the following chapter, the role of GSK-3β in the
biomechanically-induced changes in Notch signalling in VSMCs was
investigated.
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Chapter 5
Results
5.1 Introduction
Blood vessels are permanently subjected to the haemodynamic forces of
pulse pressure and shear stress. The pulsatile nature of blood flow results
in a cyclic mechanical strain in the vessel walls. Altered cyclic strain in
which there is a decrease or increase in physiological levels of cyclic
strain has been shown to be pathogenic, resulting in changes in VSMC
growth, progressing to vascular remodelling and the onset of vascular
disease (Morrow et al., 2005a).
Cyclic circumferential strain is caused by a transmural force acting
perpendicularly to the vessel wall. Vascular smooth muscle cells convert
these mechanical signals into a biochemical response through
mechanosensors including integrins, G-protein and G protein-coupled
receptors, tyrosine kinase receptors and ion channels. The intracellular
pathways of PI3-kinase and mitogen-activated protein kinases (MAPK)
are also activated in response to mechanical stimuli (Li and Xu, 2000).
The strain-induced change in VSMC growth has been in shown to be
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dependent, in part, on Notch signalling (Morrow et al., 2005a). In this
study, the mechanism involved in the Notch response to cyclic strain was
further elucidated. GSK-3β was previously shown to have the ability to
regulate Notch under static conditions, and therefore, it is possible that it
may be involved in the strain-induced change in Notch signalling.
The aim of this chapter was to examine the specific role of uniform equibiaxial
cyclic strain on GSK-3β in an in vitro model of RVSMCs. The relationship
between GSK-3β and MAPK signaling in VSMCs was investigated. The
modulation of GSK-3β and components of the Notch signalling pathway in an in
vitro model of a stented artery, in an in vivo model of altered mechanical strain
and in human arteriosclerotic tissue was also examined.
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5.2 Results
5.2.1 Cyclic strain modulates Notch Signalling and GSK-
3β in VSMCs
Our lab has demonstrated previously that Notch signalling in RVSMC is
downregulated following biomechanical strain (Morrow et al., 2005b). It
was confirmed that the commercial cell line used in this study is
haemodynamically responsive to mechanical stimulation by analysing
the levels of transfected Notch1IC-GFP following exposure to strain.
Notch 1 IC-GFP levels were significantly reduced following exposure to
10% cyclic strain for 24 h when compared to static controls (Figure 5.1).
GSK-3β is primarily regulated through inhibitory phosphorylation on its
serine 9 residue. Therefore, the levels of serine 9 phosphorylation of
GSK-3β following exposure to 10% cyclic strain for 24 h were analysed.
Phosphorylation of GSK-3β increased with cyclic strain, therefore
indicating that GSK-3β activity decreased with cyclic strain. (Figure 5.2
and Figure 5.3 A). The level of GSK-3β mRNA expression following
exposure to 10% cyclic strain for 24 h was analysed (Figure 5.2). GSK-3β
mRNA expression increased following exposure to 10% cyclic strain for
24 h(1.40 ± 0.109 fold).
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Figure 5.1: Cyclic strain modulates Notch signalling in VSMCs. GFP
Expression in RVSMCs following transfection of a Notch1IC-GFP expression
plasmid in RVSMCs. RVSMCs were exposed to 10% biaxial cyclic strain for 24
hrs and compared to static controls (left frames). The images were quantified
using Image J (right frames). The experiment was performed in triplicate, with
the image representative of n=3
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Figure 5.2: Cyclic strain modulates GSK-3β activity in VSMCs. Imaging
of phospho-GSK-3β Expression following exposure of RVSMCs to 10% biaxial
cyclic strain for 24 hrs, as compared to static controls (left frames). The images
were quantified using Image J (right frames). The experiments were performed
in triplicate, with the image representative of n=3
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Figure 5.3: Cyclic strain modulates GSK-3β phosphorylation and mRNA
Expression. A) Western Blot of phospho-GSK-3β Expression following
exposure of RVSMCs to 10% biaxial cyclic strain for 24 hrs, as compared
to static controls. Expression was normalized to Ponceau levels (right
frame).B) Real-time PCR analysis of GSK-3β mRNA following exposure
of RVSMCs to 10% biaxial cyclic strain for 24 hrs, as compared to static
controls. Expression was normalized to GAPDH levels, and expressed as
fold increase over control. ∗p< 0.05 (student’s t-test). The experiments
were performed in triplicate, with the image representative of n=3.
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5.2.2 Rapid Phosphorylation of GSK-3β, p38 and p44/42 by
cyclic strain in VSMCs
Our previous study found that the cyclic-strain dependent change in
Notch IC expression is MAPK-dependent (Morrow et al., 2005b). This
study, therefore, examined if GSK-3β was involved in this strain-induced
effect (Morrow et al., 2005b). Both p38 and p44/42 are MAPKinases,
which are activated by phosphorylation, whereas GSK-3β is a
serine-threonine kinase which is primarily negatively regulated through
phosphorylation on its serine 9 residue, which forms an inactive form of
the enzyme (Shaw and Cohen, 1999). Firstly, it was confirmed that p38
and p44/42 are activated by strain by examining their phosphorylation
states following 30 min of exposure to 10% cyclic strain (Figure 5.4).
Phospho-GSK-3β was also increased following 10% cyclic strain for 24
hrs. GSK-3β mRNA showed only a slight increase following 10% cyclic
strain for 24 hrs, indictating that GSK-3β is primarily modified
post-translationally by cyclic strain (Figure 5.2).
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Figure 5.4: Biomechanical Strain modulates MAPK activity. Western blot
of phospho-p38, phospho-p44/42 and phospho-GSK-3β and total GSK-
3β following exposure of RVSMCs to 10% cyclic strain for 30 mins. The
experiments were performed in triplicate, with the images representative
of n=3.
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5.2.3 Effect of MAPK inhibition on GSK-3β activity in
VSMCs
The effect of MAPK inhibition on phosphorylation of the serine 9 residue
of GSK-3β was firstly examined following MAPK inhibition using a
pharmacological inhibitor of p38, PD169316 (Figure 5.5). No effect on
strain-induced phosphorylation of GSK-3β was observed following p38
inhibition in VSMCs. Similarly, when p42/44 was inhibited using the
pharmacological inhibitor PD098059, there was no effect on the
strain-induced phosphorylation of GSK-3β following p42/44 inhibition
in VSMCs (Figure 5.6).
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Figure 5.5: p38 inhibition does not modulate GSK-3β phosphorylation.
Western blot analysis of phospho-p38, pGSK-3β and total GSK-3β
following exposure of quiesced RSMVCs to 10% cyclic strain and
treatment of RSVMCs with RPMI containing PD169316 (30µM) for 30
min. The experiments were performed in triplicate, with the images
representative of n=3.
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Figure 5.6: p44/42 inhibition does not modulate GSK-3β
phosphorylation. Western blot analysis of phospho-p44/42, pGSK-
3β and total GSK-3β following exposure of quiesced RSMVCs to 10%
cyclic strain and treatment of RSVMCs with RPMI containing PD098059
(30µM) for 30 min. The experiments were performed in triplicate, with
the images representative of n=3.
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5.2.4 Effect of GSK-3β inhibition on MAPK activity in
VSMCs
The effect of GSK-3β inhibition on MAPK activity in VSMCs was
examined using the pharmacological inhibitor SB216763. Inhibition of
GSK-3β resulted in increased phosphorylation of p38 and p44/42 in static
quiesced VSMCs (Figure 5.7). In addition, pharmacological inhibition of
GSK-3β with SB216763 attenuated the strain-induced increase in p38 and
p44/42 phosphorylation, respectively (Figure 5.8).
Figure 5.7: pGSK-3β modulates MAPK activity Western blot analysis
of phospho-p38, phospho-p44/42 and total p44/42, following treatment of quiesced
RSVMCs with RPMI containing SB216763 (25µM) for 30 min. The experiments were
performed in triplicate, with the images representative of n=3.
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Figure 5.8: Cyclic strain induces phosphorylation of p38 and p44/42
MAPK in a GSK3β dependent manner. Western blot analysis of
phospho-p38, phospho-p44/42 and total p44/42, following exposure
of quiesced RVSMCs to 10% cyclic strain and treatment with RPMI
containing SB216763 (25µM) for 30 min. The experiments were performed
in triplicate, with the images representative of n=3.
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5.2.5 In vitro model of a Stented Artery
Restenosis of an artery is known to occur in many instances following
deployment of a stent after angioplasty (Luscher et al., 2007). The
mechanism of regrowth is, however, not fully understood. An in vitro
model of a stented mock coronary artery (MCA) was used to examine the
role of the Notch signaling pathway and GSK-3β in in-stent restenosis.
The MCA mimics the strain and flow of a carotid artery following
expansion of a stent. Due to the rigidity of the stent material, a high mean
strain/low strain amplitude exists in the stented region, compared to a
low mean strain/high amplitude upstream and downstream of the stent.
BVSMC proliferation is increased in the stented region of the MCA,
compared to the regions upstream, and downstream of the stent
(Figure 5.9 A.)(Images provided courtesy of Alberto Columbo). The
regulation of GSK-3β and Notch1 in an in-vitro model of a stented artery
was investigated. Phosphorylation of GSK-3β protein was reduced in
BVSMCs in the stented region of the Sylgard phantom compared to a
region upstream of the stent (Figure 5.9). Notch1 protein was analysed
using an antibody targeted against full-length Notch1. The levels of
full-length Notch1 is reduced in the stented region of the artery
(Figure 5.10). This indicates therefore, that the level of Notch1 IC was
increased in the stented region of the tubing compared to a region
upstream of the stent (Figure 5.10).
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Figure 5.9: GSK-3β modulation in an in vitro model of a stented artery.
A) DAPI staining of BSMCs in stented, upstream and downstream regions of MCA
(Images provided courtesy of Alberto Columbo). B) Immunostaining of phospho-GSK-
3β in the stented region and upstream region of MCA (left frame.) The images were
quantified using Image J (right frame).
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Figure 5.10: Notch1 modulation in an in vitro model of a stented artery.
Immunostaining of Notch1 in the stented region and upstream region of
MCA (left frame.) (20x magnification) The images were quantified using
Image J (right frame).
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5.2.6 In vivo model of biomechanical-induced vascular
remodelling
The regulation of GSK-3β and Notch signaling components was
investigated in an in vivo model of biomechanical-induced vascular
remodelling in which the left carotid artery of a rat was completely
ligated. Medial thickening and neointima formation is observed in the
left carotid artery 14 days after ligation (Morrow et al., 2009). The
presence of Notch1 IC, Patched 1 and Gli2 has been previously shown in
the neointima and medial artery of the remodelled vessel (Morrow et al.,
2009). RNA was isolated 14 days post-ligation and expression levels of
GSK-3β, and HRT3 were analysed. GSK-3β mRNA decreased to 0.35 ±
0.09 fold and HRT3 mRNA levels also decreased to 0.209 ± 0.06 fold in
the ligated vessels compared to the contralateral control(Figure 5.12).
The levels of GSK-3β and HRT3 were investigated in a partially
ligated in vivo model of biomechanical-induced vascular remodelling and
the levels were found to be decreased 3 days post-ligation (to 0.32 ± 0.06
fold and 0.30 ± 0.13 fold, respectively, n=3)(Figure 5.11).
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Figure 5.11: GSK-3β and HRT3 are modulated in a totally-ligated mouse
carotid artery. Real-time analysis of GSK-3β and HRT3 following total-
ligation of the left carotid artery of a C57B16/J mice and isolation of
mRNA 14 day post-ligation (4 vessels per preparation, n=2). Expression
was normalized to GAPDH levels, and expressed as fold increase over
control. ∗p< 0.05, ∗∗ p< 0.01 as compared to contralateral control
(students t-test) 187
Figure 5.12: GSK-3β and HRT3 are modulated in a partially-ligated
mouse carotid artery. Real-time analysis of GSK-3β and HRT3 following
total-ligation of the left carotid artery of a C57B16/J mice and isolation of
mRNA 3 day post-ligation (4 vessels per preparation, n=3). Expression
was normalized to GAPDH levels, and expressed as fold increase over
control. ∗∗p< 0.01 as compared to contralateral control (students t-test)
.
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5.2.7 GSK-3β, HRT3 and Patched1 are modulated in
human arteriosclerosis
Human cDNA derived from an arteriosclerotic region of the aorta of a 76
year old, caucasian male was purchased from Biochain. cDNA derived
from a non-arteriosclerotic region of the aorta from the same donor was
purchased as control. The mRNA expression level of GSK-3β was 0.30
fold lower in the arteriosclerotic tissue compared to the
non-arteriosclerotic control. The mRNA expression levels of HRT3 and
Patched1 were also lower in the arteriosclerotic tissue compared to the
non-arteriosclerotic control (0.79 fold and 0.81 fold respectively)
(Figure 5.13).
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Figure 5.13: GSK-3β, HRT3 and Patched1 are modulated in a human
arteriosclerotic aorta. Real-time analysis of GSK-3β, HRT3 and Patched
using mRNA derived from an arteriosclerotic region of a human aorta.
Expression was normalized to GAPDH levels, and expressed as fold
increase over control. Gene expression levels were compared to a non-
arteriosclertoic region of the same aorta.
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5.3 Discussion
Haemodynamic forces play an important role in vascular pathologies and
components of the Notch signalling pathway are regulated in vascular
tissue after injury (Wang et al., 2002). Our study confirmed that Notch
signalling is decreased following cyclic strain, as previously described
(Morrow et al., 2005b). Having established a role for GSK-3β in the
regulation of Notch signalling in static cultures, the activity of GSK-3β
following exposure to cyclic strain was examined. GSK-3β activity was
found to be decreased following cyclic strain through phosphorylation of
its serine 9 residue. Interestingly, transcription of GSK-3β was increased
following exposure to strain for 24 h. While GSK-3β activity is primarily
regulated through phosphorylation, its transcriptional upregulation
following strain represents an adaptive mechanism to attenuate the
phosphorylation modification exerted by strain.
Cyclic strain has been shown to activate Akt in bovine VSMCs by
phosphorylation (Chen et al., 2001) and Akt and GSK-3β are also
phosphorylated by strain in endothelial cells (Nishimura et al., 2006).
GSK-3β is a direct substrate of Akt through the PI3-kinase pathway
(Doble and Woodgett, 2003) and it is possible that GSK-3β is
phosphorylated through this PI-3kinase pathway following strain.
MAPKinases, including p44/42 and p38, are serine-threonine kinases
that regulate a wide range of cellular activites and are activated by a
variety of stimuli. It has been demonstrated in numerous studies that
p44/42 and p38 are regulated by strain in VSMCs (Tock et al., 2003), (Li
et al., 2000), (Li et al., 1999a). Cyclic strain has a temporal effect on these
MAPK in VSMCs with rapid activation of p38 and p44/42 up to 30 mins
followed by a decline thereafter that is thought to be
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MAPK-phosphatase-1 (MKP-1) dependent (Li et al., 1999a). The rapid
induction of p38 and p44/42 activation was demonstrated and it was also
demonstrated that GSK-3β is similarly rapidly phosphorylated.
It has been previously demonstrated that the strain-dependent change
in Notch signalling in VSMCs is MAPK-dependent (Morrow et al., 2005b),
as inhibition of p44/42 activation attenuated the strain-induced decrease
in Notch signalling.
As discussed previously, GSK-3β was found to be a regulator of Notch
signaling in static VSMCs. It is possible that GSK-3β may regulate Notch
signaling in strained cells, through interaction with the intracellular
MAPK pathway Therefore, it was investigated if there was a relationship
between the strain-induced phosphorylation of GSK-3β and activation of
p38 and p44/42 in VSMCs. There was no significant change in
strain-induced GSK-3β phosphorylation following inhibition of p44/42
using the MEK inhibition PD098059. Similarly, there was no significant
change in strain-induced GSK-3β phosphorylation following inhibition of
p38 by the pharmacological inhibitor PD169316. However, as previously
discussed GSK-3β is phosphorylated by strain-activated Akt, which may
prevent detection of a MAPK- effect. Further investigation using a
PI3-kinase inhibitor such as wortmannin, may elucidate further whether
MAPK activity contributes to the strain-induced phosphorylation of
GSK-3β in VSMCs. Additionally, p44/42 or p38 may regulate GSK-3β
activity through a mechanism independent of serine 9 phosphorylation.
In mouse embryonic carcinoma F9 cells, p38 mitogen-activated protein
kinase regulates canonical Wnt-β-catenin signalling by inactivation of
GSK3 β (Bikkavilli et al., 2008) and ERK has a similar effect on the
GSK-3beta/beta-catenin pathway in human lung fibroblasts (Caraci et al.,
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2008). GSK-3β is thought to be regulated in the Wnt pathway
independently of serine 9 phosphorylation (Ding et al., 2000).
Additionally, an alternative phosphorylation pathway for GSK-3β in the
Wnt pathway has been identified, where p38 regulates GSK-3β by direct
phosphorylation at its C terminus rather then the serine 9 at the
N-terminus (Thornton et al., 2008).
GSK-3 has been shown to be a negative regulator of MAPK in a number
of cell types including human colon cancer cells (Wang et al., 2005) , rat
skeletal muscle (Macko et al., 2008) and rat primary astrocyes (Kim et al.,
2007). Similarly, pharmacological inhibition of GSK-3β in quiesced static
VSMCs was found to induce rapid activation of p38 and p44/42. This
may occur through inhibition of a kinase upstream of p38 and p44/42,
as GSK-3β has previously been shown to reduce MEKK4 stimulation of
p38 in COS-7 cells (Abell et al., 2007). It was then determined that under
strain conditions, inhibition of GSK-3β through phosphorylation accounts
for the rapid activation of p38 and p44/42.
PDGF has the ability to inactivate GSK-3β while activating p44/42 in
VSMCs (Huang and Kontos, 2002) and PDGF inhibits Notch signaling in
VSMCS through induction of p44/42 (Wang et al., 2002). A novel GSK-3β-
MAPK-Notch pathway may exist, therefore in which a stimulus such as
PDGF or, in the case of this study, strain can negatively modulate Notch
signalling.
The mediator of the MAPK effect on Notch signalling following cyclic
strain has yet to be determined. A possible mechanism is through
regulation of γ-secretase, as p44/42 but not p38 has been shown to reduce
cleavage of Notch1 through modulation of γ-secretase activity in human
embryonic kidney cells (Kim et al., 2006). A Hh-VEGF-Notch signaling
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pathway in VSMCs, in which Notch is positively regulated was
previously identified. A previous study in our lab and further confirmed
in the present study has also shown that Hh is regulated by strain
(Morrow et al., 2007). It is possible therefore that MAPK exerts its effect
on Notch signaling through downregulation of the Hh-VEGF-Notch axis.
However, cyclic strain has been shown to induce the expression of VEGF
in VSMCs (Smith et al., 2001). Additionally, retinal pericyte VEGF
expression is induced by strain independently of p44/42 or Akt (Suzuma
et al., 2002). Moreover, it has been previously shown that Notch signaling
can rescue the strain-induced decrease in Hh downstream signaling
(Morrow et al., 2007). A reduction in this feedback by Notch may,
therefore, account for the downregulation of Hh signaling observed in
VSMCs following strain.
As discussed previously, Foxc2 is a possible candidate for Notch
signalling modulation in VSMCs. Interestingly, ERK activity inhibits
Foxc2-dependent upregulation of Dll4 and Hey2 expression in ECs and
both Foxc1 and Foxc2 have 10 potential phosphorylation sites for ERK
(Hayashi and Kume, 2008). The Foxc transcription factors, therefore, may
be involved in the MAPK-dependent strain-induced modulation of
Notch signaling in VSMCs, possibly through regulation of Notch ligand
expression. An outline of our proposals are summarised in Figure 5.14.
Expression of the Notch ligand, Jagged1 was previously shown to be
decreased following cyclic strain. p38 MAP kinase negatively regulates
Jagged1 expression in FGF-2 stimulated ECs (Matsumoto et al., 2002).
Induction of Jagged-1 in bone-marrow derived macrophages (BMM)s by
soluble egg antigen (SEA) is , however, increased by ERK signalling (Goh
et al., 2008). In any case, the relationship between Jagged1 and MAPK
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signaling in VSMCs following exposure to strain warrants further
investigation.
In the vasculature, altered smooth muscle cell growth contributes to
neointima formation and vascular remodelling during arteriosclerosis,
atherosclerosis, and restenosis after angioplasty, including in-stent
restenosis (Gosens et al., 2008). Remodeling is a change in the
composition of the artery that occurs in response to chronic changes in
hemodynamic conditions (Kumar et al., 1997). Restenosis is one of the
major limitations of percutaneous transluminal coronary angioplasty
(PTCA). It occurs as a combination of neointimal formation and arterial
remodeling in response to balloon injury. Although stents are deployed
to prevent the closure of the lumen, restenosis may still occur (Post et al.,
1997). A direct consequence of stent expansion in a vessel is that the
mechanical environment changes from a low mean strain/high
amplitude to a condition of high mean strain/low strain amplitude.
Recent studies in our lab have identified that a decrease in the amplitude
of cyclic strain is more conducive to proliferation of VSCMs than the level
of mean cyclic strain (Alberto Columbo, in discussion) and may account in
part to the restenosis observed in some instances following stent
implantation. We investigated the regulation of GSK-3β in VSMCs in an
in vitro model of a stented mock coronary artery (MCA) and found that
GSK-3β activity was increased through reduction of phosphorylation on
its serine 9 residue in the stented region compared to a region upstream
of the stent. Similarly, Notch1 levels were increased in the stented region
compared to a region upstream of the stent. This correlates with our data
from the FlexercellTension System, where an increased amplitude of
strain (0%-10% compared to 0% static control) decreased the levels of
195
Figure 5.14: Summary of Hypothesised GSK-3β-MAPK-Notch Pathway
in VSMCs following Exposure to Strain
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Notch 1IC and GSK-3β activity. It suggests that GSK-3β may play a
putative role in in-stent restenosis through modulation of Notch
signaling. It also highlights the importance of the compliance of a stented
vessel in modulating the pro-proliferative Notch signaling pathway and
suggests that this is an important factor when considering stent design.
While our in vitro models assist in identifying possible key players
and the mechanisms involved in vascular diseased states, we can only be
confident of their role in pathological conditions through the use of in
vivo models. In this study, an in vivo model was used in which blood flow
in the left common carotid artery of the mouse was arrested by ligation,
causing blood statis and a low amplitude condition within the ligated
artery and a high flow environment in the contralateral non-ligated right
carotid artery. In this model, remodeling occurs proximal to the ligation
site as a consequence of the altered biomechanical forces. A recent study
has shown that Notch1 but not Notch3 mediates this neointimal
formation after vascular injury in the same carotid ligation model Li et al.
(2009). A recent study in our lab has shown that Notch1 and its target
genes are increased in the completely ligated models in a time-dependent
manner. Notch and downstream target mRNA is initially upregulated in
the artery 3 day post-ligation. This is followed by an observed increase in
Notch and target gene protein expression 14 days post-ligation,
concomitant with a reduction in Notch and target gene mRNA, perhaps
as an adaptive mechanism (Figure 5.15 A and B). Patched1, the
downstream Hh target gene is also significantly enhanced in the intima
and media of remodeled carotid arteries concomitant with a significant
increase in the expression of the Hh transcription factor Gli2 (Figure 5.15
A (ii) and B (ii) (Morrow et al., 2009).
197
Figure 5.15: Notch and Hh signaling component expression is increased
in a biomechanically-induced remodelled carotid artery (Morrow et al.,
2009). (a) (i) Haemotoxylin and eosin staining of ligated left carotid artery
compared to sham control from C57B16/J mice, 14 days after ligation.
(ii) Ptc1 and HRT3 immunohistochemical staining in LCA (iii) Gli2 and
N1 immunohistochemical staining in LCA. (B)(i) Quantification of artery
volume. (ii) Ptc1 and Gli2 mRNA expression in ligated arteries compared
to conlateral control. (iii) Notch1, HRT2 and HRT3 mRNA expression in
ligated arteries compared to conlateral control.
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This correlates with the hypothesis of a Hh-VEGF-Notch axis in
VSMCs that acts to promote VSMC growth. We have already determined
that GSK-3β is a regulator of Notch signaling and is modulated by cyclic
strain in VSMCs. Here, GSK-3β in two in vivo ligated carotid artery (LCA)
models was examined. The first involved complete ligation of the carotid
artery, causing complete interruption of flow, and the second involved a
partial ligation, allowing a low rate of flow within the ligated artery.
Notch and its downstream targets were examined in the same models
and it was determined that GSK-3β is regulated in the same manner as
Notch in these two models of biomechanically-induced vascular
remodelling.
GSK-3β has previously been studied in balloon angioplasy models.
Balloon injury has been shown to inhibit GSK-3β activity (Park et al.,
2003), which is thought to contribute to VSMC survival and subsequent
neointimal formation (Hall et al., 2001), (Park et al., 2003). In this model, it
is proposed that the growth factors, matrix protein and proteases that are
released following mechanical damage by the balloon catheter could
inhibit GSK-3β (Gosens et al., 2008). As discussed previously, GSK-3β is
known to stimulate VSMC apoptosis following growth factor withdrawal
(Beurel and Jope, 2006) and it has also been suggested that inhibition of
GSK-3β promotes neointima formation in balloon injury through
modification of β-catenin (Park et al., 2003). Interestingly, Notch3 and the
downstream HRT effector genes are also down regulated in response to
rat carotid artery ballon injury (Wang et al., 2002). Additionally, MAPK
are known to be rapidly activated in arteries following balloon
angioplasty (Pyles et al., 1997). A dual role for inhibition of GSK-3β
following balloon angioplasty may exist, firstly through upregulation of
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β-catenin signaling and secondly, through a
PDGF-GSK-3β–MAPK-Notch pathway, as previously discussed.
A similar Strain-GSK-3β-Notch pathway may exist in the LCA model.
GSK-3β is negatively regulated by strain and here, it was shown that
GSK-3β is modulated, similar to Notch in an in-vivo model of low flow. It
is proposed that GSK-3β is involved in the biomechanical-modulation of
Notch signaling to promote vascular remodeling. GSK-3β can promote
cell survival of VSMCs through regulation of Notch signalling and
GSK-3β may play an important role in controlling changes in VSMC
proliferation following biomechanical-induced vascular remodeling.
The final study examined the role of GSK-3β and Notch signaling in
human arteriosclerotic disease. The expression of GSK-3β and the
downstream targets of the Notch (HRT3) and Hh signaling pathways
(Patched1) were reduced in arteriosclerotic tissue from a human aorta
compared to non-arteriosclerotic tissue from the aorta of the same donor.
Due to restricted availability, it was only possible to perform analysis of
tissue from one donor. However, it confirms that GSK-3β and the Notch
and Hh pathways are important players in the pathogenesis of vascular
disease and that their relationship and regulation warrants further
investigation in future in vivo studies.
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5.4 Conclusion
Haemodynamic forces play an important role in vascular pathologies and
components of the Notch signaling pathway are regulated in vascular
tissue after injury (Wang et al., 2002). Our study confirmed that Notch
signaling is decreased following cyclic strain, as previously described
(Morrow et al., 2005b). Having established a role for GSK-3β in the
regulation of Notch signaling in VSMCs, GSK-3β activity was
investigated and found to be decreased following exposure of VSMCs to
cyclic strain. A strain-dependent change in Notch signaling is
MAPK-dependent has previously been demonstrated (Morrow et al.,
2005b). Inhibition of GSK-3β was found to increase both p38 and p44/42
activity in RVSMCs and attenuated the strain-induced increase in
phosphorylation. The modulation of GSK-3β was investigated in an in
vivo model of biomechanically-induced remodelling. GSK-3β was found
to be regulated in the same manner as Notch and its downstream targets,
suggesting that GSK-3β contributes to the altered cell fate that occurs in
remodelling due to impaired Notch signalling. GSK-3β and Notch
activity was then examined in an in vitro model of a stented coronary
artery. GSK-3β activity and Notch1 levels were found to be increased in
this model, suggesting a role for GSK-3β and Notch1 in in-stent
restenosis. GSK-3β, HRT3 and Patched1 expression levels were found to
be modulated in human arteriosclerosis. Taken together, these findings
implicate GSK-3β in altered vascular cell fate decisions that occur in
diseased states due to impaired Notch signaling. Increased
understanding of Notch signaling and VSMC fate may contribute to
future therapeutic strategies against cardiovascular disease.
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Chapter 6
Discussion
Altered vascular cell fate decisions are critical to the pathogenesis of
vascular diseases, including hypertension, arteriosclerosis,
atherosclerosis and restenosis after angioplasty. Notch signalling has
been widely proven to have an important role in controlling cell fate in
the development of the vasculature during embryogenesis (Gridley,
2007). A growing body of evidence suggests that Notch signalling is one
of a number of signalling pathways recapitulated in adult cells resulting
in altered fate decisions leading to vascular disease (Sweeney et al., 2004).
Haemodynamic forces play an important role in the physiological control
of vascular tone. Altered haemodynamic forces have been implicated in
the changes in cell fate associated with vascular disease. Notch signalling
is known to be responsive to changes in haemodynamic forces in VSMCs
(Morrow et al., 2005b). The canonical Notch pathway involves binding of
a ligand to a transmembrane receptor, resulting in the release of an active
Notch IC fragment. The Notch IC then translocates to the nucleus where
it associates with a CBF-1 DNA-binding protein to assemble a
transcription complex that activates downstream target genes. Notch
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signalling is a conserved pathway that is highly regulated through a
number of mechanisms including cleavage, trafficking and
post-translational modification of its ligand and receptors.
Notch IC has been shown to be hyperphosphorylated and
phosphorylated forms of Notch have been identified in the nucleus (Foltz
and Nye, 2001). GSK-3β is a serine-threonine kinase that was initially
identified as a regulator of glucose metabolism (Hall et al., 2001). Its
GSK-3α isoform is a structurally similar, but functionally distinct kinase
(Lee et al., 2007). Both enzymes are unique kinases in that they are
constitutively active in resting cells and are negatively regulated through
phosphorylation on a serine 9 residue (β form) or serine 21 residue (α
form) (Pearl and Barford, 2002). Additionally, the GSK-3β may require a
priming kinase upstream of substrate binding (Liu et al., 2004). Similar to
active NotchIC, a predominantly active form of GSK-3β is found in the
nucleus and GSK-3β has the ability to phosphorylate Notch1 and Notch2
(Espinosa et al., 2003), (Foltz et al., 2002). The regulation of Notch by
GSK-3β in VSMCs was examined and it was determined that GSK-3β
positively regulates both Notch1 and Notch3 receptor levels, Notch
downstream target gene expression of HRT 1-3 and CBF-1 promoter
activity in VSMCs. GSK-3β also regulated transcriptional expression of
Notch1 in VSMCs, suggesting that GSK-3β may regulate Notch signaling
independently of direct binding or phosphorylation. Alternatively, a
positive signalling feedback loop is known to exist in Drosophila and
vertebrate Notch signalling and this may account for transcriptional
regulation of Notch1 by GSK-3β (De Celis and Bray, 1997), (Del Monte
et al., 2007).
The Hh pathway is a developmental pathway involved in
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angiogenesis. Shh and VEGF have been shown to act upstream of Notch
during arterial endothelial differentiation (Lawson et al., 2002). It was
investigated if this crosstalk was conserved in VSMCs and it was
determined that Shh upregulates Notch signaling in VSMCs through
increased VEGF expression. Hedgehog signalling functions thorough
binding of the Hh ligand to its transmembrane receptor, Ptc1 or Ptc2.
Binding of Hh ligand to Ptc removes its repressive effect on the second
transmembrane Smo. Smo prevents degredation of downstream Gli.
Full-length Gli is stabilised and is translocated to the nucleus, where it
initates transcription of its downstream targets. The downstream targets
of the Gli gene products include both Ptc1-2 and Gli1-2 (Mullor et al.,
2002). The role of GSK-3β in Hh signaling in VSMCs was investigated
and it was found that GSK-3β negatively modulates Ptc1 expression, Gli2
expression and Gli2 promoter activity. GSK-3β has been shown to
phosphorylate Ci, the Drosophila form of Gli, and target it for
proteosomal degredation. Therefore, it was proposed that GSK-3β
negatively regulates Hh signalling in VSMCs through direct
phosphorylation of Gli.
Notch is known to be pro-proliferative and anti-apoptotic in VSMCs
(Morrow et al., 2005a) and may be a player in the altered vascular cell
phenotype observed in pathophysiological environments, such as
vunerable plaques and restenosis after injury (Fung et al., 2007). GSK-3β
is a pluripotent kinase involved in many aspects of cell signaling and is
known to regulate cell fate in a context and cell-type dependent manner.
Specifically, it has been shown to inhibit cell growth in VSMCs in
response to hypoxia and GLUT1. The role of GSK-3β in cell growth in
serum-stimulated cycling VSMCS was investigated and it was
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demonstrated that GSK-3β positively modulates proliferation and
prevents apoptosis of VSMCs. Ectopic expression of Notch3 was not
shown to attentuate the induction of apoptosis by pharmacological
inhibition of GSK-3β. GSK-3β was shown to modulates downstream
signalling of Notch and, here, it is suggested that GSK-β modulates
apoptosis of VSMCs downstream of Notch signalling. This implicates
GSK-3β in the regulation of Notch in the vascular response to injury and
the neointimal formation observed in many pathological vascular
conditions (Li et al., 2009).
The pulsatile nature of blood flow creates a haemodynamic stimuli of
cyclic stretch which is sensed by VSMCs. VSMCs have the ability to
convert the biomechanical stimuli of cyclic stretch into a biochemical
response, through mechanosensors that include G proteins, integrins,
receptor tyrosine kinases and intracellular pathways, including MAPK
signalling (Haga et al., 2007). Notch signalling in VSMCs is
downregulated by strain (Morrow et al., 2005b). The modulation of
GSK-3β by cyclic strain was investigated and it was found that it is also
down-regulated in VSMCs through phosphorylation on serine 9. Notch
sigalling is modified in VSMCs in a MAPK-dependent manner. A
relationship between GSK-3β and the MAPK, p44/42 and p38 in VSMCs
following cyclic strain was determined. This suggests an interaction
occurs through activation of p44/42 and p38, following inhibition of
GSK-3β through phosphorylation on serine 9 following strain.
The focus of this study has been the regulation of Notch signalling by
GSK-3β in VSMCs at the level of receptor modulation. The modulation
of Notch ligand has yet to be examined and there is a limited number of
studies on Notch ligand expression in VSMCs.
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The importance of Jag1 in disease pathogenesis is highlighted in
Alagille Syndrome. This is an autosomal dominant disorder
characterized by development abnormalities of a number of organs
including the liver, heart, and eye and most cases are caused by the Notch
ligand, Jagged 1, mutations (Kamath et al., 2004). There are five
mammalian Notch ligands of which Delta-like 1(Dll1),Delta-like 3 (Dll3)
and Delta-like 4 (Dll4) are structurally similar to Drosophila Delta and
Jagged1 (Jag1) and Jagged2 (Jag2) are structurally similar to Drosophila
Serrate (D’Souza et al., 2008). Notch receptors transduce signals from
intimal endothelial cells and adjacent VSMCs to regulate the proliferative,
differentiation capacity and survival of VSMCs. Of the five ligands, Dll1,
Dll4 and Jag1 are prevalently expressed in EC. Dll1 and Dll4 is critical in
Notch signaling between adjacent endothelial cells. Dll-1 is essential for
artery-vein distinction, (Limbourg et al., 2007), (Sorensen et al., 2009). Jag1
and Jag2 and, to some degree Dll1, are also found in VSMC (Cristofaro
and Emanueli, 2009). A ligand specific role for Jag1 in differentiation of
mesenchymal cells to vascular cells was identified when Jag1, but not
Dll4 stimulated the SMC marker SMC-mhc, gene expression (Doi et al.,
2006). The endothelial expression of Jag1 is crucial for VSMC fate in
development. Endothelial-specific deletion of Jag1 resulted in embryonic
lethality and cardiovascular defects. The embryos showed striking
deficits in vascular smooth muscle, whereas endothelial Notch activation
and arterial-venous differentiation appeared normal (High et al., 2008).
Notch ligands are regulated similar to the receptors through
mechanisms including glycosylation, ubiquitination, endocytosis,
proteolysis and control of ligand expression (D’Souza et al., 2008). There
are a number of studies that identify a role of crosstalk of Hh and VEGF
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in the regulation of Notch ligand expression levels. Hh is known to
stimulate Jagged1 expression in mesenchymal cells (McGlinn et al., 2005).
VEGF has been shown to stimulate both Dll1 and Dll4 in endothelial cells
during arteriogenesis and angiogenesis (Limbourg et al., 2007), (Seo et al.,
2006). As previously discussed, therefore, Jag1 may be a mediator of
VEGF upregulation of Notch signaling in VSMCs A role for the forkhead
transcription factors, Foxc1 and Foxc2, in the direct activation of Dll4 and
HRT2 promoter activity though interaction with VEGF has been
established in ECs (Seo et al., 2006). The relationship between VEGF,
forkhead transcription factors and Jag1 warrants investigation in VSMCs.
The Wnt pathway, which results in GSK-3β inhibition, has additionally
been shown to regulate Notch ligand expression. Wnt signaling is known
to regulate Dll1 expression in the presomitic mesoderm of mouse
embryos (Hofmann et al., 2004). Additionally, the GSK-3β substrate
β-catenin targets Jag1 in ectopic hair follicle formation in adult epidermis
(Estrach et al., 2006). This mechanism has also yet to be investigated in
VSMCs.
In VSMCs, PDGF downregulates Jag1 and downstream Notch target
gene expression. (Campos et al., 2002). This downregulation has been
shown to be mediated by p44/42 and p38 activity. Campos et al.
postulate that this occurs through post-translational modification of Jag1,
possibly through glycosylation. We have identified Jag1 as a Notch
signalling component that is downregulated following cyclic
strain(Morrow et al., 2005b). This suggest that GSK-3β may exert an effect
on Notch signalling following cyclic strain through modulation of Jag1
expression through activation of p44/42 and p38 but this has yet to be
confirmed.
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The pathogenesis of atherosclerosis involves progressive lipid
accumulation, inflammation and smooth muscle cell proliferation in a
period of many years. Angioplasty and in-stent restenosis differs in that
hyperlipidaemia does not play an important role in restenosis and its
pathogenesis occurs over the course of a few weeks and months (Kibos
et al., 2007). It involves a rapid vasoconstrictive response due to
endothelial disruption caused by overstretch of the vessel, known as
elastic recoil. This recoil is reduced by stent implantation. Rapid platelet
activation, thrombin secretion and an inflammatory response is followed
by VSMC proliferation, ECM production, neointimal formation and
vascular remodelling (Schillinger and Minar, 2005).
The role of GSK-3β and Notch signaling in in-stent restenosis was
investigated using a perfused stented mock coronary artery (MCA). The
MCA consists of Sylgard R©, which mimics the mechanical properties of a
coronary artery. BSMCs were seeded onto the tubing and a bare-metal
stent was deployed. The MCA was then exposed to pulsatile flow for 7
days. The environment in a stented artery changes from a low mean
strain/high amplitude to a condition of high mean strain/low strain
amplitude due to the rigidity of the stent. GSK-3β activity and Notch1
levels were shown to be upregulated in BASMCs in a stented
environment compared to the upstream non-stented environment. This
suggests that altered cyclic stretch correlates with increased VSMC
proliferation observed in in-stent restenosis through impaired Notch
signalling mediated by GSK-3β. Additionally, it highlights the
importance of the compliance of a stented vessel in modulating the
pro-proliferative Notch signaling pathway and suggests that this is an
important factor when considering stent design. Moreover, it suggests
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that there is an involvement of Notch signaling in vascular conditions in
which artery compliance is impaired, such as age-related arteriosclerosis,
which warrants further investigation.
A number of factors contribute to impaired vascular cell fate in
intimal hyperplasia, vascular remodelling and the arterial response to
injury, including the release of growth factors and inflammatory
cytokines from ECs, platelets and macrophages and impaired
haemodynamic environments. Abbregated Notch signaling is modulated
by a number of factors in these disease states. Members of the
Jagged/Notch gene families are expressed in injured arteries and
regulate cell phenotype via alterations in cell matrix and cell-cell
interaction (Lindner et al., 2001). The pro-inflammatory TNF has been
shown to induce Jag1 in endothelial cells in a NFκB-dependent manner
(Johnston et al., 2009). Notch signaling is also associated with the
differentiation of bone-marrow derived cells into SMC or SMC-like cells.
These cells attach on injured arteries and are involved in arterial lesion
formation (Doi et al., 2009). Dll4 is also associated with Notch signaling
and may mediate inflammatory responses in macrophages (Fung et al.,
2007). A critical role for Notch signaling in injury-induced vascular
remodeling was demonstrated in a study where HRT2 knockout mice
showed decreased neointimal formation after vascular injury (Sakata
et al., 2004). In the in vivo ligated carotid artery(LCA), Notch1, but not
Notch3 was identified as a mediator of SMC proliferation and neointimal
formation after vascular injury (Li et al., 2009).
The in vivo LCA model involves arresting of blood flow in the left
common carotid artery of the animal. Remodelling of the artery, leads to
stenosis, a narrowing of the lumen and, therefore, a high mean strain
209
within the artery. However, the arrest of pulsatile flow results in a
decrease in the amplitude of the strain. The LCA model, therefore, allows
us to examine Notch regulation in an in vivo model of low flow/ low
amplitude of cyclic strain, similar to the haemodynamic environment of a
stented artery. We identified the importance of impaired cyclic stretch on
GSK-3β and the Notch signaling modulation of cell fate in vitro. Using
the in vivo model LCA, a biphasic response of Hh, VEGF and Notch
signaling components was previously demonstrated in these models and
the expression of Notch and components in both the intima and media of
carotid arteries (Morrow et al., 2009). In this study, the modulation of
GSK-3β in the same manner as Notch signalling was demonstrated in
both a partially ligated and totally ligated LCA model. We additionally
investigated the role of GSK-3β and Notch and Hh downstream targets in
human arteriosclerosis and found that they were similarly modulated,
thus backing up the hypothesis that GSK-3β crosstalks with Hh and
Notch signaling during neointimal information and the vascular
response to injury.
The hypothesis is summarised in Figure 6.1. Under physiological
conditions, a high amplitude cyclic strain environment exists that
negatively regulates GSK-3β, thus inhibiting Notch signaling and VSMCs
proliferation, through activation of p44/42 and p38. In pathological
conditions, strain-induced inhibition of GSK-3β is abrogated, leading to a
decrease in MAPK-induced Notch signaling. Additionally, Hh signaling
is induced which contributes to aberrant Notch signalling through VEGF
expression.
Apart from modulation by GSK-3β, new novel methods of regulation
of Notch signalling are constantly being researched. These include
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Figure 6.1: Proposed Modulation of Notch Signalling in Altered
Haemodynamic Environments.
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non-canonical ligand activity by DNER, MAPG1 and MAPG2 (D’Souza
et al., 2008) and repression of Notch activation by soluble forms of Dll and
Jagged (Urs et al., 2008). While their are many studies on regulation of
Notch signaling since it was first identified as a neurogenic gene in
Drosophila, a nominal number of studies examine the role of
micro-RNAs in its modulation. Micro-RNAs (miRNAs) are
approximately 22 nucleotide endogenous non-coding single stranded
RNAs which are enocoded within the genome and are predicted to
regulate at least one-third of all human genes (Condorelli and Dimmeler,
2008). Following processing by the RNase III enzymes Drosha and Dicer,
the mature miRNAs act in gene silencing pathways through the
regulation of mRNA stability and protein translation. miRNAs that bind
to their mRNA targets with perfect complementarity induce target
mRNA cleavage through degredation by endoribonucleases in the RNA
Induced-Silencing complex of the RNAi pathway (Nelson and Weiss,
2008). miRNAs that bind with imperfect complementarity within the 3’
untranslated region (UTR) region repress translation of the gene, while
mRNA levels remains stable (Lim et al., 2005). Expression of miRNAs are
tissue-specific. Abundant miRNAs within the rat carotid artery include
miR-145, let-7, miR-125b, miR-125a, miR-23 and miR-143 (Zhang, 2008).
miRNAs have an essential role in vascular development as
Dicer-deficient mice that lose miRNAs suffer seriously impaired vessel
development (Zhao et al., 2007). Additionally, Dicer-deficient mice
display altered expression of several crucial genes involved in embryonic
angiogenesis, including VEGF (Yang et al., 2005). Using microarray
analysis it has been established that aberrent miRNA expression is a
characteristic of vascular walls after balloon injury, with 113 artery
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miRNAs differentially expressed 7 days after injury and 102 miRNAs
differentially expressed 28 days after injury Ji et al. (2007). Anti-sense
mediated knockdown of an aberrantly overexpressed miRNA, miR-21,
had a significantly negative effect on neointimal lesion formation in rat
artery after angioplasty (Zhang, 2008). These findings indicate that
studies of the role of miRNAs in signaling pathways involved in vascular
disease could be critical in our search for therapeutic strategies.
A number of studies of miRNA regulation of Notch signaling have
revealed the potential of this line of investigation. MicroRNA-199b-5p
has been shown to impair cancer stem cells through negative regulation
of the Notch downstream target HES1 in Medulloblastoma (Garzia et al.,
2009). GY-box-, Brd-box-, and K-box-class microRNAs were determined
to regulate Drosophila Notch bHLH target genes (Lai et al., 2005).
Additionally, MicroRNA1, in Drosophila, regulates Notch signaling and
influences cardiac differentiation(Kwon et al., 2005). miRNAs have also
been shown to be haemodynamically responsive and cyclic stretch was
shown to be upregulate miR-146a, thereby delaying C2C12 myogenic
differentiation through inhibition of the Notch regulator, Numb (Kuang
et al., 2009). The Hh pathway has also been shown to be regulated by
miRNAs in Drosophila and in mammals (Ferretti et al., 2008),
(Friggi-Grelin et al., 2008), (Katoh and Katoh, 2008). Studies in zebrafish
have identified miR-214 as a modulator of Hh signalling in specifying
muscle cell fate. Su(fu) was identified as a predicted target of miR-214.
The effects of knockdown of miR-214 were then found to be mitigated by
simulataneous knockdown of Su(fu) (Flynt et al., 2007). A study by
Thatcher et al. (2007) has important significance, when the context of our
study is taken into account. In this study, knockdown of Hh signaling by
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cyclopamine and knockdown of Notch by DAPT in zebrafish identified a
number of miRNAs involved in Hh and Notch signalling. Interestingly,
simulataneous knockdown of Hh and Notch signaling identified five
abbregated miRNAs that had both Hh and Notch predicted targets.
These include miR-27b which was positively modulated by both DAPT
and cyclopamine treatment and who’s predicted targets include ptc1 and
the zebrafish homolog of Notch1, notch1b (Thatcher et al., 2007). miRNA
regulation of Notch and Hh signalling in VSMCs has yet to be
investigated and this study suggests the potential of a common miRNA
involved in the crosstalk of Notch and Hh in VSMCs. Microanalysis of
miRNAs, therefore, of Notch signaling in VSMCs could provide
invaluable information in our investigation of the pathogenesis of
vascular diseases.
To date, traditional vascular disease therapies involve preventative
hypertension and lipid-lowering medication, and surgical interventions,
including angioplasty, stenting and by-pass grafts, which are used in
extreme risk cases (Daskalopoulou et al., 2007). Recent-advances in stent
design allow the use of slow-release anti-proliferative drugs that include
sirolimus and paclitaxel. While these drugs inhibit not only the
overeaction of wound healing and restenosis, they also have a
pro-thrombogenic potential, as they also inhibit reendothelialization and
normal wound healing (Mungamuri et al., 2006). Studies are ongoing to
develop potential therapies that will antagonise vascular proliferation,
without promoting adverse side effects. Our data, among others identify
Notch signalling as a potential key player in vascular disease and
therapies that target the Notch signaling pathways may play an
important role in the future. Pre-clinical and clinical evidence indicate
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that Notch signalling has a major function in many cancers and GSIs
(γ-secretase inhibitors) have been investigated as candidate cancer
therapeutic agents . While these have oral availability and are low cost,
they have considerable off-target effects, An alternate strategy that has
been suggested is to identify more context-specific targets within the
Notch pathway and design more selective delivery strategies for notch
inhibitors (Rizzo et al., 2008). This study highlights GSK-3β as potential
modulator of Notch signalling in the control of VSMC fate. Lithium, an
antagonist of GSK-3β, is a well-established treatment for bipolar
disorders (Martinez, 2008). The maintenance of appropriate physiological
levels of GSK-3β activity is crucial, because either too little or too much
GSK-3β activity can promote cell death in certain conditions (Doble and
Woodgett, 2003). Dose-dependent modulation of GSK-3β inhibition and
control of the timing and extent of its inhibition has been suggested as a
mechanism to treat cancer, diabetes and mood disorders (Martinez, 2008).
A similar strategy may be useful in exploiting the therapeutic capacity of
GSK-3β in vascular disease. Alternatively, the emergence of artificial
miRNAs which can target several mRNA targets at the same time, may
aid in applying intervention strategies in the treatment of vascular
disease through the treatment of multiple pathways, including Hhh,
VEGF, GSK-3β and Notch.
In conclusion, we have identified GSK-3β as a modulator of Notch
signalling in VSMCs. We have, however, yet to address the mechanism
by which GSK-3β modulates Notch signalling. As discussed previously,
γ-secretase inhibition of Notch receptor activity would confirm
modulation of Notch downstream targets by GSK-3β upstream of Notch
receptor activity. We demonstrated that GSK-3β is regulated by cyclic
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strain in VSMCs, but again the pathway involved has not been defined.
Inhibition of PI-3kinase activity would determine if this occurs via the
PI3-kinase/Akt pathway. We demonstrated that GSK-3β modulates
p44/42 and p38 following strain, but the mechanism in which p44/42,
and p38 exert their effect on Notch signalling following strain remains to
be determined. We hypothesise that this occurs through modulation of
Notch ligand expression. Analysis of Jagged1 expression in VSMCs
following strain and MAPK inhibition may confirm this hypothesis.
Similarly, the effect of GSK-3β on Jagged1 expression would further
enhance our understanding of the role of GSK-3β on Notch signaling in
vitro. We have demonstrated that GSK-3β mRNA expression is regulated
in biomechanically-induced in vivo remodelling. While this suggests that
GSK-3β activity is altered in remodelled vessels, immunohistochemical
staining of remodelled tissue will confirm this finding. Overall, we have
identified a novel regulator of Notch signalling in VSMCs that is a
potential therapeutic candidate for vascular disease states that display
impaired Notch signalling.
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Appendix 1
Materials
AGB Scientific (Dublin, Ireland)
Whatmann Chromatography paper
Amersham Pharmacia Biotech (Buckinghamshire, UK)
Anti-mouse 2o antibody, HRP conjugated
Anti-rabbit 2o antibody, HRP conjugated
ECL Hybond nitrocellulose membrane
ECL Hyperfilm
Rainbow molecular weight marker, broad range (6-175kDa)
Applied Biosystems (Warrington, UK)
Silencer Select GSK-3β siRNA
Axxora (Nottingham, UK)
Anti GSK3β monoclonal IgG
BD Biosciences (Oxford, UK)
BD FACSflowTM
FACS Caliber Flowcytometer
BioRAD (Alpha Technologies, Dublin)
iScriptTM cDNA Synthesis Kit
Bio-Sciences Ltd (Dun Laoghaire, Ireland)
DEPC-treated water
Trizol R© Reagent
Calbiochem (San Diego, CA)
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Anti PCNA mouse monoclonal IgG
Anti phospho-p38 rabbit monoclonal IgG
Anti VEGF(A) rabbit monoclonal IgG
DAPT (γ-secretase inhibitor)
Cell Applications (San Diego, CA)
Cryopreserved Rat Aortic Vascular Smooth Muscle Cells (Passage 2)
Cell Signal (Beverley, MA)
Anti-phospho-GSK3β rabbit monoclonal IgG
Anti-p38 rabbit monoclonal IgG
Anti-p44/42 rabbit monoclonal IgG
Anti-phospho-p44/42 rabbit monoclonal IgG
Dako Cytomation (UK)
Dako mounting media
Dunn Labortechnik GmBH (Asbach, Germany)
6-well Bioflex R© plates
Flexcell International Corp. (Hillsborough, NC)
Flexercell R© Tension PlusTM- FX-4000TTM - system
Invitrogen (Groningen, Netherlands)
Anti goat IgG - Alexafluor 488 conjugate
Anti mouse IgG - Alexafluor 488 conjugate
Anti rabbit IgG - Alexafluor 488 conjugate
DH5α chemically competent cells
VybrantTM Apoptosis Assay Kit # 2
VybrantTM CFDA SE Cell Tracer Kit
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Lab Vision (California, USA)
UltraVision Detection System Anti-Rabbit, HRP/DAB
Lonza, Cologne, Germany
Basic Nucleofector R© Kit for Primary Smooth Muscle Cells (SMC)
MWG Biotech (Milton Keynes, UK)
Notch 1 primer set HRT3 primer set
Ptc 1 primer set VEGF primer set
HRT 1 primer set GAPDH primer set
Gli 2 primer set GSK-3β primer set
HRT 2 primer set VEGF siRNA
Pierce Chemicals (Cheshire, UK)
BCA protein assay kit
Supersignal West Pico chemilumescent substrate
Promega (Madison, WI)
Luciferase Reporter Assay Kit
R+D Systems (Abingdon, UK)
Recombinant Shh Protein
Recombinant VEGF Protein
Roche (West Sussex, UK)
Anti HA (HRP conjugated) monoclonal IgG
Santa Cruz (Santa Cruz, California)
Anti HRT 1 goat monoclonal IgG
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Anti HRT 2 goat monoclonal IgG
Anti HRT 3 goat monoclonal IgG
Anti Patched goat monoclonal IgG
Sarstedt (Drinagh, Wexford, Ireland)
1.5 ml eppendorf tubes
T25 tissue culture flasks
T75 tissue culture flasks
T175 tissue culture flasks
6-well tissue culture plates
5,10 and 25ml serological pipettes
15 and 50ml falcone tubes
cryovials
Scientific Imaging Systems (Eastman Kodak Group, Rochester, NY)
Kodak 1D image analysis software
Sigma Chemical Company (Poole, Dorset, England)
β-glycerophosphate
β-mercaptoethanol
Acetic Acid
Acetone
Agarose
Ammonium Persulphate
Acrylamide/Bis-acrylamide
Anti α-SMC actin
(mouse monoclonal IgG)
Anti-goat 2o antibody,
(HRP conjugated)
Bovine Serum Albumin
Brightline Haemocytometer
Chloroform
DMEM
DMSO
DPX Mounting Media
EDTA
EGTA
Ethidium Bromide
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Foetal Calf Serum
Glycerol
Glycine
Hematoxylin
Hydrochloric acid
Isopropanol
Lauryl Sulphate
Lithium Chloride
(GSK3β inhibitor)
Methanol
PBS tablets
PD098059
(p44/42 inhibitor)
PD169316
(p38 inhibitor)
Penicillin-Streptomycin (100x)
Phosphatase Inhibitor Cocktail
Ponceau S
Potassium Chloride
Potassium Iodide
p-Nitroaniline
Protease Inhibitor Cocktail
RPMI-164040
SB216763
(GSK3β inhibitor)
Sodium Acetate
Sodium Chloride
Sodium Doecly Sulphate
Sodium Hydroxide
Sodium Orthovanadate
Sodium Phosphate
SYBR Green Taq Ready Mix TM
TEMED
Tris Base
Tris Chloride
Tween 20
Triton X-100
Trypsin-EDTA solution (10x)
Stratagene (California, USA)
β-galactosidase Assay Kit
Thermofisher Scientific (Langenselbold, Germany)
White 96-well plates
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Appendix 2
Transfection of VSMCs with Lipofectamine
Figure 6.2: Transfection of GFP-Expression Plasmid in VSMCs using
LipofectamineTM.
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Appendix 3
GSK-3β Knockdown Strategies
Figure 6.3: GSK-3β Knockdown Stratagies Western blot analysis of GSK-
3β in VSMCs following (a) nucleofection of non-commercially designed GSK-
3β targeted siRNA siRNA (b) nucleofection of GSK-3β-targed shRNA and (c)
nucleofection of DN-GSK-3β plasmid.
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Appendix 4
Preparation of Mock Stented Artery in a Novel Vascular Bioreactor
Manufacture of Sylgard R© Tube
A Sylgard R© tube, with mechanical properties similar to that of real
coronary arteries was manufactured using a custom-made device
consisting of a mandrel of 3 mm diameter surrounded co-axially by a
plastic tube with internal diameter of 3.3 mm. In brief, Sylgard R© was
sucked between the co-axial mandrel and tube, which was then placed
into an external rig to prevent further deformation. The system was then
cured by baking at 120oC. The plastic tube was then peeled off and the
cured Sylgard R© detached from the mandrel by injection of acetone.
Seeding of BASMCs on MCA
The Sylgard R© tubing was initially dipped in a 70% sulphuric acid
solution for 60s to create a hyrophilic surface suitable for VSMC
adherence. The MCA was cut to a length of 5cm, washed in distilled
water and sterilised by autoclaving. The MCA was incubated in
fibronectin (8µg/ml) in PBS and rotated for 3h, allowing uniform
deposition of the fibronectin. BASMCs were seeded on to the treated
MCA and left to attach by rotating for 48hrs in quiescence.
MCA Stenting
A Driver BMS (a cobalt alloy stent with internal diameter of 3mm, and
nominal and burst pressure of 9 and 16 atm, respectively) was crimped
on an angioplasty balloon catheter of 9mm length. Following
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autoclaving, the BMS was deployed inside the MCA under sterile
conditions, using a Basix 25 angioplasty inflation syringe (Merit Medical
Systems, South Jordan, Utah) to expand the angioplasty balloon.
Preparation and Assembly of the Culture Chamber
The tubing system of the culture chamber was sterilised by ethanol and
sterile PBS rinsing for 48 h. All other components of the culture chamber
and attachments were sterilised by autoclaving and assembly was carried
out in a laminar airflow cabinet. The previously stented and seeded MCA
was attached to the culture chamber by luer slips and the extraluminal
space of the culture chamber was filled with PBS with 1% primocin. A
deformable elastomeric gasket (RTV 102, Radionics) was placed inside a
groove around the chamber to ensure sealing. The culture chamber cover
was then sealed by a series of screws.
Set-up of CellMax R© bioreactor tubing system
The culture chamber was connected to the CellMax R© tubing systems
(Spectrum Laboratories, Rancho Dominguez, CA) by luer locks (Value
Plastic R©, Fort Collins, CO) in a laminar airflow cabinet. Media was then
perfused through the system by a pulsatile pump. The Cell Max R© pump
creates a medium flow waveform similar to the stroke of the heart
through two pins, which push against the flexible and thin silicon tube.
Different pin lengths and pump speed set by an electronic controller
allow for different flow rates. For these experiments an inital low
flowrate was used for 24 h, to allow the BASMC to adapt to the flow
before raising it to a medium flow rate. The system was allowed to run
for 7 days before analysis.
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